Method for producing objective substance

ABSTRACT

A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism having an objective substance-producing ability, which microorganism has been modified to have a Bacteroidetes O-methyltransferase (OMT) gene, especially an OMT gene encoding OMT having a specific mutation.

This application is a Continuation of, and claims priority under 35U.S.C. § 120 to, International Application No. PCT/JP2017/038795, filedOct. 26, 2017, and claims priority therethrough under 35 U.S.C. § 119 toU.S. Provisional Patent Application No. 62/413,061, filed Oct. 26, 2016,and U.S. Provisional Patent Application No. 62/417,617, filed Nov. 4,2016, the entireties of which are incorporated by reference herein.Also, the Sequence Listing filed electronically herewith is herebyincorporated by reference (File name: 2019-04-24T_US-555_Seq_List; Filesize: 245 KB; Date recorded: Apr. 24, 2019).

BACKGROUND General Field

The present invention relates to a method for producing an objectivesubstance such as vanillin and vanillic acid by using a microorganism.

Brief Description of the Related Art

Vanillin is the major ingredient that provides the smell of vanilla, andis used as an aromatic in foods, drinks, perfumes, and so forth.Vanillin is usually produced by extraction from natural products or bychemical synthesis.

Bioengineering techniques have been tried in methods of producingvanillin, such as by using various microorganisms and raw materials,such as eugenol, isoeugenol, ferulic acid, glucose, vanillic acid,coconut husk, or the like (Kaur B. and Chakraborty D., Biotechnologicaland molecular approaches for vanillin production: a review. Appl BiochemBiotechnol. 2013 February; 169(4):1353-72). In addition, other methodsfor producing vanillin using bioengineering techniques include producingvanillin as a glycoside (WO2013/022881 and WO2004/111254), producingvanillin from ferulic acid using vanillin synthase (JP2015-535181),producing vanillic acid by fermentation of Escherichia coli and thenenzymatically converting vanillic acid into vanillin (U.S. Pat. No.6,372,461).

Vanillin can be produced via the intermediate protocatechuic acid.Specifically, protocatechuic acid can be converted to vanillic acid orprotocatechualdehyde, and vanillic acid or protocatechualdehyde can thenbe converted to vanillin. O-methyltransferase (OMT) catalyzes thereaction of methylating protocatechuic acid and/or protocatechualdehydeto generate vanillic acid and/or vanillin, that is, methylation ofhydroxyl group at the meta-position. OMT may also catalyze the reactionof methylating protocatechuic acid and/or protocatechualdehyde togenerate isovanillic acid and/or isovanillin, that is methylation ofhydroxyl group at the para-position, as a side reaction. Mutant OMTsthat selectively catalyze the methylation of hydroxyl group at themeta-position can be used for the production of an objective substancesuch as vanillin (See WO2013/022881).

SUMMARY

The present invention describes a novel technique for improvingproduction of an objective substance, such as vanillin and vanillicacid, and thereby provides a method for efficiently producing theobjective substance.

It is one aspect of the present invention that a microorganism canproduce an objective substance such as vanillic acid in a significantlyimproved manner by mutating an O-methyltransferase (OMT) so that it hasa specific mutation in a chosen microorganism have.

It is an aspect of the present invention to provide a method forproducing an objective substance, the method comprising the followingstep: producing the objective substance by using a microorganism havingan ability to produce the objective substance, wherein the microorganismhas been modified to have an O-methyltransferase gene native to abacterium belonging to the phylum Bacteroidetes, and wherein theobjective substance is selected from the group consisting of vanillin,vanillic acid, ferulic acid, guaiacol, 4-vinylguaiacol, 4-ethylguaiacol,and combinations thereof.

It is a further aspect of the present invention to provide the method asdescribed above, wherein said producing comprises cultivating themicroorganism in a culture medium containing a carbon source to produceand accumulate the objective substance in the culture medium.

It is a further aspect of the present invention to provide the method asdescribed above, wherein said producing comprises converting a precursorof the objective substance into the objective substance by using themicroorganism.

It is a further aspect of the present invention to provide the method asdescribed above, wherein said converting comprises cultivating themicroorganism in a culture medium containing the precursor to produceand accumulate the objective substance in the culture medium.

It is a further aspect of the present invention to provide the method asdescribed above, wherein said converting comprises allowing cells of themicroorganism to act on the precursor in a reaction mixture to produceand accumulate the objective substance in the reaction mixture.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the cells are cells present in a culture brothof the microorganism, cells collected from the culture broth, cellspresent in a processed product of the culture broth, cells present in aprocessed product of the collected cells, or a combination of these.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the precursor is selected from the groupconsisting of protocatechuic acid, protocatechualdehyde,L-phenylalanine, L-tyrosine, and combinations thereof.

It is a further aspect of the present invention to provide the method asdescribed above, the method further comprising collecting the objectivesubstance.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the bacterium belonging to the phylumBacteroidetes is a bacterium belonging to the genus Niastella,Terrimonas, or Chitinophaga.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the O-methyltransferase gene is a gene encodinga protein selected from the group consisting of:

(a) a protein comprising the amino acid sequence of SEQ ID NO: 141,

(b) a protein comprising the amino acid sequence of SEQ ID NO: 141 butthat includes substitution, deletion, insertion, and/or addition of 1 to10 amino acid residues, and wherein said protein has O-methyltransferaseactivity,

(c) a protein comprising an amino acid sequence having an identity of90% or higher to the amino acid sequence of SEQ ID NO: 141, and whereinsaid protein has O-methyltransferase activity, and

(d) a protein comprising the amino acid sequence of the protein definedin (a), (b), or (c) but having a specific mutation, wherein the specificmutation is a mutation at an amino acid residue selected from the groupconsisting of D21, L31, M36, S42, L67, Y90, P144, and combinationsthereof.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the specific mutation is selected from thegroup consisting of D21Y, L31H, M36(K, V), S42C, L67F, Y90(A, C, G, S),P144(E, G, S, V, Y), and combinations thereof.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the specific mutation is selected from thegroup consisting of D21Y/M36K/L67F, D21Y/M36K/L67F/Y90A,L31H/M36K/L67F/P144V, L31H/L67F/Y90A, M36K/S42C/L67F, M36K/L67F,M36K/L67F/Y90A, M36K/L67F/Y90A/P144E, M36K/L67F/Y90C,M36K/L67F/Y90C/P144V, M36K/L67F/Y90G, M36K/L67F/Y90S/P144G,M36K/L67F/P144S, M36K/L67F/P144Y, M36K/Y90A/P144V, M36K/P144E, andM36V/L67F/P144S.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism is a bacterium belonging tothe family Enterobacteriaceae, a coryneform bacterium, or yeast.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism is a bacterium belonging tothe genus Corynebacterium.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism is Corynebacteriumglutamicum.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism is a bacterium belonging tothe genus Escherichia.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism is Escherichia coli.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism has been further modified sothat the activity of an enzyme that is involved in the biosynthesis ofthe objective substance is increased as compared with a non-modifiedstrain.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the enzyme that is involved in the biosynthesisof the objective substance is selected from the group consisting of3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase,3-dehydroquinate synthase, 3-dehydroquinate dehydratase,3-dehydroshikimate dehydratase, aromatic aldehyde oxidoreductase, andcombinations thereof.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism has been further modified sothat the activity of phosphopantetheinyl transferase is increased ascompared with a non-modified strain.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism has been further modified sothat the activity of an enzyme that is involved in the by-production ofa substance other than the objective substance is reduced as comparedwith a non-modified strain.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the enzyme that is involved in theby-production of a substance other than the objective substance isselected from the group consisting of vanillate demethylase,protocatechuate 3,4-dioxygenase, alcohol dehydrogenase, shikimatedehydrogenase, and combinations thereof.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism has been further modified sothat the activity of an L-cysteine biosynthesis enzyme is increased ascompared with a non-modified strain.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the L-cysteine biosynthesis enzyme is a proteinencoded by a gene selected from the group consisting of cysI gene, cysXgene, cysH gene, cysD gene, cysN gene, cysY gene, cysZ gene, fpr2 gene,and combinations thereof.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the activity of the L-cysteine biosynthesisenzyme is increased by increasing the activity of a protein encoded bycysR gene.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism has been further modified sothat the activity of a protein encoded by NCgl2048 gene is reduced ascompared with a non-modified strain.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism has been further modified sothat the activity of enolase is reduced as compared with a non-modifiedstrain.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism has been further modified sothat the activity of S-adenosyl-L-homocysteine hydrolase is increased ascompared with a non-modified strain.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the microorganism has been further modified tohave a result selected from the group consisting of: (i) the activity ofAICAR formyltransferase/IMP cyclohydrolase is reduced as compared with anon-modified strain, (ii) a gene encoding AICAR formyltransferase/IMPcyclohydrolase has a mutation that improves the ability of themicroorganism to produce the objective substance, and (iii) combinationsthereof.

It is a further aspect of the present invention to provide the method asdescribed above, wherein the objective substance is selected from thegroup consisting of vanillin, vanillic acid, and combinations thereof.

It is a further aspect of the present invention to provide a method forproducing vanillin, the method comprising producing vanillic acid by themethod as described above; and converting said vanillic acid tovanillin.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

<1> Microorganism

The microorganism as described herein is a microorganism that has anability to produce an objective substance, which microorganism has beenmodified to have, that is, to harbor, an O-methyltransferase (OMT) genederived from, or native to, a bacterium belonging to the phylumBacteroidetes. Such an OMT gene can also be referred to as a“Bacteroidetes OMT gene”. The ability to produce an objective substancecan also be referred to as an “objective substance-producing ability”.

<1-1> Microorganism Having Objective Substance-Producing Ability

The phrase “microorganism having an objective substance-producingability” can refer to a microorganism that is able to produce anobjective substance.

The phrase “microorganism having an objective substance-producingability” can refer to a microorganism that is able to produce anobjective substance by fermentation, if the microorganism is used in afermentation method. That is, the phrase “microorganism having anobjective substance-producing ability” can refer to a microorganism thatis able to produce an objective substance from a carbon source.Specifically, the phrase “microorganism having an objectivesubstance-producing ability” can refer to a microorganism that is ableto, upon being cultured in a culture medium, such as a culture mediumcontaining a carbon source, produce and accumulate the objectivesubstance in the culture medium to such a degree that the objectivesubstance can be collected from the culture medium.

Also, the phrase “microorganism having an objective substance-producingability” can refer to a microorganism that is able to produce anobjective substance by bioconversion, if the microorganism is used in abioconversion method. That is, the phrase “microorganism having anobjective substance-producing ability” can refer to a microorganism thatis able to produce an objective substance from a precursor of theobjective substance. Specifically, the phrase “microorganism having anobjective substance-producing ability” can refer to a microorganism thatis able to, upon being cultured in a culture medium containing aprecursor of an objective substance, produce and accumulate theobjective substance in the culture medium to such a degree that theobjective substance can be collected from the culture medium. Also,specifically, the phrase “microorganism having an objectivesubstance-producing ability” can refer to a microorganism that is ableto, upon being allowed to act on a precursor of an objective substancein a reaction mixture, produce and accumulate the objective substance inthe reaction mixture to such a degree that the objective substance canbe collected from the reaction mixture.

The microorganism having an objective substance-producing ability can beable to produce and accumulate the objective substance in the culturemedium or reaction mixture in an amount larger than that can be obtainedwith a non-modified strain. A non-modified strain can also be referredto as a “strain of a non-modified microorganism” or a “non-modifiedmicroorganism”. The phrase “strain of a non-modified microorganism” or“non-modified strain” can refer to a control strain that has not beenmodified to have a Bacteroidetes OMT gene. Examples of such a controlstrain can include a strain having an OMT gene other than theBacteroidetes OMT gene, such as the OMT gene native to Homo sapiens,instead of the Bacteroidetes OMT gene. The microorganism having anobjective substance-producing ability can be able to accumulate theobjective substance in the culture medium or reaction mixture in anamount of, for example, 0.01 g/L or more, 0.05 g/L or more, or 0.09 g/Lor more.

The objective substance can be metabolites the biosynthesis of which caninclude a step catalyzed by Bacteroidetes OMT. Examples of suchmetabolites can include, for example, vanillin, vanillic acid, ferulicacid, guaiacol, 4-vinylguaiacol, and 4-ethylguaiacol. Particularexamples of such metabolites can include vanillin and vanillic acid. Themicroorganism may be able to produce only one objective substance, ormay be able to produce two or more objective substances. Also, themicroorganism may be able to produce an objective substance from oneprecursor of the objective substance or from two or more precursors ofthe objective sub stance.

When the objective substance is a compound that can form a salt, theobjective substance may be obtained as a free compound, a salt thereof,or a mixture of these. That is, the term “objective substance” can referto an objective substance in a free form, a salt thereof, or a mixturethereof, unless otherwise stated. Examples of the salt can include, forexample, sulfate salt, hydrochloride salt, carbonate salt, ammoniumsalt, sodium salt, and potassium salt. As the salt of the objectivesubstance, one kind of salt may be employed, or two or more kinds ofsalts may be employed in combination.

A microorganism that can be used as a parent strain to construct themicroorganism as described herein is not particularly limited. Examplesof the microorganism can include bacteria and yeast.

Examples of the bacteria can include bacteria belonging to the familyEnterobacteriaceae and coryneform bacteria.

Examples of bacteria belonging to the family Enterobacteriaceae caninclude bacteria belonging to the genus Escherichia, Enterobacter,Pantoea, Klebsiella, Serratia, Erwinia, Photorhabdus, Providencia,Salmonella, Morganella, or the like. Specifically, bacteria classifiedinto the family Enterobacteriaceae according to the taxonomy used in theNCBI (National Center for Biotechnology Information) database(ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=91347) can be used.

The Escherichia bacteria are not particularly limited, and examplesthereof can include those classified into the genus Escherichiaaccording to the taxonomy known to those skilled in the field ofmicrobiology. Examples of the Escherichia bacteria can include, forexample, those described in the work of Neidhardt et al. (Backmann B.J., 1996, Derivations and Genotypes of some mutant derivatives ofEscherichia coli K-12, pp. 2460-2488, Table 1, In F. D. Neidhardt (ed.),Escherichia coli and Salmonella Cellular and Molecular Biology/SecondEdition, American Society for Microbiology Press, Washington, D.C.).Examples of the Escherichia bacteria can include, for example,Escherichia coli. Specific examples of Escherichia coli can include, forexample, Escherichia coli K-12 strains such as W3110 strain (ATCC 27325)and MG1655 strain (ATCC 47076); Escherichia coli K5 strain (ATCC 23506);Escherichia coli B strains such as BL21 (DE3) strain; and derivativestrains thereof.

The Enterobacter bacteria are not particularly limited, and examples caninclude those classified into the genus Enterobacter according to thetaxonomy known to those skilled in the field of microbiology. Examplesthe Enterobacter bacterium can include, for example, Enterobacteragglomerans and Enterobacter aerogenes. Specific examples ofEnterobacter agglomerans can include, for example, the Enterobacteragglomerans ATCC 12287 strain. Specific examples of Enterobacteraerogenes can include, for example, the Enterobacter aerogenes ATCC13048 strain, NBRC 12010 strain (Biotechnol. Bioeng., 2007, Mar. 27;98(2):340-348), and AJ110637 strain (FERM BP-10955). Examples theEnterobacter bacteria can also include, for example, the strainsdescribed in European Patent Application Laid-open (EP-A) No. 0952221.In addition, Enterobacter agglomerans can also include some strainsclassified as Pantoea agglomerans.

The Pantoea bacteria are not particularly limited, and examples caninclude those classified into the genus Pantoea according to thetaxonomy known to those skilled in the field of microbiology. Examplesthe Pantoea bacteria can include, for example, Pantoea ananatis, Pantoeastewartii, Pantoea agglomerans, and Pantoea citrea. Specific examples ofPantoea ananatis can include, for example, the Pantoea ananatis LMG20103strain, AJ13355 strain (FERM BP-6614), AJ13356 strain (FERM BP-6615),AJ13601 strain (FERM BP-7207), SC17 strain (FERM BP-11091), SC17(0)strain (VKPM B-9246), and SC17sucA strain (FERM BP-8646). Some ofEnterobacter bacteria and Erwinia bacteria were reclassified into thegenus Pantoea (Int. J. Syst. Bacteriol., 39, 337-345 (1989); Int. J.Syst. Bacteriol., 43, 162-173 (1993)). For example, some strains ofEnterobacter agglomerans were recently reclassified into Pantoeaagglomerans, Pantoea ananatis, Pantoea stewartii, or the like on thebasis of nucleotide sequence analysis of 16S rRNA etc. (Int. J. Syst.Bacteriol., 39, 337-345 (1989)). The Pantoea bacteria can include thosereclassified into the genus Pantoea as described above.

Examples of the Erwinia bacteria can include Erwinia amylovora andErwinia carotovora. Examples of the Klebsiella bacteria can includeKlebsiella planticola.

Examples of coryneform bacteria can include bacteria belonging to thegenus Corynebacterium, Brevibacterium, Microbacterium, or the like.

Specific examples of such coryneform bacteria can include the followingspecies:

Corynebacterium acetoacidophilum

Corynebacterium acetoglutamicum

Corynebacterium alkanolyticum

Corynebacterium callunae

Corynebacterium crenatum

Corynebacterium glutamicum

Corynebacterium lilium

Corynebacterium melassecola

Corynebacterium thermoaminogenes (Corynebacterium efficiens)

Corynebacterium herculis

Brevibacterium divaricatum (Corynebacterium glutamicum)

Brevibacterium flavum (Corynebacterium glutamicum)

Brevibacterium immariophilum

Brevibacterium lactofermentum (Corynebacterium glutamicum)

Brevibacterium roseum

Brevibacterium saccharolyticum

Brevibacterium thiogenitalis

Corynebacterium ammoniagenes (Corynebacterium stationis)

Brevibacterium album

Brevibacterium cerinum

Microbacterium ammoniaphilum

Specific examples of the coryneform bacteria can include the followingstrains:

Corynebacterium acetoacidophilum ATCC 13870

Corynebacterium acetoglutamicum ATCC 15806

Corynebacterium alkanolyticum ATCC 21511

Corynebacterium callunae ATCC 15991

Corynebacterium crenatum AS1.542

Corynebacterium glutamicum ATCC 13020, ATCC 13032, ATCC 13060, ATCC13869, FERM BP-734

Corynebacterium lilium ATCC 15990

Corynebacterium melassecola ATCC 17965

Corynebacterium efficiens (Corynebacterium thermoaminogenes) AJ12340(FERM BP-1539)

Corynebacterium herculis ATCC 13868

Brevibacterium divaricatum (Corynebacterium glutamicum) ATCC 14020

Brevibacterium flavum (Corynebacterium glutamicum) ATCC 13826, ATCC14067, AJ12418 (FERM BP-2205)

Brevibacterium immariophilum ATCC 14068

Brevibacterium lactofermentum (Corynebacterium glutamicum) ATCC 13869

Brevibacterium roseum ATCC 13825

Brevibacterium saccharolyticum ATCC 14066

Brevibacterium thiogenitalis ATCC 19240

Corynebacterium ammoniagenes (Corynebacterium stationis) ATCC 6871, ATCC6872

Brevibacterium album ATCC 15111

Brevibacterium cerinum ATCC 15112

Microbacterium ammoniaphilum ATCC 15354

The coryneform bacteria can include bacteria that had previously beenclassified into the genus Brevibacterium, but are now united into thegenus Corynebacterium (Int. J. Syst. Bacteriol., 41, 255 (1991)).Moreover, Corynebacterium stationis can include bacteria that hadpreviously been classified as Corynebacterium ammoniagenes, but are nowre-classified into Corynebacterium stationis on the basis of nucleotidesequence analysis of 16S rRNA etc. (Int. J. Syst. Evol. Microbiol., 60,874-879 (2010)).

The yeast may be a budding or fission yeast. The yeast may be a haploid,diploid, or more polyploid yeast. Examples of the yeast can includeyeast belonging to the genus Saccharomyces such as Saccharomycescerevisiae; the genus Pichia, which can also be referred to as the genusWickerhamomyces, such as Pichia ciferrii, Pichia sydowiorum, and Pichiapastoris; the genus Candida such as Candida utilis; the genus Hansenulasuch as Hansenula polymorpha; and the genus Schizosaccharomyces such asSchizosaccharomyces pombe.

These strains are available from, for example, the American Type CultureCollection (Address: P.O. Box 1549, Manassas, Va. 20108, United Statesof America; or atcc.org). That is, registration numbers are given to therespective strains, and the strains can be ordered using theseregistration numbers (refer to atcc.org). The registration numbers ofthe strains are listed in the catalogue of the American Type CultureCollection. These strains can also be obtained from, for example, thedepositories at which the strains were deposited.

The microorganism may inherently have an objective substance-producingability, or may have been modified so that it has an objectivesubstance-producing ability. The microorganism having an objectivesubstance-producing ability can be obtained by imparting an objectivesubstance-producing ability to such a microorganism as described above,or enhancing an objective substance-producing ability of such amicroorganism as mentioned above.

Hereafter, specific examples of the methods for imparting or enhancingan objective substance-producing ability will be explained. Suchmodifications as exemplified below for imparting or enhancing anobjective substance-producing ability may be employed independently, orin an appropriate combination.

An objective substance can be generated by the action of an enzyme thatis involved in the biosynthesis of the objective substance. Such anenzyme can also be referred to as an “objective substance biosynthesisenzyme”. Therefore, the microorganism may have an objective substancebiosynthesis enzyme. In other words, the microorganism may have a geneencoding an objective substance biosynthesis enzyme. Such a gene canalso be referred to as an “objective substance biosynthesis gene”. Themicroorganism may inherently have an objective substance biosynthesisgene, or may have been introduced with an objective substancebiosynthesis gene. The methods for introducing a gene will be explainedherein.

Also, an objective substance-producing ability of a microorganism can beimproved by increasing the activity of an objective substancebiosynthesis enzyme. That is, examples of the method for imparting orenhancing an objective substance-producing ability can include a methodof increasing the activity of an objective substance biosynthesisenzyme. That is, the microorganism can be modified so that the activityof an objective substance biosynthesis enzyme is increased. The activityof one objective substance biosynthesis enzyme may be increased, or theactivities of two or more objective substance biosynthesis enzymes maybe increased. The method for increasing the activity of a protein, suchas an enzyme etc., will be described herein. The activity of a protein,such as an enzyme etc., can be increased by, for example, increasing theexpression of a gene encoding the protein.

An objective substance can be generated from, for example, a carbonsource and/or a precursor of the objective substance. Hence, examples ofthe objective substance biosynthesis enzyme can include, for example,enzymes that catalyze the conversion of the carbon source and/or theprecursor into the objective substance. For example, 3-dehydroshikimicacid can be produced via a part of shikimate pathway, which may includesteps catalyzed by 3-deoxy-D-arabino-heptulosonic acid 7-phosphatesynthase (DAHP synthase), 3-dehydroquinate synthase, and3-dehydroquinate dehydratase; 3-dehydroshikimic acid can be converted toprotocatechuic acid by the action of 3-dehydroshikimate dehydratase(DHSD); protocatechuic acid can be converted to vanillic acid orprotocatechualdehyde by the action of O-methyltransferase (OMT) oraromatic aldehyde oxidoreductase, such as aromatic carboxylic acidreductase; ACAR, respectively; and vanillic acid or protocatechualdehydecan be converted to vanillin by the action of ACAR or OMT, respectively.That is, specific examples of the objective substance biosynthesisenzyme can include, for example, DAHP synthase, 3-dehydroquinatesynthase, 3-dehydroquinate dehydratase, DHSD, OMT, and ACAR.

The term “3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase (DAHPsynthase)” can refer to a protein that has the activity of catalyzingthe reaction of converting D-erythrose 4-phosphate andphosphoenolpyruvic acid into 3-deoxy-D-arabino-heptulosonate 7-phosphate(DAHP) and phosphate (EC 2.5.1.54). A gene encoding a DAHP synthase canalso be referred to as a “DAHP synthase gene”. Examples of a DAHPsynthase can include the AroF, AroG, and AroH proteins, which areencoded by the aroF, aroG, and aroH genes, respectively. Among these,AroG may function as the major DAHP synthase. Examples of a DAHPsynthase such as the AroF, AroG, and AroH proteins can include thosenative to various organisms such as Enterobacteriaceae bacteria andcoryneform bacteria. Specific examples of a DAHP synthase can includethe AroF, AroG, and AroH proteins native to E. coli. The nucleotidesequence of the aroG gene native to the E. coli K-12 MG1655 strain isshown as SEQ ID NO: 1, and the amino acid sequence of the AroG proteinencoded by this gene is shown as SEQ ID NO: 2.

The DAHP synthase activity can be measured by, for example, incubatingthe enzyme with substrates, such as D-erythrose 4-phosphate andphosphoenolpyruvic acid, and measuring the enzyme- andsubstrate-dependent generation of DAHP.

The term “3-dehydroquinate synthase” can refer to a protein that has theactivity of catalyzing the reaction of dephosphorylating DAHP togenerate 3-dehydroquinic acid (EC 4.2.3.4). A gene encoding a3-dehydroquinate synthase can also be referred to as a “3-dehydroquinatesynthase gene”. Examples of a 3-dehydroquinate synthase can include theAroB protein, which is encoded by the aroB gene. Examples of a3-dehydroquinate synthase such as the AroB protein can include thosenative to various organisms such as Enterobacteriaceae bacteria andcoryneform bacteria. Specific examples of a 3-dehydroquinate synthasecan include the AroB native to E. coli. The nucleotide sequence of thearoB gene native to the E. coli K-12 MG1655 strain is shown as SEQ IDNO: 3, and the amino acid sequence of the AroB protein encoded by thisgene is shown as SEQ ID NO: 4.

The 3-dehydroquinate synthase activity can be measured by, for example,incubating the enzyme with a substrate, such as DAHP, and measuring theenzyme- and substrate-dependent generation of 3-dehydroquinic acid.

The term “3-dehydroquinate dehydratase” can refer to a protein that hasthe activity of catalyzing the reaction of dehydrating 3-dehydroquinicacid to generate 3-dehydroshikimic acid (EC 4.2.1.10). A gene encoding a3-dehydroquinate dehydratase can also be referred to as a“3-dehydroquinate dehydratase gene”. Examples of a 3-dehydroquinatedehydratase can include the AroD protein, which is encoded by the aroDgene. Examples of a 3-dehydroquinate dehydratase such as the AroDprotein can include those native to various organisms such asEnterobacteriaceae bacteria and coryneform bacteria. Specific examplesof a 3-dehydroquinate dehydratase can include the AroD protein native toE. coli. The nucleotide sequence of the aroD gene native to the E. coliK-12 MG1655 strain is shown as SEQ ID NO: 5, and the amino acid sequenceof the AroD protein encoded by this gene is shown as SEQ ID NO: 6.

The 3-dehydroquinate dehydratase activity can be measured by, forexample, incubating the enzyme with a substrate, such as 3-dehydroquinicacid, and measuring the enzyme- and substrate-dependent generation of3-dehydroshikimic acid.

The term “3-dehydroshikimate dehydratase (DHSD)” can refer to a proteinthat has the activity of catalyzing the reaction of dehydrating3-dehydroshikimic acid to generate protocatechuic acid (EC 4.2.1.118). Agene encoding a DHSD can also be referred to as a “DHSD gene”. Examplesof a DHSD can include the AsbF protein, which is encoded by the asbFgene. Examples of a DHSD such as the AsbF protein can include thosenative to various organisms such as Bacillus thuringiensis, Neurosporacrassa, and Podospora pauciseta. The nucleotide sequence of the asbFgene native to the Bacillus thuringiensis BMB171 strain is shown as SEQID NO: 7, and the amino acid sequence of the AsbF protein encoded bythis gene is shown as SEQ ID NO: 8.

The DHSD activity can be measured by, for example, incubating the enzymewith a substrate, such as 3-dehydroshikimic acid, and measuring theenzyme- and substrate-dependent generation of protocatechuic acid.

The expression of a gene encoding an enzyme of the shikimate pathway,such as a DAHP synthase, 3-dehydroquinate synthase, and 3-dehydroquinatedehydratase, is repressed by the tyrosine repressor TyrR, which isencoded by the tyrR gene. Therefore, the activity of an enzyme of theshikimate pathway can also be increased by reducing the activity of thetyrosine repressor TyrR. The nucleotide sequence of the tyrR gene nativeto the E. coli K-12 MG1655 strain is shown as SEQ ID NO: 9, and theamino acid sequence of the TyrR protein encoded by this gene is shown asSEQ ID NO: 10.

O-methyltransferase (OMT) is described below in “Introduction ofO-methyltransferase gene native to a bacterium belonging to phylumBacteroidetes”.

The term “aromatic aldehyde oxidoreductase (aromatic carboxylic acidreductase; ACAR)” can refer to a protein that has an activity ofcatalyzing the reaction of reducing vanillic acid and/or protocatechuicacid in the presence of an electron donor and ATP to generate vanillinand/or protocatechualdehyde (EC 1.2.99.6 etc.). This activity can alsobe referred to as “ACAR activity”. A gene encoding ACAR can also bereferred to as an “ACAR gene”. ACAR may generally use both vanillic acidand protocatechuic acid as the substrate, but is not necessarily limitedthereto. That is, ACAR can have a required substrate specificitydepending on the specific biosynthesis pathway via which an objectivesubstance is produced in the method as described herein. For example,when an objective substance is produced via the conversion of vanillicacid into vanillin, ACAR that is specific for at least vanillic acid canbe used. Also, for example, when an objective substance is produced viathe conversion of protocatechuic acid into protocatechualdehyde, ACARthat is specific for at least protocatechuic acid can be used. Examplesof the electron donor can include NADH and NADPH. Examples of ACAR caninclude ACARs native to various organisms such as Nocardia sp. strainNRRL 5646, Actinomyces sp., Clostridium thermoaceticum, Aspergillusniger, Corynespora melonis, Coriolus sp., and Neurospora sp. (J. Biol.Chem., 2007, Vol. 282, No. 1, pp. 478-485). The Nocardia sp. strain NRRL5646 has been classified into Nocardia iowensis. Examples of ACARfurther can include ACARs native to other Nocardia bacteria such asNocardia brasiliensis and Nocardia vulneris. The nucleotide sequence ofthe ACAR gene native to Nocardia brasiliensis ATCC 700358 is shown asSEQ ID NO: 17, and the amino acid sequence of ACAR encoded by this geneis shown as SEQ ID NO: 18. The nucleotide sequence of an example ofvariant ACAR gene native to Nocardia brasiliensis ATCC 700358 is shownas SEQ ID NO: 19, and the amino acid sequence of ACAR encoded by thisgene is shown as SEQ ID NO: 20.

The ACAR activity can be measured by, for example, incubating the enzymewith a substrate, such as vanillic acid or protocatechuic acid, in thepresence of ATP and NADPH, and measuring the enzyme- andsubstrate-dependent oxidation of NADPH (modification of the methoddescribed in J. Biol. Chem., 2007, Vol. 282, No. 1, pp. 478-485).

ACAR can be made into an active enzyme by phosphopantetheinylation (J.Biol. Chem., 2007, Vol. 282, No. 1, pp. 478-485). Therefore, ACARactivity can also be increased by increasing the activity of an enzymethat catalyzes phosphopantetheinylation of a protein, which can also bereferred to as a “phosphopantetheinylation enzyme”. That is, examples ofthe method for imparting or enhancing an objective substance-producingability can include a method of increasing the activity of aphosphopantetheinylation enzyme. That is, the microorganism can bemodified so that the activity of a phosphopantetheinylation enzyme isincreased. Examples of the phosphopantetheinylation enzyme can includephosphopantetheinyl transferase (PPT).

The term “phosphopantetheinyl transferase (PPT)” can refer to a proteinthat has an activity of catalyzing the reaction ofphosphopantetheinylating ACAR in the presence of a phosphopantetheinylgroup donor. This activity can also be referred to as “PPT activity”. Agene encoding PPT can also be referred to as a “PPT gene”. Examples ofthe phosphopantetheinyl group donor can include coenzyme A (CoA).Examples of PPT can include the EntD protein, which is encoded by theentD gene. Examples of PPT such as the EntD protein can include thosenative to various organisms. Specific examples of PPT can include theEntD protein native to E. coli. The nucleotide sequence of the entD genenative to the E. coli K-12 MG1655 strain is shown as SEQ ID NO: 21, andthe amino acid sequence of the EntD protein encoded by this gene isshown as SEQ ID NO: 22. Specific examples of PPT can also include PPTnative to Nocardia brasiliensis, PPT native to Nocardia farcinicaIFM10152 (J. Biol. Chem., 2007, Vol. 282, No. 1, pp. 478-485), and PPTnative to Corynebacterium glutamicum (App. Env. Microbiol. 2009, Vol.75, No. 9, pp. 2765-2774). The nucleotide sequence of the PPT genenative to the C. glutamicum ATCC 13032 strain is shown as SEQ ID NO: 23,and the amino acid sequence of PPT encoded by this gene is shown as SEQID NO: 24.

The PPT activity can be measured on the basis of, for example,enhancement of the ACAR activity observed when the enzyme is incubatedwith ACAR in the presence of CoA (J. Biol. Chem., 2007, Vol. 282, No. 1,pp. 478-485).

Guaiacol can be produced from vanillic acid. Hence, the aforementioneddescriptions concerning objective substance biosynthesis enzymes forvanillic acid can be applied mutatis mutandis to objective substancebiosynthesis enzymes for guaiacol. Vanillic acid can be converted toguaiacol by the action of vanillic acid decarboxylase (VDC). That is,examples of the objective substance biosynthesis enzyme can also includeVDC.

Ferulic acid, 4-vinylguaiacol, and 4-ethylguaiacol can be produced fromL-phenylalanine or L-tyrosine. That is, examples of the objectivesubstance biosynthesis enzyme can also include, for example,L-phenylalanine biosynthesis enzymes, L-tyrosine biosynthesis enzymes,and enzymes that catalyze the conversion of L-phenylalanine orL-tyrosine into ferulic acid, 4-vinylguaiacol, or 4-ethylguaiacol.Examples of the L-phenylalanine biosynthesis enzymes can include thecommon biosynthesis enzymes of aromatic amino acids exemplified above,as well as chorismate mutase (pheA), prephenate dehydratase (pheA), andtyrosine amino transferase (tyrB). Chorismate mutase and prephenatedehydratase may be encoded by the pheA gene as a bifunctional enzyme.Examples of the L-tyrosine biosynthesis enzymes can include the commonbiosynthesis enzymes of aromatic amino acids exemplified above, as wellas chorismate mutase (tyrA), prephenate dehydrogenase (tyrA), andtyrosine amino transferase (tyrB). Chorismate mutase and prephenatedehydrogenase may be encoded by the tyrA gene as a bifunctional enzyme.L-phenylalanine can be converted to cinnamic acid by the action ofphenylalanine ammonia lyase (PAL; EC 4.3.1.24), and then to p-coumaricacid by the action of cinnamic acid 4-hydroxylase (C4H; EC 1.14.13.11).Also, L-tyrosine can be converted to p-coumaric acid by the action oftyrosine ammonia lyase (TAL; EC 4.3.1.23). p-Coumaric acid can beconverted successively to caffeic acid, ferulic acid, 4-vinylguaiacol,and 4-ethylguaiacol by the action of hydroxycinnamic acid 3-hydroxylase(C3H), O-methyltransferase (OMT), ferulic acid decarboxylase (FDC), andvinylphenol reductase (VPR), respectively. That is, examples of enzymesthat catalyze the conversion of L-phenylalanine or L-tyrosine intoferulic acid, 4-vinylguaiacol, or 4-ethylguaiacol can include theseenzymes.

Examples of a method for imparting or enhancing an objectivesubstance-producing ability can also include the method of increasingthe activity of an uptake system of a substance other than an objectivesubstance, such as a substance generated as an intermediate duringproduction of an objective substance and a substance used as a precursorof an objective substance. That is, the microorganism can be modified sothat the activity of such an uptake system is increased. The term“uptake system of a substance” can refer to a protein having a functionof incorporating the substance from the outside of a cell into the cell.This activity can also be referred to as an “uptake activity of asubstance”. A gene encoding such an uptake system can also be referredto as an “uptake system gene”. Examples of such an uptake system caninclude a vanillic acid uptake system and a protocatechuic acid uptakesystem. Examples of the vanillic acid uptake system can include the VanKprotein, which is encoded by the vanK gene (M. T. Chaudhry, et al.,Microbiology, 2007, 153:857-865). The nucleotide sequence of the vanKgene (NCgl2302) native to the C. glutamicum ATCC 13869 strain is shownas SEQ ID NO: 25, and the amino acid sequence of the VanK proteinencoded by this gene is shown as SEQ ID NO: 26. Examples of theprotocatechuic acid uptake system gene can include the PcaK protein,which is encoded by the pcaK gene (M. T. Chaudhry, et al., Microbiology,2007, 153:857-865). The nucleotide sequence of the pcaK gene (NCgl1031)native to the C. glutamicum ATCC 13869 strain is shown as SEQ ID NO: 27,and the amino acid sequence of the PcaK protein encoded by this gene isshown as SEQ ID NO: 28.

The uptake activity of a substance can be measured according to, forexample, a known method (M. T. Chaudhry, et al., Microbiology, 2007.153:857-865).

Examples of the method for imparting or enhancing an objectivesubstance-producing ability further can include a method of reducing theactivity of an enzyme that is involved in the by-production of asubstance other than an objective substance. Such a substance other thanan objective substance can also be referred to as a “byproduct”. Such anenzyme can also be referred to as a “byproduct generation enzyme”.Examples of the byproduct generation enzyme can include, for example,enzymes that are involved in the utilization of an objective substance,and enzymes that catalyze a reaction branching away from thebiosynthetic pathway of an objective substance to generate a substanceother than the objective substance. The method for reducing the activityof a protein, such as an enzyme etc., will be described herein. Theactivity of a protein, such as an enzyme etc., can be reduced by, forexample, disrupting a gene that encodes the protein. For example, it hasbeen reported that, in coryneform bacteria, vanillin is metabolized inthe order of vanillin→vanillic acid→protocatechuic acid, and utilized(Current Microbiology, 2005, Vol. 51, pp. 59-65). That is, specificexamples of the byproduct generation enzyme can include an enzyme thatcatalyzes the conversion of vanillin into protocatechuic acid andenzymes that catalyze further metabolization of protocatechuic acid.Examples of such enzymes can include vanillate demethylase,protocatechuate 3,4-dioxygenase, and various enzymes that furtherdecompose the reaction product of protocatechuate 3,4-dioxygenase tosuccinyl-CoA and acetyl-CoA (Appl. Microbiol. Biotechnol., 2012, Vol.95, p 77-89). In addition, vanillin can be converted into vanillylalcohol by the action of alcohol dehydrogenase (Kunjapur A M. et al., J.Am. Chem. Soc., 2014, Vol. 136, p 11644-11654; Hansen E H. et al., App.Env. Microbiol., 2009, Vol. 75, p 2765-2774). That is, specific examplesof the byproduct generation enzyme can also include alcoholdehydrogenase (ADH). In addition, 3-dehydroshikimic acid, which is anintermediate of the biosynthetic pathway of vanillic acid and vanillin,can also be converted into shikimic acid by the action of shikimatedehydrogenase. That is, specific examples of the byproduct generationenzyme can also include shikimate dehydrogenase.

The term “vanillate demethylase” can refer to a protein having anactivity for catalyzing the reaction of demethylating vanillic acid togenerate protocatechuic acid. This activity can also be referred to as“vanillate demethylase activity”. A gene encoding vanillate demethylasecan also be referred to as a “vanillate demethylase gene”. Examples ofvanillate demethylase can include the VanAB proteins, which are encodedby the vanAB genes (Current Microbiology, 2005, Vol. 51, pp. 59-65). ThevanA gene and vanB gene encode the subunit A and subunit B of vanillatedemethylase, respectively. To reduce the vanillate demethylase activity,both the vanAB genes may be disrupted or the like, or only one of thetwo may be disrupted or the like. The nucleotide sequences of the vanABgenes native to the C. glutamicum ATCC 13869 strain are shown as SEQ IDNOS: 29 and 31, and the amino acid sequences of the VanAB proteinsencoded by these genes are shown as SEQ ID NOS: 30 and 32, respectively.The vanAB genes usually constitute the vanABK operon together with thevanK gene. Therefore, in order to reduce the vanillate demethylaseactivity, the vanABK operon may be totally disrupted or the like, forexample, deleted. In such a case, the vanK gene may be introduced to ahost again. For example, when vanillic acid present outside cells isused, and the vanABK operon is totally disrupted or the like, forexample, deleted, it is preferable to introduce the vanK gene anew.

The vanillate demethylase activity can be measured by, for example,incubating the enzyme with a substrate, such as vanillic acid, andmeasuring the enzyme- and substrate-dependent generation ofprotocatechuic acid (J Bacteriol, 2001, Vol. 183, p 3276-3281).

The term “protocatechuate 3,4-dioxygenase” can refer to a protein havingan activity for catalyzing the reaction of oxidizing protocatechuic acidto generate beta-Carboxy-cis,cis-muconic acid. This activity can also bereferred to as “protocatechuate 3,4-dioxygenase activity”. A geneencoding protocatechuate 3,4-dioxygenase can also be referred to as a“protocatechuate 3,4-dioxygenase gene”. Examples of protocatechuate3,4-dioxygenase can include the PcaGH proteins, which are encoded by thepcaGH genes (Appl. Microbiol. Biotechnol., 2012, Vol. 95, p 77-89). ThepcaG gene and pcaH gene encode the alpha subunit and beta subunit ofprotocatechuate 3,4-dioxygenase, respectively. To reduce theprotocatechuate 3,4-dioxygenase activity, both the pcaGH genes may bedisrupted or the like, or only one of the two may be disrupted or thelike. The nucleotide sequences of the pcaGH genes native to the C.glutamicum ATCC 13032 strain are shown as SEQ ID NOS: 33 and 35, and theamino acid sequences of the PcaGH proteins encoded by these genes areshown as SEQ ID NOS: 34 and 36, respectively.

The protocatechuate 3,4-dioxygenase activity can be measured by, forexample, incubating the enzyme with a substrate, such as protocatechuicacid, and measuring the enzyme- and substrate-dependent oxygenconsumption (Meth. Enz., 1970, Vol. 17A, p 526-529).

The term “alcohol dehydrogenase (ADH)” can refer to a protein that hasan activity for catalyzing the reaction of reducing an aldehyde in thepresence of an electron donor to generate an alcohol (EC 1.1.1.1, EC1.1.1.2, EC 1.1.1.71, etc.). This activity can also be referred to as“ADH activity”. A gene encoding ADH can also be referred to as an “ADHgene”. Examples of the electron donor can include NADH and NADPH.

As ADH, one having an activity for catalyzing the reaction of reducingvanillin in the presence of an electron donor to generate vanillylalcohol is a particular example. This activity can also be especiallyreferred to as “vanillyl alcohol dehydrogenase activity”. Furthermore,ADH having the vanillyl alcohol dehydrogenase activity can also beespecially referred to as “vanillyl alcohol dehydrogenase”.

Examples of ADH can include the YqhD protein, NCgl0324 protein, NCgl0313protein, NCgl2709 protein, NCgl0219 protein, and NCgl2382 protein, whichare encoded by the yqhD gene, NCgl0324 gene, NCgl0313 gene, NCgl2709gene, NCgl0219 gene, and NCgl2382 gene, respectively. The yqhD gene andthe NCgl0324 gene encode vanillyl alcohol dehydrogenase. The yqhD genecan be found in, for example, bacteria belonging to the familyEnterobacteriaceae such as E. coli. The NCgl0324 gene, NCgl0313 gene,NCgl2709 gene, NCgl0219 gene, and NCgl2382 gene can be found in, forexample, coryneform bacteria such as C. glutamicum. The nucleotidesequence of the yqhD gene native to E. coli K-12 MG1655 strain is shownas SEQ ID NO: 37, and the amino acid sequence of the YqhD proteinencoded by this gene is shown as SEQ ID NO: 38. The nucleotide sequencesof the NCgl0324 gene, NCgl0313 gene, and NCgl2709 gene native to the C.glutamicum ATCC 13869 strain are shown as SEQ ID NOS: 39, 41, and 43,respectively, and the amino acid sequences of the proteins encoded bythese genes are shown as SEQ ID NOS: 40, 42, and 44, respectively. Thenucleotide sequences of the NCgl0219 gene and NCgl2382 gene native tothe C. glutamicum ATCC 13032 strain are shown as SEQ ID NOS: 45 and 47,respectively, and the amino acid sequences of the proteins encoded bythese genes are shown as SEQ ID NOS: 46 and 48, respectively. Theactivity of one kind of ADH may be reduced, or the activities of two ormore kinds of ADHs may be reduced. For example, the activity oractivities of one or more of the NCgl0324 protein, NCgl2709 protein, andNCgl0313 protein may be reduced. Particularly, at least the activity ofNCgl0324 protein may be reduced.

The ADH activity can be measured by, for example, incubating the enzymewith a substrate, such as an aldehyde such as vanillin, in the presenceof NADPH or NADH, and measuring the enzyme- and substrate-dependentoxidation of NADPH or NADH.

The term “shikimate dehydrogenase” can refer to a protein that has theactivity of catalyzing the reaction of reducing 3-dehydroshikimic acidin the presence of an electron donor to generate shikimic acid (EC1.1.1.25). This activity can also be referred to as “shikimatedehydrogenase activity”. A gene encoding shikimate dehydrogenase canalso be referred to as a “shikimate dehydrogenase gene”. Examples of theelectron donor can include NADH and NADPH. Examples of a shikimatedehydrogenase can include the AroE protein, which is encoded by the aroEgene. The nucleotide sequence of the aroE gene native to the E. coliK-12 MG1655 strain is shown as SEQ ID NO: 49, and the amino acidsequence of the AroE protein encoded by this gene is shown as SEQ ID NO:50.

The shikimate dehydrogenase activity can be measured by, for example,incubating the enzyme with a substrate, such as 3-dehydroshikimic acidin the presence of NADPH or NADH, and measuring the enzyme- andsubstrate-dependent oxidation of NADPH or NADH.

Examples of the method for imparting or enhancing an objectivesubstance-producing ability further can include a method of increasingthe activity of an L-cysteine biosynthesis enzyme.

The term “L-cysteine biosynthesis enzyme” can refer to a protein that isinvolved in L-cysteine biosynthesis. A gene encoding the L-cysteinebiosynthesis enzyme can also be referred to as an “L-cysteinebiosynthesis gene”. Examples of the L-cysteine biosynthesis enzyme caninclude proteins that are involved in sulfur utilization. Examples ofthe proteins that are involved in sulfur utilization can include theCysIXHDNYZ proteins and Fpr2 protein, which are encoded by thecysIXHDNYZ genes and fpr2 gene, respectively. CysIXHDNYZ proteins areinvolved specifically in the reduction of inorganic sulfur compoundssuch as sulfate and sulfite. Fpr2 protein may be involved specificallyin electron transport for the reduction of sulfite. Examples of theL-cysteine biosynthesis enzyme can also include O-acetylserine(thiol)-lyase. Examples of O-acetylserine (thiol)-lyase can include CysKprotein, which is encoded by cysK gene. Examples of L-cysteinebiosynthesis enzyme can include those native to various organisms suchas Enterobacteriaceae bacteria and coryneform bacteria. Specificexamples of L-cysteine biosynthesis enzyme can include the CysIXHDNYZproteins, Fpr2 protein, and CysK protein native to C. glutamicum. Thenucleotide sequences of the cysIXHDNYZ genes and fpr2 gene native to theC. glutamicum ATCC 13869 are shown as SEQ ID NOS: 88, 90, 92, 94, 96,98, 100, and 102, respectively, and the amino acid sequences of theproteins encoded by these genes are shown as SEQ ID NOS: 89, 91, 93, 95,97, 99, 101, and 103, respectively. The activity of one L-cysteinebiosynthesis enzyme may be increased, or the activities of two or moreL-cysteine biosynthesis enzymes may be increased. For example, theactivities of one or more of the CysIXHDNYZ proteins, Fpr2 protein, andCysK protein may be increased, or the activities of one or more of theCysIXHDNYZ proteins and Fpr2 protein may be increased.

The activity of an L-cysteine biosynthesis enzyme can be increased by,for example, increasing the expression of a gene encoding the L-cysteinebiosynthesis enzyme, such as the cysIXHDNYZ genes, fpr2 gene, and cysKgene.

The expression of an L-cysteine biosynthesis gene can be increased by,for example, modifying, such as increasing or reducing, the activity ofan expression regulator of the gene. That is, the expression of anL-cysteine biosynthesis gene can be increased by, for example,increasing the activity of a positive expression regulator, such as anactivator, of the gene. Also, the expression of an L-cysteinebiosynthesis gene can be increased by, for example, reducing theactivity of a negative expression regulator, such as a repressor, of thegene. Such a regulator can also be referred to as a “regulator protein”.A gene encoding such a regulator can also be referred to as a “regulatorgene”.

Examples of such an activator can include the CysR and SsuR proteins,which are encoded by the cysR and ssuR genes, respectively. An increasedactivity of the CysR protein may result in increased expression of oneor more of the cysIXHDNYZ genes, fpr2 gene, and ssuR gene. Also, anincreased activity of the SsuR protein may result in increasedexpression of gene(s) involved in utilization of organic sulfurcompounds. Examples of such an activator can include those native tovarious organisms such as Enterobacteriaceae bacteria and coryneformbacteria. Specific examples of such an activator can include the CysRand SsuR proteins native to C. glutamicum. The nucleotide sequences ofthe cysR gene (NCgl0120) and ssuR gene native to the C. glutamicum ATCC13869 strain are shown as SEQ ID NOS: 104 and 106, respectively, and theamino acid sequences of the proteins encoded by these genes are shown asSEQ ID NOS: 105 and 107, respectively. The activity or activities ofeither one or both of the CysR protein and SsuR protein may beincreased. For example, the activity of at least the CysR protein may beincreased. The activity of such an activator can be increased by, forexample, increasing the expression of a gene encoding the activator.

An example of such a repressor is the McbR protein, which is encoded bythe mcbR gene. A reduced activity of the McbR protein may result inincreased expression of one or more of the cysR and ssuR genes, andthereby may further result in increased expression of one or more of thecysIXHDNYZ genes and fpr2 gene. The activity of such a repressor can bereduced by, for example, reducing the expression of a gene encoding therepressor or by disrupting a gene encoding the repressor.

That is, specifically, the activity of an L-cysteine biosynthesis enzymecan be increased by, for example, increasing the expression of one ormore of the cysIXHDNYZ genes, fpr2 gene, cysR gene, and ssuR gene.Therefore, the phrase “the activity of an L-cysteine biosynthesis enzymeis increased” may mean that, for example, the expression of one or moreof the cysIXHDNYZ genes, fpr2 gene, cysR gene, and ssuR gene isincreased. For example, the expression of at least the cysR gene may beincreased. Also, for example, the expression of all of these genes maybe increased. The expression of one or more of the cysIXHDNYZ genes,fpr2 gene, and ssuR gene may be increased by increasing the expressionof cysR gene.

Examples of the method for imparting or enhancing an objectivesubstance-producing ability further can include a method of reducing theactivity of the NCgl2048 protein.

The term “NCgl2048 protein” can refer to a protein encoded by a NCgl2048gene. Examples of a NCgl2048 protein can include those native to variousorganisms such as Enterobacteriaceae bacteria and coryneform bacteria.Specific examples of a NCgl2048 protein can include the NCgl2048 proteinnative to C. glutamicum. The nucleotide sequence of the NCgl2048 genenative to the C. glutamicum ATCC 13869 strain is shown as SEQ ID NO:119, and the amino acid sequence of the protein encoded by this gene isshown as SEQ ID NO: 120. Incidentally, the original function of theNCgl2048 protein regarding conservative variants described herein maymean the function of the protein having the amino acid sequence shown asSEQ ID NO: 120, or may also mean a property that a reduction in theactivity of the protein in a microorganism provides an increasedproduction of an objective substance.

Examples of the method for imparting or enhancing an objectivesubstance-producing ability further can include a method of reducing theactivity of enolase.

The term “enolase” can refer to a protein that has the activity ofcatalyzing the reaction of dehydrating 2-phospho-D-glyceric acid togenerate phosphoenolpyruvic acid (EC 4.2.1.11). This activity can alsobe referred to as “enolase activity”. Enolase can also be referred to as“phosphopyruvate hydratase”. A gene encoding enolase can also bereferred to as an “enolase gene”. Examples of enolase can include theEno protein, which is encoded by the eno gene. Examples of enolase suchas the Eno protein can include those native to various organisms such asEnterobacteriaceae bacteria and coryneform bacteria. Specific examplesof enolase can include the Eno protein native to C. glutamicum. Thenucleotide sequence of the eno gene (NCgl0935) native to the C.glutamicum ATCC 13869 strain is shown as SEQ ID NO: 128, and the aminoacid sequence of the Eno protein encoded by this gene is shown as SEQ IDNO: 129.

The enolase activity can be measured by, for example, incubating theenzyme with a substrate, such as 2-phospho-D-glyceric acid, andmeasuring the enzyme- and substrate-dependent generation ofphosphoenolpyruvic acid.

Examples of the method for imparting or enhancing an objectivesubstance-producing ability further can include a method of increasingthe activity of S-adenosyl-L-homocysteine hydrolase.

The term “S-adenosyl-L-homocysteine hydrolase” can refer to a proteinthat has the activity of catalyzing the reaction of hydrolyzingS-adenosyl-L-homocysteine (SAH) to generate L-homocysteine and adenosine(EC 3.3.1.1). This activity can also be referred to as“S-adenosyl-L-homocysteine hydrolase activity”.S-adenosyl-L-homocysteine hydrolase can also be referred to as“adenosylhomocysteinase”. A gene encoding S-adenosyl-L-homocysteinehydrolase can also be referred to as an “S-adenosyl-L-homocysteinehydrolase gene”. Examples of S-adenosyl-L-homocysteine hydrolase caninclude the SahH protein, which is encoded by the sahH gene. Examples ofS-adenosyl-L-homocysteine hydrolase such as the SahH protein can includethose native to various organisms such as yeast, Streptomyces bacteria,and coryneform bacteria. Specific examples of S-adenosyl-L-homocysteinehydrolase can include the SahH protein native to C. glutamicum. Thenucleotide sequence of the sahH gene (NCgl0719) native to the C.glutamicum ATCC 13869 strain is shown as SEQ ID NO: 175, and the aminoacid sequence of the SahH protein encoded by this gene is shown as SEQID NO: 176.

The S-adenosyl-L-homocysteine hydrolase activity can be measured by, forexample, incubating the enzyme with a substrate, such asS-adenosyl-L-homocysteine, and DTNB (5,5′-Dithiobis(2-nitrobenzoicacid), and measuring the product, such as homocysteine, -dependentgeneration of TNB (5-Mercapto-2-nitrobenzoic acid) at 412 nm (J MolMicrobiol Biotechnol 2008, 15: 277-286).

Examples of the method for imparting or enhancing an objectivesubstance-producing ability further can include a method of reducing theactivity of AICAR formyltransferase/IMP cyclohydrolase or modifying agene encoding AICAR formyltransferase/IMP cyclohydrolase so as to havethe “specific mutation” described later.

The term “AICAR formyltransferase/IMP cyclohydrolase” can refer to AICARformyltransferase and/or IMP cyclohydrolase, that is, either one or bothof AICAR formyltransferase and IMP cyclohydrolase. The term “AICARformyltransferase” can refer to a protein that has the activity ofcatalyzing the reaction of converting5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide (AICAR) and10-formyltetrahydrofolate into5-formamido-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide (FAICAR) andtetrahydrofolate (EC 2.1.2.3). This activity can also be referred to as“AICAR formyltransferase activity”. The term “IMP cyclohydrolase” canrefer to a protein that has the activity of catalyzing the reaction ofdehydrating FAICAR to generate IMP (EC 3.5.4.10). This activity can alsobe referred to as “IMP cyclohydrolase activity”. A gene encoding AICARformyltransferase/IMP cyclohydrolase can also be referred to as an“AICAR formyltransferase/IMP cyclohydrolase gene”. AICARformyltransferase and IMP cyclohydrolase may be encoded as abifunctional enzyme. Hence, the term “AICAR formyltransferase/IMPcyclohydrolase” can specifically refer to bifunctional AICARformyltransferase/IMP cyclohydrolase, i.e. a protein having both theAICAR formyltransferase activity and IMP cyclohydrolase activity.Examples of AICAR formyltransferase/IMP cyclohydrolase can include thePurH protein, which is bifunctional AICAR formyltransferase/IMPcyclohydrolase encoded by the purH gene. Examples of AICARformyltransferase/IMP cyclohydrolase such as the PurH protein caninclude those native to various organisms such as Enterobacteriaceaebacteria and coryneform bacteria. Specific examples of AICARformyltransferase/IMP cyclohydrolase can include the PurH protein nativeto C. glutamicum. The nucleotide sequence of the purH gene (NCgl0827)native to the C. glutamicum ATCC 13869 strain is shown as SEQ ID NO:177, and the amino acid sequence of the PurH protein encoded by thisgene is shown as SEQ ID NO: 178.

The AICAR formyltransferase/IMP cyclohydrolase activity can be measuredby, for example, incubating the enzyme with a substrate, such as AICARand 10-formyltetrahydrofolate for AICAR formyltransferase; FAICAR forIMP cyclohydrolase, and measuring the enzyme- and substrate-dependentgeneration of the corresponding product, such as FAICAR ortetrahydrofolate for AICAR formyltransferase; IMP for IMPcyclohydrolase. Generation of tetrahydrofolate can be measured on thebasis of absorbance at 298 nm (Rayl E A, et al (1996) JBC 271:2225-33).Furthermore, the AICAR formyltransferase activity and the IMPcyclohydrolase activity can be collectively measured by, for example,incubating the enzyme with the substrate for AICAR formyltransferase,such as AICAR and 10-formyltetrahydrofolate, and measuring the enzyme-and substrate-dependent generation of the product for IMPcyclohydrolase, such as IMP. It is sufficient that AICARformyltransferase/IMP cyclohydrolase has the AICAR formyltransferase/IMPcyclohydrolase activity that is measured under at least one appropriatecondition. In other words, it is sufficient that the microorganism ismodified so that the activity of AICAR formyltransferase/IMPcyclohydrolase is reduced when the activity is measured under at leastone appropriate condition. Incidentally, it is also sufficient that allthe other proteins referred to herein have the respective activitiesthat are each measured under at least one appropriate condition.

Methods for reducing the activity of a protein such as AICARformyltransferase/IMP cyclohydrolase will be explained herein. Theactivity of AICAR formyltransferase/IMP cyclohydrolase can be reducedby, for example, attenuating the expression of a gene encoding AICARformyltransferase/IMP cyclohydrolase, or disrupting a gene encodingAICAR formyltransferase/IMP cyclohydrolase. Furthermore, in anembodiment, the activity of AICAR formyltransferase/IMP cyclohydrolasemay also be reduced by, for example, modifying a gene encoding AICARformyltransferase/IMP cyclohydrolase so as to have the “specificmutation”. Such methods for reducing the activity of AICARformyltransferase/IMP cyclohydrolase may be used independently or in anarbitrary combination.

The microorganism may be modified so that a gene encoding AICARformyltransferase/IMP cyclohydrolase has the “specific mutation”.

The “specific mutation” is a mutation that results in improving anobjective substance-producing ability of the microorganism. The term“specific mutation” in reference to the AICAR formyltransferase/IMPcyclohydrolase gene can refer to a change in the nucleotide sequence ofthe AICAR formyltransferase/IMP cyclohydrolase gene. The “specificmutation” can provide a change in the amino acid sequence of the encodedAICAR formyltransferase/IMP cyclohydrolase. Accordingly, the term“specific mutation” may also be used for AICAR formyltransferase/IMPcyclohydrolase as a term referring to a change in the amino acidsequence of AICAR formyltransferase/IMP cyclohydrolase provided by the“specific mutation” in the AICAR formyltransferase/IMP cyclohydrolasegene. That is, the expression “an AICAR formyltransferase/IMPcyclohydrolase gene has the “specific mutation”” may be read as thatAICAR formyltransferase/IMP cyclohydrolase encoded by the gene has the“specific mutation”.

AICAR formyltransferase/IMP cyclohydrolase having the “specificmutation” can also be referred to as “mutant AICAR formyltransferase/IMPcyclohydrolase”. A gene encoding a mutant AICAR formyltransferase/IMPcyclohydrolase, that is, an AICAR formyltransferase/IMP cyclohydrolasegene having the “specific mutation”, can also be referred to as “mutantAICAR formyltransferase/IMP cyclohydrolase gene”.

AICAR formyltransferase/IMP cyclohydrolase not having the “specificmutation” can also be referred to as a “wild-type AICARformyltransferase/IMP cyclohydrolase”. A gene encoding a wild-type AICARformyltransferase/IMP cyclohydrolase, that is, an AICARformyltransferase/IMP cyclohydrolase gene not having the “specificmutation”, can also be referred to as “wild-type AICARformyltransferase/IMP cyclohydrolase gene”. Examples of the wild-typeAICAR formyltransferase/IMP cyclohydrolase gene or wild-type AICARformyltransferase/IMP cyclohydrolase can include, for example, the AICARformyltransferase/IMP cyclohydrolase genes or AICARformyltransferases/IMP cyclohydrolases exemplified above andconservative variants thereof.

The “specific mutation” is not particularly limited, so long as themutation improves an objective substance-producing ability of themicroorganism. The “specific mutation” may be, for example, a mutationfor reducing the activity of AICAR formyltransferase/IMP cyclohydrolase.The “specific mutation” may also be, for example, a mutation forincreasing the intracellular concentration of AICAR.

Specific examples of the “specific mutation” can include a mutation thatresults in the serine residue at position 37 (S37) of the encoded AICARformyltransferase/IMP cyclohydrolase being replaced with another aminoacid residue.

In the mutation at “S37”, the amino acid residue after the modificationmay be any amino acid residue other than the amino acid residue beforethe modification, which is at least a residue other than a serineresidue, so long as the mutation improves an objectivesubstance-producing ability of the microorganism. Examples of the aminoacid residue after modification can include K (Lys), R (Arg), H (His), A(Ala), V (Val), L (Leu), I (Ile), G (Gly), T (Thr), P (Pro), F (Phe), W(Trp), Y (Tyr), C (Cys), M (Met), D (Asp), E (Glu), N (Asn), and Q(Gln). Particular examples of the amino acid residue after modificationcan include F (Phe). That is, particular examples of the “specificmutation” can include a mutation that results in replacing S37 with F(S37F mutation).

“S37” in an arbitrary wild-type AICAR formyltransferase/IMPcyclohydrolase can refer to an amino acid residue corresponding to theglutamic acid residue at position 37 of the amino acid sequence shown asSEQ ID NO: 178. The descriptions regarding the mutations at “L198” or“E199” for OMT, such as those that define the absolute positionsthereof, can be applied mutatis mutandis to the mutation at “S37” forAICAR formyltransferase/IMP cyclohydrolase, provided that the amino acidsequence shown in SEQ ID NO: 178” is used as the reference sequence ofthe wild-type protein.

Methods for modifying a microorganism so that the AICARformyltransferase/IMP cyclohydrolase gene has the “specific mutation”are not particularly limited. The expression “a microorganism ismodified so that a gene encoding AICAR formyltransferase/IMPcyclohydrolase has the “specific mutation”” may specifically mean thatthe microorganism is modified so as to have a mutant AICARformyltransferase/IMP cyclohydrolase gene instead of a native wild-typeAICAR formyltransferase/IMP cyclohydrolase gene. The expression “amicroorganism has a mutant AICAR formyltransferase/IMP cyclohydrolasegene instead of a native wild-type AICAR formyltransferase/IMPcyclohydrolase gene” may mean that the microorganism has the mutantAICAR formyltransferase/IMP cyclohydrolase gene while it no longer hasthe normally-functional native wild-type AICAR formyltransferase/IMPcyclohydrolase gene, that is, the native wild-type AICARformyltransferase/IMP cyclohydrolase gene has been modified so as not tonormally function. It is sufficient that the native wild-type AICARformyltransferase/IMP cyclohydrolase gene has been modified in such amanner that an objective substance-producing ability of themicroorganism is improved. The phrase “native wild-type AICARformyltransferase/IMP cyclohydrolase gene” can refer to a wild-typeAICAR formyltransferase/IMP cyclohydrolase gene inherently present inthe microorganism. That is, a microorganism can be modified so that theAICAR formyltransferase/IMP cyclohydrolase gene has the “specificmutation” by, for example, introducing a mutant AICARformyltransferase/IMP cyclohydrolase gene into the microorganism. Insuch a case, the native wild-type AICAR formyltransferase/IMPcyclohydrolase gene on the chromosome or the like of the microorganismshould be modified, e.g. disrupted or deleted, in such a manner that anobjective substance-producing ability of the microorganism is improvedin combination with the introduction of the mutant AICARformyltransferase/IMP cyclohydrolase gene. For example, the nativewild-type AICAR formyltransferase/IMP cyclohydrolase gene may bereplaced with the mutant AICAR formyltransferase/IMP cyclohydrolasegene, or may be disrupted or deleted independently from the introductionof the mutant AICAR formyltransferase/IMP cyclohydrolase gene.Alternatively, the microorganism can also be modified so that the AICARformyltransferase/IMP cyclohydrolase gene has the “specific mutation”by, for example, introducing the “specific mutation” into a wild-typeAICAR formyltransferase/IMP cyclohydrolase gene, such as the nativewild-type AICAR formyltransferase/IMP cyclohydrolase gene, on thechromosome or the like of the microorganism. A mutation can beintroduced into a gene on a chromosome or the like by, for example,natural mutation, mutagenesis treatment, or genetic engineering.

A mutant AICAR formyltransferase/IMP cyclohydrolase gene can be obtainedby, for example, modifying a wild-type AICAR formyltransferase/IMPcyclohydrolase gene so that AICAR formyltransferase/IMP cyclohydrolaseencoded thereby has the “specific mutation”. The wild-type AICARformyltransferase/IMP cyclohydrolase gene to be modified can be obtainedby, for example, cloning from an organism having the wild-type AICARformyltransferase/IMP cyclohydrolase gene, or chemical synthesis. Thewild-type AICAR formyltransferase/IMP cyclohydrolase gene to be modifiedmay or may not be derived from the microorganism from which themicroorganism is derived. Alternatively, a mutant AICARformyltransferase/IMP cyclohydrolase gene can also be obtained withoutusing a wild-type AICAR formyltransferase/IMP cyclohydrolase gene. Forexample, a mutant AICAR formyltransferase/IMP cyclohydrolase gene may bedirectly obtained by, for example, cloning from an organism having themutant AICAR formyltransferase/IMP cyclohydrolase gene, or chemicalsynthesis. The obtained mutant AICAR formyltransferase/IMPcyclohydrolase gene may be further modified before use. Genes can bemodified by using a known method. For example, an objective mutation canbe introduced into a target site of DNA by the site-specific mutagenesismethod.

The protein of which the activity is to be modified can be appropriatelychosen depending on the type of biosynthesis pathway via which anobjective substance is produced and on the types and activities of theproteins inherently present in the chosen microorganism. For example,when vanillin is produced by bioconversion of protocatechuic acid, itmay be preferable to enhance the activity or activities of one or moreof OMT, ACAR, PPT, and the protocatechuic acid uptake system. Also, whenvanillin is produced by bioconversion of protocatechualdehyde, it may bepreferable to enhance the activity of OMT. The microorganism has beenmodified to have a Bacteroidetes OMT gene, and thus at least OMTactivity may be enhanced.

The genes and proteins used for breeding a microorganism having anobjective substance-producing ability may have, for example, theabove-exemplified or other known nucleotide sequences and amino acidsequences, respectively. Also, the genes and proteins used for breedinga microorganism having an objective substance-producing ability may beconservative variants of the genes and proteins exemplified above, suchas genes and proteins having the above-exemplified or other knownnucleotide sequences and amino acid sequences, respectively.Specifically, for example, the genes used for breeding a microorganismhaving an objective substance-producing ability may each be a geneencoding a protein having the amino acid sequence exemplified above orthe amino acid sequence of a known protein, but which can includesubstitution, deletion, insertion, and/or addition of one or severalsome amino acid residues at one or several positions, so long as theoriginal function of the protein, such as its enzymatic activity,transporter activity, etc., is maintained. As for conservative variantsof genes and proteins, the descriptions concerning conservative variantsof the OMT gene and OMT described herein can be applied mutatismutandis.

<1-2> Introduction of O-Methyltransferase Gene Derived from BacteriumBelonging to Phylum Bacteroidetes

The microorganism can be modified to have an O-methyltransferase (OMT)gene derived from a bacterium belonging to the phylum Bacteroidetes(Bacteroidetes OMT gene), such as wild-type OMT genes and mutant OMTgenes described herein. A microorganism having an OMT gene can also bereferred to as a “microorganism having OMT”. Also, a microorganismhaving a mutant OMT gene or a mutant OMT can also be referred to as“microorganism having a mutation in an OMT gene or in OMT”. By modifyinga microorganism to have a Bacteroidetes OMT gene, an objectivesubstance-producing ability of the microorganism can be improved, andthat is, the production of an objective substance by using themicroorganism can be increased. That is, an improved objectivesubstance-producing ability and an increased production of an objectivesubstance can be obtained for the microorganism, as compared with anon-modified strain, e.g. as compared with a strain having an OMT geneother than the Bacteroidetes OMT gene instead of the Bacteroidetes OMTgene. The increase in the production of an objective substance may be anincrease in the absolute degree of production, such as the absoluteamount and absolute yield, of the objective substance, or may be in therelative degree of production, such as relative amount and relativeyield, of the objective substance with respect to that of a by-product.Examples of the by-product can include, for example, isovanillic acidand isovanillin for vanillic acid or vanillin production.

The microorganism can be obtained by modifying a microorganism having anobjective substance-producing ability to have a Bacteroidetes OMT gene.The microorganism can also be obtained by modifying a microorganism tohave a Bacteroidetes OMT gene, and then imparting an objectivesubstance-producing ability to the microorganism or enhancing anobjective substance-producing ability of the microorganism. In addition,the microorganism may have an objective substance-producing ability as aresult of a modification to the microorganism so that it has aBacteroidetes OMT gene, or as a result of a combination of amodification to the microorganism so that it has a Bacteroidetes OMTgene and other modification(s) for imparting or enhancing an objectivesubstance-producing ability. The modifications for constructing themicroorganism can be performed in an arbitrary order.

The term “O-methyltransferase (OMT)” can refer to a protein that has theactivity of catalyzing the reaction of methylating hydroxyl group of asubstance in the presence of a methyl group donor (EC 2.1.1.68 etc.).This activity can also be referred to as an “OMT activity”. A geneencoding OMT can also be referred to as an “OMT gene”. OMT can have arequired substrate specificity depending on the specific biosynthesispathway via which an objective substance is produced in the method asdescribed herein. For example, when an objective substance is producedvia the conversion of protocatechuic acid into vanillic acid, OMT thatis specific for at least protocatechuic acid can be used. Also, forexample, when an objective substance is produced via the conversion ofprotocatechualdehyde into vanillin, OMT that is specific for at leastprotocatechualdehyde can be used. That is, specifically, the term“O-methyltransferase (OMT)” can refer to a protein that has the activityof catalyzing the reaction of methylating protocatechuic acid and/orprotocatechualdehyde in the presence of a methyl group donor to generatevanillic acid and/or vanillin, that is, methylation of hydroxyl group atthe meta-position. OMT may use both protocatechuic acid andprotocatechualdehyde as the substrate, but is not necessarily limitedthereto. Also, when ferulic acid, 4-vinylguaiacol, or 4-ethylguaiacol isproduced, OMT that is specific for at least caffeic acid can be used.That is, specifically, the term “O-methyltransferase (OMT)” can alsorefer to a protein that has the activity of catalyzing the reaction ofmethylating caffeic acid in the presence of a methyl group donor togenerate ferulic acid. Examples of the methyl group donor can includeS-adenosylmethionine (SAM).

OMT may also catalyze the reaction of methylating protocatechuic acidand/or protocatechualdehyde to generate isovanillic acid and/orisovanillin, that is, methylation of hydroxyl group at thepara-position, as a side reaction. OMT may selectively catalyze themethylation of a hydroxyl group at the meta-position. The expression“selectively catalyzing the methylation of hydroxyl group at themeta-position” can mean that OMT selectively generates vanillic acidfrom protocatechuic acid and/or that OMT selectively generates vanillinfrom protocatechualdehyde. The expression “selectively generatingvanillic acid from protocatechuic acid” may mean that OMT generatesvanillic acid in an amount of, for example, 60% or more, 65% or more,70% or more, 75% or more, 80% or more, 85% or more, 90% or more, or 95%or more, with respect to the total amount of vanillic acid andisovanillic acid in terms of molar ratio, when OMT is allowed to act onprotocatechuic acid. This ratio, that is, ratio of the amount ofvanillic acid with respect to the total amount of vanillic acid andisovanillic acid, can also be referred to as “VA/(VA+iVA) ratio”. Also,the expression “selectively generating vanillic acid fromprotocatechualdehyde” can mean that OMT generates vanillin in an amountof, for example, 60% or more, 65% or more, 70% or more, 75% or more, 80%or more, 85% or more, 90% or more, or 95% or more, with respect to thetotal amount of vanillin and isovanillin in terms of molar ratio, whenOMT is allowed to act on protocatechualdehyde. This ratio, that is,ratio of the amount of vanillin with respect to the total amount ofvanillin and isovanillin, can also be referred to as “Vn/(Vn+iVn)ratio”.

The OMT activity can be measured by, for example, incubating the enzymewith a substrate, such as protocatechuic acid or protocatechualdehyde,in the presence of SAM, and measuring the enzyme- andsubstrate-dependent generation of the corresponding product, such asvanillic acid or vanillin) (WO2013/022881A1). Furthermore, by measuringthe generation of the corresponding by-product, such as isovanillic acidor isovanillin, under the same conditions, and comparing the generationof the by-product with the generation of the product, it can bedetermined whether OMT selectively generates the product.

The phrase “OMT gene derived from a bacterium belonging to the phylumBacteroidetes (Bacteroidetes OMT gene)” can refer to a gene encoding OMTderived from or native to a bacterium belonging to the phylumBacteroidetes. Such OMT can also be referred to as “Bacteroidetes OMT”.The term “OMT derived from or native to a bacterium belonging to thephylum Bacteroidetes (Bacteroidetes OMT)” collectively can refer to OMTsfound in Bacteroidetes bacteria, that is, bacteria belonging to thephylum Bacteroidetes, and variations thereof within a specific range,such as conservative variants and specific mutants described below.

Examples of the Bacteroidetes bacteria can include bacteria belonging tothe genus Niastella, Terrimonas, Chitinophaga, or the like(International Journal of Systematic and Evolutionary Microbiology(2007), 57, 1828-1833). Examples of the Niastella bacteria can includeNiastella koreensis. That is, examples of the Bacteroidetes OMT gene andthe Bacteroidetes OMT can include the OMT gene and OMT native toNiastella koreensis, respectively. The nucleotide sequence of the OMTgene native to Niastella koreensis is shown as SEQ ID NO: 140, and theamino acid sequence of OMT encoded by this gene is shown as SEQ ID NO:141. That is, the Bacteroidetes OMT gene may be, for example, a genehaving the nucleotide sequence shown as SEQ ID NO: 140. Also, theBacteroidetes OMT may be, for example, a protein having the amino acidsequence shown as SEQ ID NO: 141. The expression “a gene or protein hasa nucleotide or amino acid sequence” encompasses when a gene or proteinincludes the nucleotide or amino acid sequence, and when a gene orprotein includes only the nucleotide or amino acid sequence.

The Bacteroidetes OMT gene may be a variant of any of the OMT genesexemplified above, that is, a gene having the nucleotide sequence shownas SEQ ID NO: 140, so long as the original function thereof ismaintained. Similarly, the Bacteroidetes OMT may be a variant of any ofOMTs exemplified above, that is a protein having the amino acid sequenceshown as SEQ ID NO: 141, so long as the original function thereof ismaintained. A variant that maintains the original function thereof canalso be referred to as “conservative variant”. That is, examples of theBacteroidetes OMT gene and the Bacteroidetes OMT further can includesuch conservative variants. Such conservative variants may be or may notbe found in Bacteroidetes bacteria. Examples of the conservativevariants can include, for example, homologues and artificially modifiedversions of the genes and proteins exemplified above.

The expression “the original function is maintained” means that avariant of gene or protein has a function, such as activity or property,corresponding to the function, such as activity or property, of theoriginal gene or protein. The expression “the original function ismaintained” when referring to a gene can mean that a variant of the geneencodes a protein that maintains the original function. That is, theexpression “the original function is maintained” when referring to anOMT gene can mean that the variant of the gene encodes OMT. Theexpression “the original function is maintained” when referring to OMTcan mean that the variant of the protein has OMT activity.

Hereafter, examples of the conservative variants will be explained.

Homologues of the Bacteroidetes OMT gene or homologues of theBacteroidetes OMT can be easily obtained from public databases by, forexample, BLAST search or FASTA search using any of the nucleotidesequences of the OMT genes exemplified above or any of the amino acidsequences of OMTs exemplified above as a query sequence. Furthermore,homologues of the Bacteroidetes OMT gene can be obtained by, forexample, PCR using a chromosome of an organism such as Bacteroidetesbacteria as the template, and oligonucleotides prepared on the basis ofany of the nucleotide sequences of the OMT genes exemplified above asprimers.

The Bacteroidetes OMT gene may encode a protein having any of theaforementioned amino acid sequences, such as the amino acid sequencesshown as SEQ ID NO: 141, but that includes substitution, deletion,insertion, and/or addition of one or several amino acid residues at oneor several positions, so long as the original function is maintained.For example, the encoded protein may have an extended or deletedN-terminus and/or C-terminus. Although the number meant by the term “oneor several” used above may differ depending on the positions of aminoacid residues in the three-dimensional structure of the protein or thetypes of amino acid residues, specifically, it is, for example, 1 to 50,1 to 40, 1 to 30, 1 to 20, 1 to 10, 1 to 5, or 1 to 3.

The aforementioned substitution, deletion, insertion, and/or addition ofone or several amino acid residues can each be a conservative mutationthat maintains the original function of the protein. Typical examples ofthe conservative mutation are conservative substitutions. Theconservative substitution is a mutation wherein substitution takes placemutually among Phe, Trp, and Tyr, if the substitution site is anaromatic amino acid; among Leu, Ile, and Val, if it is a hydrophobicamino acid; between Gln and Asn, if it is a polar amino acid; among Lys,Arg, and His, if it is a basic amino acid; between Asp and Glu, if it isan acidic amino acid; and between Ser and Thr, if it is an amino acidhaving a hydroxyl group. Examples of substitutions considered asconservative substitutions can include, specifically, substitution ofSer or Thr for Ala, substitution of Gln, His, or Lys for Arg,substitution of Glu, Gln, Lys, His, or Asp for Asn, substitution of Asn,Glu, or Gln for Asp, substitution of Ser or Ala for Cys, substitution ofAsn, Glu, Lys, His, Asp, or Arg for Gln, substitution of Gly, Asn, Gln,Lys, or Asp for Glu, substitution of Pro for Gly, substitution of Asn,Lys, Gln, Arg, or Tyr for His, substitution of Leu, Met, Val, or Phe forIle, substitution of Ile, Met, Val, or Phe for Leu, substitution of Asn,Glu, Gln, His, or Arg for Lys, substitution of Ile, Leu, Val, or Phe forMet, substitution of Trp, Tyr, Met, Ile, or Leu for Phe, substitution ofThr or Ala for Ser, substitution of Ser or Ala for Thr, substitution ofPhe or Tyr for Trp, substitution of His, Phe, or Trp for Tyr, andsubstitution of Met, Ile, or Leu for Val. Furthermore, suchsubstitution, deletion, insertion, addition, or the like of amino acidresidues as mentioned above can include a naturally occurring mutationdue to an individual difference, or a difference of species of theorganism from which the gene is derived (mutant or variant).

Furthermore, the Bacteroidetes OMT gene may be a gene encoding a proteinhaving an amino acid sequence having a homology of, for example, 50% ormore, 65% or more, 80% or more, 90% or more, 95% or more, 97% or more,or 99% or more, to the total amino acid sequence of any of theaforementioned amino acid sequences, so long as the original function ismaintained. In addition, in this specification, “homology” is equivalentto “identity”.

Furthermore, the Bacteroidetes OMT gene may be a gene, such as a DNA,that is able to hybridize under stringent conditions with a probe thatcan be prepared from any of the aforementioned nucleotide sequences,such as the nucleotide sequence shown as SEQ ID NO: 140, for example,with a sequence complementary to the whole sequence or a partialsequence of any of the aforementioned nucleotide sequences, so long asthe original function is maintained. The “stringent conditions” canrefer to conditions under which a so-called specific hybrid is formed,and a non-specific hybrid is not formed. Examples of the stringentconditions can include those under which highly homologous DNAshybridize to each other, for example, DNAs not less than 50%, 65%, or80% homologous, not less than 90% homologous, not less than 95%homologous, not less than 97% homologous, or not less than 99%homologous, hybridize to each other, and DNAs less homologous than theabove do not hybridize to each other, or conditions of washing oftypical Southern hybridization, that is, conditions of washing once, or2 or 3 times, at a salt concentration and temperature corresponding to1×SSC, 0.1% SDS at 60° C.; 0.1×SSC, 0.1% SDS at 60° C.; or 0.1×SSC, 0.1%SDS at 68° C.

The probe used for the aforementioned hybridization may be a part of asequence that is complementary to the gene as described above. Such aprobe can be prepared by PCR using oligonucleotides prepared on thebasis of a known gene sequence as primers and a DNA fragment containingany of the aforementioned genes as a template. As the probe, forexample, a DNA fragment having a length of about 300 bp can be used.When a DNA fragment having a length of about 300 bp is used as theprobe, in particular, the washing conditions of the hybridization maybe, for example, 50° C., 2×SSC and 0.1% SDS.

Furthermore, since properties concerning the degeneracy of codonschanges depending on the host, the Bacteroidetes OMT gene can includesubstitution of respective equivalent codons for arbitrary codons. Thatis, the Bacteroidetes OMT gene may be a variant of any of the OMT genesexemplified above due to the degeneracy of the genetic code. Forexample, the Bacteroidetes OMT gene may be a gene modified so that ithas optimal codons according to codon frequencies in the chosen host.Examples of the codon-optimized Bacteroidetes OMT gene can include, forexample, the OMT gene having the nucleotide sequence shown as SEQ ID NO:145, which has been codon-optimized for the codon usage of C.glutamicum.

The percentage of the sequence identity between two sequences can bedetermined by, for example, a mathematical algorithm. Non-limitingexamples of such a mathematical algorithm can include the algorithm ofMyers and Miller (1988) CABIOS 4:11-17, the local homology algorithm ofSmith et al (1981) Adv. Appl. Math. 2:482, the homology alignmentalgorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453, themethod for searching homology of Pearson and Lipman (1988) Proc. Natl.Acad. Sci. 85:2444-2448, and a modified version of the algorithm ofKarlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, such asthat described in Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA90:5873-5877.

By using a program based on such a mathematical algorithm, sequencecomparison, and an alignment for determining the sequence identity canbe performed. The program can be appropriately executed by a computer.Examples of such a program can include, but are not limited to, CLUSTALof PC/Gene program (available from Intelligenetics, Mountain View,Calif.), ALIGN program (Version 2.0), and GAP, BESTFIT, BLAST, FASTA,and TFASTA of Wisconsin Genetics Software Package, Version 8 (availablefrom Genetics Computer Group (GCG), 575 Science Drive, Madison, Wis.,USA). Alignment using these programs can be performed by using, forexample, initial parameters. The CLUSTAL program is well described inHiggins et al. (1988) Gene 73:237-244 (1988), Higgins et al. (1989)CABIOS 5:151-153, Corpet et al. (1988) Nucleic Acids Res. 16:10881-90,Huang et al. (1992) CABIOS 8:155-65, and Pearson et al. (1994) Meth.Mol. Biol. 24:307-331.

In order to obtain a nucleotide sequence homologous to a targetnucleotide sequence, in particular, for example, BLAST nucleotide searchcan be performed by using BLASTN program with score of 100 and wordlength of 12. In order to obtain an amino acid sequence homologous to atarget protein, in particular, for example, BLAST protein search can beperformed by using BLASTX program with score of 50 and word length of 3.See ncbi.nlm.nih.gov for BLAST nucleotide search and BLAST proteinsearch. In addition, Gapped BLAST (BLAST 2.0) can be used in order toobtain an alignment including gap(s) for the purpose of comparison. Inaddition, PSI-BLAST can be used in order to perform repetitive searchfor detecting distant relationships between sequences. See Altschul etal. (1997) Nucleic Acids Res. 25:3389 for Gapped BLAST and PSI-BLAST.When using BLAST, Gapped BLAST, or PSI-BLAST, initial parameters of eachprogram (e.g. BLASTN for nucleotide sequences, and BLASTX for amino acidsequences) can be used. Alignment can also be manually performed.

The sequence identity between two sequences is calculated as the ratioof residues matching in the two sequences when aligning the twosequences so as to fit maximally with each other. The term “identity”between amino acid sequences may specifically mean an identitycalculated by blastp with default scoring parameters (i.e. Matrix,BLOSUM62; Gap Costs, Existence=11, Extension=1; CompositionalAdjustments, Conditional compositional score matrix adjustment), unlessotherwise stated. The term “identity” between nucleotide sequences mayspecifically mean an identity calculated by blastn with default scoringparameters (i.e. Match/Mismatch Scores=1, −2; Gap Costs=Linear), unlessotherwise stated.

The aforementioned descriptions concerning conservative variants of thegenes and proteins can be applied mutatis mutandis to variants ofarbitrary proteins such as objective substance biosynthesis enzymes andgenes encoding them.

Examples of the Bacteroidetes OMT further can include OMTs having a“specific mutation”. Also, examples of the Bacteroidetes OMT genefurther can include OMT genes encoding OMTs having a “specificmutation”. OMT having a “specific mutation” can also be referred to as a“mutant OMT”. A gene encoding a mutant OMT can also be referred to as a“mutant OMT gene”.

OMT not having a “specific mutation” can also be referred to as a“wild-type OMT”. A gene encoding a wild-type OMT can also be referred toas a “wild-type OMT gene”. The term “wild-type” referred to herein isused for convenience to distinguish the “wild-type” OMT from the“mutant” OMT, and the “wild-type” OMT is not limited to those obtainedas natural substances, and can include any OMT not having the “specificmutation”. Examples of the wild-type OMT can include, for example, OMTsexemplified above. In addition, all conservative variants of OMTsexemplified above should be included in wild-type OMTs, provided thatsuch conservative variants do not have the “specific mutation”.

A mutant OMT may be identical to a wild-type OMT, such as OMTsexemplified above and conservative variants thereof, provided that themutant OMT has the “specific mutation”. That is, a mutant OMT may be aprotein having any of the amino acid sequences of wild-type OMTs, buthaving the “specific mutation”. Specifically, a mutant OMT may be, forexample, a protein having the amino acid sequence shown as SEQ ID NO:141, provided that the mutant OMT has the “specific mutation”. Also,specifically, a mutant OMT may be, for example, a protein having theamino acid sequence shown as SEQ ID NO: 141, but that includessubstitution, deletion, insertion, and/or addition of one or severalamino acid residues, provided that the mutant OMT has the “specificmutation”. Also, specifically, a mutant OMT may be, for example, aprotein having an amino acid sequence showing an identity of 50% ormore, 65% or more, or 80% or more, 90% or more, 95% or more, 97% ormore, or 99% or more to the amino acid sequence of SEQ ID NO: 141,provided that the mutant OMT has the “specific mutation”.

In a conservative variant to be used as a wild-type OMT, conservativemutation(s) may occur at position(s) other than the position(s) of the“specific mutation”. That is, in other words, a mutant OMT may be aprotein having any of the amino acid sequences of OMTs exemplifiedabove, but having the “specific mutation” and further includingconservative mutation(s), such as substitution, deletion, insertion,and/or addition of one or several amino acid residues, at position(s)other than the position(s) of the “specific mutation”.

The “specific mutation” may be a mutation effective for production of anobjective substance, such as a mutation resulting in an increase in theVA/(VA+iVA) ratio and/or Vn/(Vn+iVn) ratio of OMT.

Examples of a “specific mutation” can include mutations at the followingamino acid residues: D21, L31, M36, S42, L67, Y90, and P144. The“specific mutation” can be a mutation at one amino acid residue, or canbe a combination of mutations at two or more amino acid residues. Thatis, the “specific mutation” may include, for example, mutations at oneor more of the following amino acid residues: D21, L31, M36, S42, L67,Y90, and P144.

In the aforementioned notation used for defining amino acid residues,the numbers represent the positions in the amino acid sequence shown asSEQ ID NO: 141, and the letters at the left side of the numbersrepresent the amino acid residues at the respective positions in theamino acid sequence shown as SEQ ID NO: 141, that is the amino acidresidues before modification at the respective positions. That is, forexample, “D21” represents D (Asp) residue at position 21 in the aminoacid sequence shown as SEQ ID NO: 141. These amino acid residues in anarbitrary wild-type OMT each can refer to “an amino acid residuecorresponding to the indicated amino acid residue in the amino acidsequence shown as SEQ ID NO: 141”. That is, for example, “D21” in anarbitrary wild-type OMT represents an amino acid residue correspondingto D (Asp) residue at position 21 in the amino acid sequence shown asSEQ ID NO: 141.

In each of the aforementioned mutations, the amino acid residue aftermodification may be any amino acid residue other than the amino acidresidue before modification. Examples of the amino acid residue aftermodification can include K (Lys), R (Arg), H (His), A (Ala), V (Val), L(Leu), I (Ile), G (Gly), S (Ser), T (Thr), P (Pro), F (Phe), W (Trp), Y(Tyr), C (Cys), M (Met), D (Asp), E (Glu), N (Asn), and Q (Gln),provided that the amino acid residues after modification is other thanthe amino acid residue before modification. As the amino acid residuesafter modification, there may be selected those effective for productionof an objective substance, such as those resulting in an increase in theVA/(VA+iVA) ratio and/or Vn/(Vn+iVn) ratio of OMT.

Specific examples of the “specific mutation” can include the followingmutations: D21Y, L31H, M36(K, V), S42C, L67F, Y90(A, C, G, S), andP144(E, G, S, V, Y). That is, the mutations at amino acid residues D21,L31, M36, S42, L67, Y90, and P144 may be, for example, the mutationsD21Y, L31H, M36(K, V), S42C, L67F, Y90(A, C, G, S), and P144(E, G, S, V,Y), respectively. The “specific mutation” may include, for example, oneor more of the following mutations: D21Y, L31H, M36(K, V), S42C, L67F,Y90(A, C, G, S), and P144(E, G, S, V, Y).

In the aforementioned notation for defining mutations, the numbers andthe letters at the left side of the numbers represent the same asdescribed above. In the aforementioned notation for defining mutations,the letters at the right side of the numbers represent the amino acidresidues after modification at the respective positions. That is, forexample, “D21Y” represents a mutation for replacing D (Asp) residue atposition 21 in the amino acid sequence shown as SEQ ID NO: 141 with Y(Tyr) residue. Also, for example, M36(K, V) represents a mutation forreplacing M (Met) residue at position 36 in the amino acid sequenceshown as SEQ ID NO: 141 with K (Lys) or V (Val) residue. These mutationsin an arbitrary wild-type OMT each can refer to “a mutationcorresponding to the indicated mutation in the amino acid sequence shownas SEQ ID NO: 141”. A “mutation corresponding to a mutation at the aminoacid residue at position X in the amino acid sequence shown in SEQ IDNO: 141” should be read as a mutation at an amino acid residuecorresponding to the amino acid residue at position X in the amino acidsequence shown in SEQ ID NO: 141”. That is, for example, “D21Y” in anarbitrary wild-type OMT represents a mutation for replacing an aminoacid residue corresponding to D (Asp) residue at position 21 in theamino acid sequence shown as SEQ ID NO: 141 with Y (Tyr) residue.

The number of combinations of mutations is not particularly limited.Specific examples of combination of mutations can includeD21Y/M36K/L67F, D21Y/M36K/L67F/Y90A, L31H/M36K/L67F/P144V,L31H/L67F/Y90A, M36K/S42C/L67F, M36K/L67F, M36K/L67F/Y90A,M36K/L67F/Y90A/P144E, M36K/L67F/Y90C, M36K/L67F/Y90C/P144V,M36K/L67F/Y90G, M36K/L67F/Y90S/P144G, M36K/L67F/P144S, M36K/L67F/P144Y,M36K/Y90A/P144V, M36K/P144E, and M36V/L67F/P144S. That is, the “specificmutation” can include, for example, any of these combinations.

In the aforementioned notation used for defining combinations, thenumbers and the letters at the left and right sides of the numbersrepresent the same as described above. In the aforementioned notationused for defining combinations, two or more mutations noted together andinserted with “I” represent a double or more multiple mutation. That is,for example, “M36K/P144E” represents a double mutation of M36K andP144E.

The “position X” in an amino acid sequence can refer to the X-thposition counted from the N-terminus of the amino acid sequence, and theamino acid residue of the N-terminus is the amino acid residue atposition 1. The positions defined in the aforementioned mutationsrepresent relative positions, and their absolute positions may shift dueto deletion, insertion, addition, and so forth of amino acid residue(s).For example, if one amino acid residue is deleted or inserted at aposition on the N-terminus side of position X in the amino acid sequenceshown as SEQ ID NO: 141, the amino acid residue originally at position Xis relocated at position X−1 or X+1, however, it is still regarded asthe “amino acid residue corresponding to the amino acid residue atposition X of the amino acid sequence shown as SEQ ID NO: 141”.

The amino acid residues before modifications defined in theabove-exemplified mutations are typical ones, but may not necessarily belimited thereto. For example, the “amino acid residue corresponding toD21” may typically be a D (Asp) residue, however, it may not necessarilybe a D (Asp) residue. That is, when a wild-type OMT has an amino acidsequence other than that shown in SEQ ID NO: 141, the “amino acidresidue corresponding to D21” may be an amino acid residue other than D(Asp) residue. Therefore, the “mutation corresponding to D21Y” caninclude not only a mutation, when the “amino acid residue correspondingto D21” is a D (Asp) residue, for replacing this D (Asp) residue with Y(Tyr) residue, but can also include a mutation, when the “amino acidresidue corresponding to D21” is K (Lys), R (Arg), H (His), A (Ala), V(Val), L (Leu), I (Ile), G (Gly), S (Ser), T (Thr), P (Pro), F (Phe), W(Trp), C (Cys), M (Met), E (Glu), N (Asn), or Q (Gln) residue, forreplacing this residue with Y (Tyr) residue. The same can be appliedmutatis mutandis to the other mutations.

In the amino acid sequence of an arbitrary OMT, which amino acid residueis an “amino acid residue corresponding to the amino acid residue atposition X in the amino acid sequence shown in SEQ ID NO: 141” can bedetermined by aligning the amino acid sequence of the arbitrary OMT andthe amino acid sequence of SEQ ID NO: 141. The alignment can beperformed by, for example, using known gene analysis software. Specificexamples of such software can include DNASIS produced by HitachiSolutions, GENETYX produced by Genetyx, and so forth (Elizabeth C. Tyleret al., Computers and Biomedical Research, 24 (1) 72-96, 1991; Barton GJ et al., Journal of Molecular Biology, 198 (2), 327-37, 1987).

A mutant OMT gene can be obtained by, for example, modifying a wild-typeOMT gene so that OMT encoded thereby has the “specific mutation”. Thewild-type OMT gene to be modified can be obtained by, for example,cloning from an organism having the wild-type OMT gene, or chemicalsynthesis. Furthermore, a mutant OMT gene can also be obtained withoutusing a wild-type OMT gene. For example, a mutant OMT gene may bedirectly obtained by chemical synthesis. The obtained mutant OMT genemay be used as it is, or may be further modified before use.

Genes can be modified using a known method. For example, an objectivemutation can be introduced into a target site of DNA by thesite-specific mutagenesis method. Examples of the site-specificmutagenesis method can include a method using PCR (Higuchi, R., 61, inPCR Technology, Erlich, H. A. Eds., Stockton Press (1989); Carter P.,Meth. In Enzymol., 154, 382 (1987)), and a method of using a phage(Kramer, W. and Frits, H. J., Meth. in Enzymol., 154, 350 (1987);Kunkel, T. A. et al., Meth. in Enzymol., 154, 367 (1987)).

A microorganism can be modified to have a Bacteroidetes OMT gene, suchas wild-type OMT genes and mutant OMT genes described above, byintroducing the gene into the microorganism. Alternatively, when amicroorganism already has an OMT gene on the chromosome thereof or thelike, the microorganism can also be modified to have a mutant OMT geneby introducing the “specific mutation” into the OMT gene on thechromosome or the like. A mutation can be introduced into a gene on achromosome or the like by, for example, natural mutation, mutagenesistreatment, or genetic engineering.

Methods for introducing a Bacteroidetes OMT gene into a microorganismare not particularly limited. It is sufficient that a Bacteroidetes OMTgene is able to be expressed by the microorganism. The microorganism mayhave one copy of a Bacteroidetes OMT gene, or may have two or morecopies of a Bacteroidetes OMT gene. The microorganism may have one kindof Bacteroidetes OMT gene, or may have two or more kinds ofBacteroidetes OMT genes. A Bacteroidetes OMT gene can be introduced intoa microorganism by the same way as that for introduction of a genedescribed below in the “Methods for increasing activity of protein”.

The microorganism may or may not have an OMT gene other than theBacteroidetes OMT gene.

<1-3> Methods for Increasing Activity of Protein

Hereafter, the methods for increasing the activity of a protein,including methods for introduction of a gene, will be explained.

The expression “the activity of a protein is increased” means that theactivity of the protein is increased as compared with a non-modifiedstrain. Specifically, the expression “the activity of a protein isincreased” can mean that the activity of the protein per cell isincreased as compared with that of a non-modified strain. The term“non-modified strain” or “strain of a non-modified microorganism” canrefer to a control strain that has not been modified so that theactivity of an objective protein is increased. Examples of thenon-modified strain can include a wild-type strain and parent strain.Specific examples of the non-modified strain can include the respectivetype strains of the species of microorganisms. Specific examples of thenon-modified strain can also include strains exemplified above inrelation to the description of microorganisms. That is, in anembodiment, the activity of a protein may be increased as compared witha type strain, i.e. the type strain of the species to which amicroorganism belongs. In another embodiment, the activity of a proteinmay also be increased as compared with the C. glutamicum ATCC 13869strain. In another embodiment, the activity of a protein may also beincreased as compared with the C. glutamicum ATCC 13032 strain. Inanother embodiment, the activity of a protein may also be increased ascompared with the E. coli K-12 MG1655 strain. The phrase “the activityof a protein is increased” may also be expressed as “the activity of aprotein is enhanced”. More specifically, the expression “the activity ofa protein is increased” may mean that the number of molecules of theprotein per cell is increased, and/or the function of each molecule ofthe protein is increased as compared with those of a non-modifiedstrain. That is, the term “activity” in the expression “the activity ofa protein is increased” is not limited to the catalytic activity of theprotein, but may also mean the transcription amount of a gene, that is,the amount of mRNA, encoding the protein, or the translation amount ofthe protein, that is, the amount of the protein. Furthermore, the phrase“the activity of a protein is increased” can include not only when theactivity of an objective protein is increased in a strain inherentlyhaving the activity of the objective protein, but also when the activityof an objective protein is imparted to a strain not inherently havingthe activity of the objective protein. Furthermore, so long as theactivity of the protein is eventually increased, the activity of anobjective protein inherently present in a host may be attenuated and/oreliminated, and then an appropriate type of the objective protein may beimparted to the host.

The degree of the increase in the activity of a protein is notparticularly limited, so long as the activity of the protein isincreased as compared with a non-modified strain. The activity of theprotein may be increased to, for example, 1.2 times or more, 1.5 timesor more, 2 times or more, or 3 times or more of that of a non-modifiedstrain. Furthermore, when the non-modified strain does not have theactivity of the objective protein, it is sufficient that the protein isproduced as a result of introduction of the gene encoding the protein,and for example, the protein may be produced to such an extent that theactivity thereof can be measured.

The modification for increasing the activity of a protein can beattained by, for example, increasing the expression of a gene encodingthe protein. The phrase “the expression of a gene is increased” meansthat the expression of the gene is increased as compared with anon-modified strain, such as a wild-type strain and parent strain.Specifically, the phrase “the expression of a gene is increased” maymean that the expression amount of the gene per cell is increased ascompared with that of a non-modified strain. More specifically, thephrase “the expression of a gene is increased” may mean that thetranscription amount of the gene, that is, the amount of mRNA, isincreased, and/or the translation amount of the gene, that is, theamount of the protein expressed from the gene, is increased. The phrase“the expression of a gene is increased” can also be referred to as “theexpression of a gene is enhanced”. The expression of a gene may beincreased to, for example, 1.2 times or more, 1.5 times or more, 2 timesor more, or 3 times or more of that of a non-modified strain.Furthermore, the phrase “the expression of a gene is increased” caninclude not only when the expression amount of an objective gene isincreased in a strain that inherently expresses the objective gene, butalso when the gene is introduced into a strain that does not inherentlyexpress the objective gene, and is expressed therein. That is, thephrase “the expression of a gene is increased” may also mean, forexample, that an objective gene is introduced into a strain that doesnot possess the gene, and is expressed therein.

The expression of a gene can be increased by, for example, increasingthe copy number of the gene.

The copy number of a gene can be increased by introducing the gene intothe chromosome of a host. A gene can be introduced into a chromosome by,for example, using homologous recombination (Miller, J. H., Experimentsin Molecular Genetics, 1972, Cold Spring Harbor Laboratory). Examples ofthe gene transfer method utilizing homologous recombination can include,for example, a method of using a linear DNA such as Red-drivenintegration (Datsenko, K. A., and Wanner, B. L., Proc. Natl. Acad. Sci.USA, 97:6640-6645 (2000)), a method of using a plasmid containing atemperature sensitive replication origin, a method of using a plasmidcapable of conjugative transfer, a method of using a suicide vector nothaving a replication origin that functions in a host, and a transductionmethod using a phage. Only one copy of a gene may be introduced, or twoor more copies of a gene may be introduced. For example, by performinghomologous recombination using a sequence which is present in multiplecopies on a chromosome as a target, multiple copies of a gene can beintroduced into the chromosome. Examples of such a sequence which ispresent in multiple copies on a chromosome can include repetitive DNAs,and inverted repeats located at the both ends of a transposon.Alternatively, homologous recombination may be performed by using anappropriate sequence on a chromosome, such as a gene, unnecessary forthe production of an objective substance as a target. Furthermore, agene can also be randomly introduced into a chromosome by using atransposon or Mini-Mu (Japanese Patent Laid-open (Kokai) No. 2-109985,U.S. Pat. No. 5,882,888, EP 805867 B1).

Introduction of a target gene into a chromosome can be confirmed bySouthern hybridization using a probe having a sequence complementary tothe whole gene or a part thereof, PCR using primers prepared on thebasis of the sequence of the gene, or the like.

Furthermore, the copy number of a gene can also be increased byintroducing a vector containing the gene into a host. For example, thecopy number of a target gene can be increased by ligating a DNA fragmentcontaining the target gene with a vector that functions in a host toconstruct an expression vector of the gene, and transforming the hostwith the expression vector. The DNA fragment containing the target genecan be obtained by, for example, PCR using the genomic DNA of amicroorganism having the target gene as the template. As the vector, avector autonomously replicable in the cell of the host can be used. Thevector can be a multi-copy vector. Furthermore, the vector can have amarker such as an antibiotic resistance gene for selection oftransformant. Furthermore, the vector can have a promoter and/orterminator for expressing the introduced gene. The vector may be, forexample, a vector derived from a bacterial plasmid, a vector derivedfrom a yeast plasmid, a vector derived from a bacteriophage, cosmid,phagemid, or the like. Specific examples of a vector autonomouslyreplicable in Enterobacteriaceae bacteria such as Escherichia coli caninclude, for example, pUC19, pUC18, pHSG299, pHSG399, pHSG398, pBR322,pSTV29 (all of these are available from Takara Bio), pACYC184, pMW219(NIPPON GENE), pTrc99A (Pharmacia), pPROK series vectors (Clontech),pKK233-2 (Clontech), pET series vectors (Novagen), pQE series vectors(QIAGEN), pCold TF DNA (TaKaRa), pACYC series vectors, and the broadhost spectrum vector RSF1010. Specific examples of a vector autonomouslyreplicable in coryneform bacteria can include, for example, pHM1519(Agric. Biol. Chem., 48, 2901-2903 (1984)); pAM330 (Agric. Biol. Chem.,48, 2901-2903 (1984)); plasmids obtained by improving these and having adrug resistance gene; plasmid pCRY30 described in Japanese PatentLaid-open (Kokai) No. 3-210184; plasmids pCRY21, pCRY2KE, pCRY2KX,pCRY31, pCRY3KE, and pCRY3KX described in Japanese Patent Laid-open(Kokai) No. 2-72876 and U.S. Pat. No. 5,185,262; plasmids pCRY2 andpCRY3 described in Japanese Patent Laid-open (Kokai) No. 1-191686;pAJ655, pAJ611, and pAJ1844 described in Japanese Patent Laid-open(Kokai) No. 58-192900; pCG1 described in Japanese Patent Laid-open(Kokai) No. 57-134500; pCG2 described in Japanese Patent Laid-open(Kokai) No. 58-35197; pCG4 and pCG11 described in Japanese PatentLaid-open (Kokai) No. 57-183799; pVK7 described in Japanese PatentLaid-open (Kokai) No. 10-215883; pVK9 described in WO2007/046389; pVS7described in WO2013/069634; and pVC7 described in Japanese PatentLaid-open (Kokai) No. 9-070291.

When a gene is introduced, it is sufficient that the gene can beexpressed by a host. Specifically, it is sufficient that the gene ispresent in a host so that it is expressed under control of a promoterthat functions in the host. The term “a promoter that functions in ahost” can refer to a promoter that shows a promoter activity in thehost. The promoter may be a promoter derived from the host, or aheterogenous promoter. The promoter may be the native promoter of thegene to be introduced, or a promoter of another gene. As the promoter,for example, such a stronger promoter as described herein may also beused.

A terminator for termination of gene transcription may be locateddownstream of the gene. The terminator is not particularly limited solong as it functions in the chosen host. The terminator may be aterminator derived from the host, or a heterogenous terminator. Theterminator may be the native terminator of the gene to be introduced, ora terminator of another gene. Specific examples of the terminator caninclude, for example, T7 terminator, T4 terminator, fd phage terminator,tet terminator, and trpA terminator.

Vectors, promoters, and terminators available in various microorganismsare disclosed in detail in “Fundamental Microbiology Vol. 8, GeneticEngineering, KYORITSU SHUPPAN CO., LTD, 1987”, and those can be used.

Furthermore, when two or more of genes are introduced, it is sufficientthat the genes each can be expressed by a host. For example, all thegenes may be carried by a single expression vector or a chromosome.Furthermore, the genes may be separately carried by two or moreexpression vectors, or separately carried by a single or two or moreexpression vectors and a chromosome. An operon constituted by two ormore genes may also be introduced. The phrase “introducing two or moregenes” can mean, for example, introducing respective genes encoding twoor more kinds of proteins, such as enzymes, introducing respective genesencoding two or more subunits constituting a single protein complex,such as an enzyme complex, and a combination thereof.

The gene to be introduced is not particularly limited so long as itencodes a protein that functions in the host. The gene to be introducedmay be a gene derived from the host, or may be a heterogenous gene. Thegene to be introduced can be obtained by, for example, PCR using primersdesigned on the basis of the nucleotide sequence of the gene, and usingthe genomic DNA of an organism having the gene, a plasmid carrying thegene, or the like as a template. The gene to be introduced may also betotally synthesized, for example, on the basis of the nucleotidesequence of the gene (Gene, 60(1), 115-127 (1987)). The obtained genecan be used as it is, or after being modified as required. That is, avariant of a gene may be obtained by modifying the gene. A gene can bemodified by a known technique. For example, an objective mutation can beintroduced into an objective site of DNA by the site-specific mutationmethod. That is, the coding region of a gene can be modified by thesite-specific mutation method so that a specific site of the encodedprotein includes substitution, deletion, insertion, and/or addition ofamino acid residues. Examples of the site-specific mutation method caninclude the method utilizing PCR (Higuchi, R., 61, in PCR Technology,Erlich, H. A. Eds., Stockton Press (1989); Carter, P., Meth. inEnzymol., 154, 382 (1987)), and the method utilizing phage (Kramer, W.and Frits, H. J., Meth. in Enzymol., 154, 350 (1987); Kunkel, T. A. etal., Meth. in Enzymol., 154, 367 (1987)). Alternatively, a variant of agene may be totally synthesized.

In addition, when a protein functions as a complex made up of aplurality of subunits, a part or all of the plurality of subunits may bemodified, so long as the activity of the protein is eventuallyincreased. That is, for example, when the activity of a protein isincreased by increasing the expression of a gene, the expression of apart or all of the plurality of genes that encode the subunits may beenhanced. It is usually preferable to enhance the expression of all ofthe plurality of genes encoding the subunits. Furthermore, the subunitsconstituting the complex may be derived from a single kind of organismor two or more kinds of organisms, so long as the complex has a functionof the objective protein. That is, for example, genes of the sameorganism encoding a plurality of subunits may be introduced into a host,or genes of different organisms encoding a plurality of subunits may beintroduced into a host.

Furthermore, the expression of a gene can be increased by improving thetranscription efficiency of the gene. In addition, the expression of agene can also be increased by improving the translation efficiency ofthe gene. The transcription efficiency of the gene and the translationefficiency of the gene can be improved by, for example, modifying anexpression control sequence of the gene. The term “expression controlsequence” collectively can refer to sites that affect the expression ofa gene. Examples of the expression control sequence can include, forexample, a promoter, a Shine-Dalgarno (SD) sequence, which can also bereferred to as ribosome binding site (RBS), and a spacer region betweenRBS and the start codon. Expression control sequences can be identifiedby using a promoter search vector or gene analysis software such asGENETYX. These expression control sequences can be modified by, forexample, a method of using a temperature sensitive vector, or the Reddriven integration method (WO2005/010175).

The transcription efficiency of a gene can be improved by, for example,replacing the promoter of the gene on a chromosome with a strongerpromoter. The term “stronger promoter” can refer to a promoter providingan improved transcription of a gene compared with the inherent wild-typepromoter of the gene. Examples of stronger promoters can include, forexample, the known high expression promoters such as T7 promoter, trppromoter, lac promoter, thr promoter, tac promoter, trc promoter, tetpromoter, araBAD promoter, rpoH promoter, msrA promoter, Pm1 promoter(derived from the genus Bifidobacterium), PR promoter, and PL promoter.Examples of stronger promoters usable in coryneform bacteria caninclude, for example, the artificially modified P54-6 promoter (Appl.Microbiol. Biotechnol., 53, 674-679 (2000)), pta, aceA, aceB, adh, andamyE promoters inducible in coryneform bacteria with acetic acid,ethanol, pyruvic acid, or the like, cspB, SOD, and tuf (EF-Tu)promoters, which are potent promoters capable of providing a largeexpression amount in coryneform bacteria (Journal of Biotechnology, 104(2003) 311-323; Appl. Environ. Microbiol., 2005 December; 71(12):8587-96), P2 promoter (position 942-1034 of SEQ ID NO: 108), and P3promoter (SEQ ID NO: 111), as well as lac promoter, tac promoter, andtrc promoter. Furthermore, as the stronger promoter, a highly-activetype of an existing promoter may also be obtained by using variousreporter genes. For example, by making the −35 and −10 regions in apromoter region closer to the consensus sequence, the activity of thepromoter can be enhanced (WO00/18935). Examples of a highly active-typepromoter can include various tac-like promoters (Katashkina J I et al.,Russian Federation Patent Application No. 2006134574). Methods forevaluating the strength of promoters and examples of strong promotersare described in the paper of Goldstein et al. (Prokaryotic Promoters inBiotechnology, Biotechnol. Annu. Rev., 1, 105-128 (1995)), and so forth.

The translation efficiency of a gene can be improved by, for example,replacing the Shine-Dalgarno (SD) sequence, which can also be referredto as ribosome binding site (RBS), for the gene on a chromosome with astronger SD sequence. The term “stronger SD sequence” can refer to a SDsequence that provides an improved translation of mRNA compared with theinherent wild-type SD sequence of the gene. Examples of stronger SDsequences can include, for example, RBS of the gene 10 derived fromphage T7 (Olins P. O. et al, Gene, 1988, 73, 227-235). Furthermore, itis known that substitution, insertion, or deletion of severalnucleotides in a spacer region between RBS and the start codon,especially in a sequence immediately upstream of the start codon(5′-UTR), significantly affects the stability and translation efficiencyof mRNA, and hence, the translation efficiency of a gene can also beimproved by modification.

The translation efficiency of a gene can also be improved by, forexample, modifying codons. For example, the translation efficiency ofthe gene can be improved by replacing a rare codon present in the genewith a more frequently used synonymous codon. That is, the gene to beintroduced may be modified, for example, so as to contain optimal codonsaccording to the frequencies of codons observed in the chosen host.Codons can be replaced by, for example, the site-specific mutationmethod for introducing an objective mutation into an objective site ofDNA. Alternatively, a gene fragment in which objective codons arereplaced may be entirely synthesized. Frequencies of codons in variousorganisms are disclosed in the “Codon Usage Database”(kazusa.or.jp/codon; Nakamura, Y. et al, Nucl. Acids Res., 28, 292(2000)).

Furthermore, the expression of a gene can also be increased byamplifying a regulator that increases the expression of the gene, ordeleting or attenuating a regulator that reduces the expression of thegene.

Such methods for increasing the gene expression as described above maybe used independently or in an arbitrary combination.

Furthermore, the modification that increases the activity of a proteincan also be attained by, for example, enhancing the specific activity ofthe enzyme. Enhancement of the specific activity can also includedesensitization to feedback inhibition. That is, when a protein issubject to feedback inhibition by a metabolite, the activity of theprotein can be increased by mutating a gene or protein in the chosenhost to be desensitized to the feedback inhibition. The phrase“desensitized to feedback inhibition” can include complete eliminationof the feedback inhibition, and attenuation of the feedback inhibition,unless otherwise stated. Also, the phrase “being desensitized tofeedback inhibition”, that is, when feedback inhibition is eliminated orattenuated, can also be referred to as “tolerant to feedbackinhibition”. A protein showing an enhanced specific activity can beobtained by, for example, searching various organisms. Furthermore, ahighly-active type of an existing protein may also be obtained byintroducing a mutation into the existing protein. The mutation to beintroduced may be, for example, substitution, deletion, insertion,and/or addition of one or several amino acid residues at one or severalpositions of the protein. The mutation can be introduced by, forexample, such a site-specific mutation method as mentioned above. Themutation may also be introduced by, for example, a mutagenesistreatment. Examples of the mutagenesis treatment can include irradiationof X-ray, irradiation of ultraviolet, and a treatment with a mutationagent such as N-methyl-N′-nitro-N-nitrosoguanidine (MNNG), ethylmethanesulfonate (EMS), and methyl methanesulfonate (MMS). Furthermore,a random mutation may be induced by directly treating DNA in vitro withhydroxylamine. Enhancement of the specific activity may be independentlyused, or may be used in an arbitrary combination with such methods forenhancing gene expression as mentioned above.

The method for the transformation is not particularly limited, andconventionally known methods can be used. There can be used, forexample, a method of treating recipient cells with calcium chloride soas to increase the permeability thereof for DNA, which has been reportedfor the Escherichia coli K-12 strain (Mandel, M. and Higa, A., J. Mol.Biol., 1970, 53, 159-162), and a method of preparing competent cellsfrom cells which are in the growth phase, followed by transformationwith DNA, which has been reported for Bacillus subtilis (Duncan, C. H.,Wilson, G. A. and Young, F. E., Gene, 1977, 1:153-167). Alternatively, amethod can be used of making DNA-recipient cells into protoplasts orspheroplasts, which can easily take up recombinant DNA, followed byintroducing a recombinant DNA into the DNA-recipient cells, which isknown to be applicable to Bacillus subtilis, actinomycetes, and yeasts(Chang, S. and Choen, S. N., 1979, Mol. Gen. Genet., 168:111-115; Bibb,M. J., Ward, J. M. and Hopwood, O. A., 1978, Nature, 274:398-400;Hinnen, A., Hicks, J. B. and Fink, G. R., 1978, Proc. Natl. Acad. Sci.USA, 75:1929-1933). Furthermore, the electric pulse method reported forcoryneform bacteria (Japanese Patent Laid-open (Kokai) No. 2-207791) canalso be used.

An increase in the activity of a protein can be confirmed by measuringthe activity of the protein.

An increase in the activity of a protein can also be confirmed byconfirming an increase in the expression of a gene encoding the protein.An increase in the expression of a gene can be confirmed by confirmingan increase in the transcription amount of the gene, or by confirming anincrease in the amount of a protein expressed from the gene.

An increase of the transcription amount of a gene can be confirmed bycomparing the amount of mRNA transcribed from the gene with that of anon-modified strain such as a wild-type strain or parent strain.Examples of the method for evaluating the amount of mRNA can includeNorthern hybridization, RT-PCR, and so forth (Sambrook, J., et al.,Molecular Cloning A Laboratory Manual/Third Edition, Cold Spring HarborLaboratory Press, Cold Spring Harbor (USA), 2001). The amount of mRNAmay be increased to, for example, 1.2 times or more, 1.5 times or more,2 times or more, or 3 times or more of that of a non-modified strain.

An increase in the amount of a protein can be confirmed by Westernblotting using antibodies (Molecular Cloning, Cold Spring HarborLaboratory Press, Cold Spring Harbor (USA), 2001). The amount of theprotein, such as the number of molecules of the protein per cell, may beincreased to, for example, 1.2 times or more, 1.5 times or more, 2 timesor more, or 3 times or more of that of a non-modified strain.

The aforementioned methods for increasing the activity of a protein canbe applied to enhancement of the activities of arbitrary proteins suchas an objective substance biosynthesis enzyme, phosphopantetheinylationenzyme, and uptake system of a substance, and enhancement of theexpression of arbitrary genes such as genes encoding those arbitraryproteins, besides introduction of a Bacteroidetes OMT gene.

<1-4> Method for Reducing Activity of Protein

Hereafter, the methods for reducing the activity of a protein will beexplained.

The expression “the activity of a protein is reduced” means that theactivity of the protein is reduced as compared with a non-modifiedstrain. Specifically, the expression “the activity of a protein isreduced” may mean that the activity of the protein per cell is reducedas compared with that of a non-modified strain. The term “non-modifiedstrain” can refer to a control strain that has not been modified so thatthe activity of an objective protein is reduced. Examples of thenon-modified strain can include a wild-type strain and parent strain.Specific examples of the non-modified strain can include the respectivetype strains of the species of microorganisms. Specific examples of thenon-modified strain can also include strains exemplified above inrelation to the description of microorganisms. That is, in anembodiment, the activity of a protein may be reduced as compared with atype strain, i.e. the type strain of the species to which amicroorganism belongs. In another embodiment, the activity of a proteinmay also be reduced as compared with the C. glutamicum ATCC 13869strain. In another embodiment, the activity of a protein may also bereduced as compared with the C. glutamicum ATCC 13032 strain. In anotherembodiment, the activity of a protein may also be reduced as comparedwith the E. coli K-12 MG1655 strain. The phrase “the activity of aprotein is reduced” can also include when the activity of the proteinhas completely disappeared. More specifically, the expression “theactivity of a protein is reduced” may mean that the number of moleculesof the protein per cell is reduced, and/or the function of each moleculeof the protein is reduced as compared with those of a non-modifiedstrain. That is, the term “activity” in the expression “the activity ofa protein is reduced” is not limited to the catalytic activity of theprotein, but may also mean the transcription amount of a gene, that is,the amount of mRNA, encoding the protein or the translation amount ofthe protein, that is, the amount of the protein. The phrase “the numberof molecules of the protein per cell is reduced” can also include whenthe protein does not exist at all. The phrase “the function of eachmolecule of the protein is reduced” can also include when the functionof each protein molecule has completely disappeared. The degree of thereduction in the activity of a protein is not particularly limited, solong as the activity is reduced as compared with that of a non-modifiedstrain. The activity of a protein may be reduced to, for example, 50% orless, 20% or less, 10% or less, 5% or less, or 0% of that of anon-modified strain.

The modification for reducing the activity of a protein can be attainedby, for example, reducing the expression of a gene encoding the protein.The phrase “the expression of a gene is reduced” means that theexpression of the gene is reduced as compared with a non-modifiedstrain, such as a wild-type strain and parent strain. Specifically, thephrase “the expression of a gene is reduced” may mean that theexpression of the gene per cell is reduced as compared with that of anon-modified strain. More specifically, the phrase “the expression of agene is reduced” may mean that the transcription amount of the gene,that is the amount of mRNA, is reduced, and/or the translation amount ofthe gene, that is, the amount of the protein expressed from the gene, isreduced. The phrase “the expression of a gene is reduced” can alsoinclude when the gene is not expressed at all. The phrase “theexpression of a gene is reduced” can also be referred to as “theexpression of a gene is attenuated”. The expression of a gene may bereduced to, for example, 50% or less, 20% or less, 10% or less, 5% orless, or 0% of that of a non-modified strain.

The reduction in gene expression may be due to, for example, a reductionin the transcription efficiency, a reduction in the translationefficiency, or a combination. The expression of a gene can be reduced bymodifying an expression control sequence of the gene, such as apromoter, the Shine-Dalgarno (SD) sequence, which can also be referredto as ribosome-binding site (RBS), and a spacer region between RBS andthe start codon of the gene. When an expression control sequence ismodified, one or more nucleotides, two or more nucleotides, or three ormore nucleotides, of the expression control sequence are modified. Forexample, the transcription efficiency of a gene can be reduced by, forexample, replacing the promoter of the gene on a chromosome with aweaker promoter. The term “weaker promoter” can refer to a promoterproviding an attenuated transcription of a gene compared with aninherent wild-type promoter of the gene. Examples of weaker promoterscan include, for example, inducible promoters. That is, an induciblepromoter may function as a weaker promoter under a non-inducedcondition, such as in the absence of the corresponding inducer. Examplesof weaker promoters can also include, for example, P4 and P8 promoters(position 872-969 of SEQ ID NO: 109 and position 901-1046 of SEQ ID NO:110, respectively). Furthermore, a part of or the entire expressioncontrol sequence may be deleted. The expression of a gene can also bereduced by, for example, manipulating a factor responsible forexpression control. Examples of the factor responsible for expressioncontrol can include low molecules responsible for transcription ortranslation control, such as inducers, inhibitors, etc., proteinsresponsible for transcription or translation control, such astranscription factors etc., nucleic acids responsible for transcriptionor translation control, such as siRNA etc., and so forth. Furthermore,the expression of a gene can also be reduced by, for example,introducing a mutation that reduces the expression of the gene into thecoding region of the gene. For example, the expression of a gene can bereduced by replacing a codon in the coding region of the gene with asynonymous codon used less frequently in a host. Furthermore, forexample, the gene expression may be reduced due to disruption of a geneas described herein.

The modification for reducing the activity of a protein can also beattained by, for example, disrupting a gene encoding the protein. Thephrase “a gene is disrupted” can mean that a gene is modified so that aprotein that can normally function is not produced. The phrase “aprotein that normally functions is not produced” can include when theprotein is not produced at all from the gene, and when the protein ofwhich the function, such as activity or property, per molecule isreduced or eliminated is produced from the gene.

Disruption of a gene can be attained by, for example, deleting the geneon a chromosome. The term “deletion of a gene” can refer to deletion ofa partial or entire region of the coding region of the gene.Furthermore, the whole of a gene including sequences upstream anddownstream from the coding region of the gene on a chromosome may bedeleted. The region to be deleted may be any region, such as anN-terminal region (i.e. a region encoding an N-terminal region of aprotein), an internal region, or a C-terminal region (i.e. a regionencoding a C-terminal region of a protein), so long as the activity ofthe protein can be reduced. Deletion of a longer region will usuallymore surely inactivate the gene. The region to be deleted may be, forexample, a region having a length of 10% or more, 20% or more, 30% ormore, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more,90% or more, or 95% or more of the total length of the coding region ofthe gene. Furthermore, it is preferred that reading frames of thesequences upstream and downstream from the region to be deleted are notthe same. Inconsistency of reading frames may cause a frameshiftdownstream of the region to be deleted.

Disruption of a gene can also be attained by, for example, introducing amutation for an amino acid substitution (missense mutation), a stopcodon (nonsense mutation), addition or deletion of one or two nucleotideresidues (frame shift mutation), or the like into the coding region ofthe gene on a chromosome (Journal of Biological Chemistry, 272:8611-8617(1997); Proceedings of the National Academy of Sciences, USA, 955511-5515 (1998); Journal of Biological Chemistry, 26 116, 20833-20839(1991)).

Disruption of a gene can also be attained by, for example, insertinganother nucleotide sequence into a coding region of the gene on achromosome. Site of the insertion may be in any region of the gene, andinsertion of a longer nucleotide sequence will usually more surelyinactivate the gene. It is preferred that reading frames of thesequences upstream and downstream from the insertion site are not thesame. Inconsistency of reading frames may cause a frameshift downstreamof the region to be deleted. The other nucleotide sequence is notparticularly limited so long as a sequence that reduces or eliminatesthe activity of the encoded protein is chosen, and examples thereof caninclude, for example, a marker gene such as antibiotic resistance genes,and a gene useful for production of an objective substance.

Particularly, disruption of a gene may be carried out so that the aminoacid sequence of the encoded protein is deleted. In other words, themodification for reducing the activity of a protein can be attained by,for example, deleting the amino acid sequence of the protein,specifically, modifying a gene so as to encode a protein of which theamino acid sequence is deleted. The phrase “deletion of the amino acidsequence of a protein” can refer to deletion of a partial or entireregion of the amino acid sequence of the protein. In addition, thephrase “deletion of the amino acid sequence of a protein” can mean thatthe original amino acid sequence disappears in the protein, and can alsoinclude when the original amino acid sequence is changed to anotheramino acid sequence. That is, for example, a region that was changed toanother amino acid sequence by frameshift may be regarded as a deletedregion. When the amino acid sequence of a protein is deleted, the totallength of the protein is typically shortened, but there can also becases where the total length of the protein is not changed or isextended. For example, by deletion of a partial or entire region of thecoding region of a gene, a region encoded by the deleted region can bedeleted in the encoded protein. In addition, for example, byintroduction of a stop codon into the coding region of a gene, a regionencoded by the downstream region of the introduction site can be deletedin the encoded protein. In addition, for example, by frameshift in thecoding region of a gene, a region encoded by the frameshift region canbe deleted in the encoded protein. The aforementioned descriptionsconcerning the position and length of the region to be deleted indeletion of a gene can be applied mutatis mutandis to the position andlength of the region to be deleted in deletion of the amino acidsequence of a protein.

Such modification of a gene on a chromosome as described above can beattained by, for example, preparing a disruption-type gene modified sothat it is unable to produce a protein that normally functions, andtransforming a host with a recombinant DNA containing thedisruption-type gene to cause homologous recombination between thedisruption-type gene and the wild-type gene on a chromosome and therebysubstitute the disruption-type gene for the wild-type gene on thechromosome. In this procedure, if a marker gene selected according tothe characteristics of the host such as auxotrophy is included in therecombinant DNA, the operation becomes easier. Examples of thedisruption-type gene can include a gene of which a partial or entireregion of the coding region is deleted, a gene including a missensemutation, a gene including a nonsense mutation, a gene including a frameshift mutation, and a gene including insertion of a transposon or markergene. The protein encoded by the disruption-type gene has a conformationdifferent from that of the wild-type protein, even if it is produced,and thus the function thereof is reduced or eliminated. Such genedisruption based on gene substitution utilizing homologous recombinationhas already been established, and there are methods of using a linearDNA such as a method called “Red driven integration” (Datsenko, K. A,and Wanner, B. L., Proc. Natl. Acad. Sci. USA, 97:6640-6645 (2000)), anda method utilizing the Red driven integration in combination with anexcision system derived from λ phage (Cho, E. H., Gumport, R. I.,Gardner, J. F., J. Bacteriol., 184:5200-5203 (2002)) (refer toWO2005/010175), a method of using a plasmid having a temperaturesensitive replication origin, a method of using a plasmid capable ofconjugative transfer, a method of utilizing a suicide vector not havinga replication origin that functions in a host (U.S. Pat. No. 6,303,383,Japanese Patent Laid-open (Kokai) No. 05-007491), and so forth.

Modification for reducing activity of a protein can also be attained by,for example, a mutagenesis treatment. Examples of the mutagenesistreatment can include irradiation of X-ray or ultraviolet and treatmentwith a mutation agent such as N-methyl-N′-nitro-N-nitrosoguanidine(MNNG), ethyl methanesulfonate (EMS), and methyl methanesulfonate (MMS).

Such methods for reducing the activity of a protein as mentioned abovemay be used independently or in an arbitrary combination.

When a protein functions as a complex made up of a plurality ofsubunits, a part or all of the plurality of subunits may be modified, solong as the activity of the protein is eventually reduced. That is, forexample, a part or all of a plurality of genes that encode therespective subunits may be disrupted or the like. Furthermore, whenthere is a plurality of isozymes of a protein, a part or all of theactivities of the plurality of isozymes may be reduced, so long as theactivity of the protein is eventually reduced. That is, for example, apart or all of a plurality of genes that encode the respective isozymesmay be disrupted or the like.

A reduction in the activity of a protein can be confirmed by measuringthe activity of the protein.

A reduction in the activity of a protein can also be confirmed byconfirming a reduction in the expression of a gene encoding the protein.A reduction in the expression of a gene can be confirmed by confirming areduction in the transcription amount of the gene or a reduction in theamount of the protein expressed from the gene.

A reduction in the transcription amount of a gene can be confirmed bycomparing the amount of mRNA transcribed from the gene with thatobserved in a non-modified strain. Examples of the method for evaluatingthe amount of mRNA can include Northern hybridization, RT-PCR, and soforth (Molecular Cloning, Cold Spring Harbor Laboratory Press, ColdSpring Harbor (USA), 2001). The amount of mRNA can be reduced to, forexample, 50% or less, 20% or less, 10% or less, 5% or less, or 0%, ofthat of a non-modified strain.

A reduction in the amount of a protein can be confirmed by Westernblotting using antibodies (Molecular Cloning, Cold Spring HarborLaboratory Press, Cold Spring Harbor (USA) 2001). The amount of theprotein, such as the number of molecules of the protein per cell, can bereduced to, for example, 50% or less, 20% or less, 10% or less, 5% orless, or 0%, of that of a non-modified strain.

Disruption of a gene can be confirmed by determining nucleotide sequenceof a part or the whole of the gene, restriction enzyme map, full length,or the like of the gene depending on the means used for the disruption.

The aforementioned methods for reducing the activity of a protein can beapplied to reduction in the activities of arbitrary proteins such as abyproduct generation enzyme, and reduction in the expression ofarbitrary genes such as genes encoding those arbitrary proteins.

<2> Method for Producing Objective Substance

The method as described herein is a method for producing an objectivesubstance by using the microorganism as described herein.

<2-1> Fermentation Method

An objective substance can be produced by, for example, fermentation ofthe microorganism as described herein. That is, an embodiment of themethod as described herein may be a method for producing an objectivesubstance by fermentation of the microorganism. This embodiment can alsobe referred to as a “fermentation method”. Also, the step of producingan objective substance by fermentation of the microorganism as describedherein can also be referred to as a “fermentation step”.

The fermentation step can be performed by cultivating the microorganismas described herein. Specifically, in the fermentation method, anobjective substance can be produced from a carbon source. That is, thefermentation step may be, for example, a step of cultivating themicroorganism in a culture medium, such as a culture medium containing acarbon source, to produce and accumulate the objective substance in theculture medium. That is, the fermentation method may be a method forproducing an objective substance that comprises the step of cultivatingthe microorganism in a culture medium, such as a culture mediumcontaining a carbon source, to produce and accumulate the objectivesubstance in the culture medium. Also, in other words, the fermentationstep may be, for example, a step of producing an objective substancefrom a carbon source by using the microorganism.

The culture medium to be used is not particularly limited, so long asthe microorganism can proliferate in it and produce an objectivesubstance. As the culture medium, for example, a typical culture mediumused for culture of microorganisms such as bacteria and yeast can beused. The culture medium may contain carbon source, nitrogen source,phosphate source, and sulfur source, as well as other medium componentssuch as various organic components and inorganic components as required.The types and concentrations of the medium components can beappropriately determined according to various conditions such as thetype of the chosen microorganism.

The carbon source is not particularly limited, so long as themicroorganism can utilize it and produce an objective substance.Specific examples of the carbon source can include, for example,saccharides such as glucose, fructose, sucrose, lactose, galactose,xylose, arabinose, blackstrap molasses, hydrolysates of starches, andhydrolysates of biomass; organic acids such as acetic acid, citric acid,succinic acid, and gluconic acid; alcohols such as ethanol, glycerol,and crude glycerol; and fatty acids. As the carbon source, inparticular, plant-derived materials can be used. Examples of the plantcan include, for example, corn, rice, wheat, soybean, sugarcane, beet,and cotton. Examples of the plant-derived materials can include, forexample, organs such as root, stem, trunk, branch, leaf, flower, andseed, plant bodies including them, and decomposition products of theseplant organs. The forms of the plant-derived materials at the time ofuse thereof are not particularly limited, and they can be used in anyform such as unprocessed product, juice, ground product, and purifiedproduct. Pentoses such as xylose, hexoses such as glucose, or mixturesof them can be obtained from, for example, plant biomass, and used.Specifically, these saccharides can be obtained by subjecting a plantbiomass to such a treatment as steam treatment, hydrolysis withconcentrated acid, hydrolysis with diluted acid, hydrolysis with anenzyme such as cellulase, and alkaline treatment. Since hemicellulose isgenerally more easily hydrolyzed compared with cellulose, hemicellulosein a plant biomass may be hydrolyzed beforehand to liberate pentoses,and then cellulose may be hydrolyzed to generate hexoses. Furthermore,xylose may be supplied by conversion from hexoses by, for example,imparting a pathway for converting hexose such as glucose to xylose tothe microorganism. As the carbon source, one carbon source may be used,or two or more carbon sources may be used in combination.

The concentration of the carbon source in the culture medium is notparticularly limited, so long as the microorganism can proliferate andproduce an objective substance. The concentration of the carbon sourcein the culture medium may be as high as possible within such a rangethat production of the objective substance is not inhibited. The initialconcentration of the carbon source in the culture medium may be, forexample, 5 to 30% (w/v), or 10 to 20% (w/v). Furthermore, the carbonsource may be added to the culture medium as required. For example, thecarbon source may be added to the culture medium in proportion todecrease or depletion of the carbon source accompanying progress of thefermentation. While the carbon source may be temporarily depleted solong as an objective substance can be eventually produced, it may bepreferable to perform the culture so that the carbon source is notdepleted or the carbon source does not continue to be depleted.

Specific examples of the nitrogen source can include, for example,ammonium salts such as ammonium sulfate, ammonium chloride, and ammoniumphosphate, organic nitrogen sources such as peptone, yeast extract, meatextract, and soybean protein decomposition products, ammonia, and urea.Ammonia gas and aqueous ammonia used for pH adjustment may also be usedas a nitrogen source. As the nitrogen source, one nitrogen source may beused, or two or more nitrogen sources may be used in combination.

Specific examples of the phosphate source can include, for example,phosphate salts such as potassium dihydrogenphosphate and dipotassiumhydrogenphosphate, and phosphoric acid polymers such as pyrophosphoricacid. As the phosphate source, one phosphate source may be used, or twoor more phosphate sources may be used in combination.

Specific examples of the sulfur source can include, for example,inorganic sulfur compounds such as sulfates, thiosulfates, and sulfites,and sulfur-containing amino acids such as cysteine, cystine, andglutathione. As the sulfur source, one sulfur source may be used, or twoor more sulfur sources may be used in combination.

Specific examples of other various organic and inorganic components caninclude, for example, inorganic salts such as sodium chloride andpotassium chloride; trace metals such as iron, manganese, magnesium, andcalcium; vitamins such as vitamin B1, vitamin B2, vitamin B6, nicotinicacid, nicotinamide, and vitamin B12; amino acids; nucleic acids; andorganic components containing these such as peptone, casamino acid,yeast extract, and soybean protein decomposition product. As the othervarious organic and inorganic components, one component may be used, ortwo or more components may be used in combination.

Furthermore, when an auxotrophic mutant strain that requires a nutrientsuch as amino acids for growth thereof is used, it is preferred that theculture medium contains such a required nutrient. Furthermore, theculture medium may contain a component used for production of anobjective substance. Specific examples of such a component can include,for example, methyl group donors such as SAM and precursors thereof suchas methionine.

Culture conditions are not particularly limited, so long as themicroorganism can proliferate, and an objective substance is produced.The culture can be performed with, for example, typical conditions usedfor culture of microorganisms such as bacteria and yeast. The cultureconditions may be appropriately determined according to variousconditions such as the type of the chosen microorganism.

The culture can be performed by using a liquid medium. At the time ofthe culture, for example, the microorganism cultured on a solid mediumsuch as agar medium may be directly inoculated into a liquid medium, orthe microorganism cultured in a liquid medium as seed culture may beinoculated into a liquid medium for main culture. That is, the culturemay be performed separately as seed culture and main culture. In such acase, the culture conditions of the seed culture and the main culturemay be or may not be the same. It is sufficient that an objectivesubstance is produced at least during the main culture. The amount ofthe microorganism present in the culture medium at the time of the startof the culture is not particularly limited. For example, a seed culturebroth showing an OD660 of 4 to 100 may be inoculated to a culture mediumfor main culture in an amount of 0.1 to 100 mass %, or 1 to 50 mass %,at the time of the start of the culture.

The culture can be performed as batch culture, fed-batch culture,continuous culture, or a combination of these. The culture medium usedat the start of the culture can also be referred to as a “startingmedium”. The culture medium added to the culture system (e.g.fermentation tank) in the fed-batch culture or the continuous culturecan also be referred to as a “feed medium”. To add a feed medium to theculture system in the fed-batch culture or the continuous culture canalso be referred to as “feed”. Furthermore, when the culture isperformed separately as seed culture and main culture, the cultureschemes of the seed culture and the main culture may be or may not bethe same. For example, both the seed culture and the main culture may beperformed as batch culture. Alternatively, for example, the seed culturemay be performed as batch culture, and the main culture may be performedas fed-batch culture or continuous culture.

The various components such as the carbon source may be present in thestarting medium, feed medium, or both. That is, the various componentssuch as the carbon source may be added to the culture mediumindependently or in an arbitrary combination during the culture. Thesecomponents may be added once or a plurality of times, or may becontinuously added. The types of the components present in the startingmedium may be or may not be the same as the types of the componentspresent in the feed medium. Furthermore, the concentrations of thecomponents present in the starting medium may be or may not be the sameas the concentrations of the components present in the feed medium.Furthermore, two or more kinds of feed media containing components ofdifferent types and/or different concentrations may be used. Forexample, when feeding is intermittently performed two or more times, thetypes and/or concentrations of components present in the feed medium maybe or may not be the same for each feeding.

The culture can be performed, for example, under an aerobic condition.The term “aerobic condition” can refer to a condition where thedissolved oxygen concentration in the culture medium is 0.33 ppm orhigher, or 1.5 ppm or higher. The oxygen concentration can be controlledto be, for example, 1 to 50%, or about 5%, of the saturated oxygenconcentration. The culture can be performed, for example, with aerationor shaking. The pH of the culture medium may be, for example, 3 to 10,or 4.0 to 9.5. The pH of the culture medium can be adjusted during theculture as required. The pH of the culture medium can be adjusted byusing various alkaline and acidic substances such as ammonia gas,aqueous ammonia, sodium carbonate, sodium bicarbonate, potassiumcarbonate, potassium bicarbonate, magnesium carbonate, sodium hydroxide,calcium hydroxide, and magnesium hydroxide. The culture temperature maybe, for example, 20 to 45° C., or 25 to 37° C. The culture time may be,for example, 10 to 120 hours. The culture may be continued, for example,until the carbon source present in the culture medium is consumed, oruntil the activity of the microorganism is lost.

By cultivating the microorganism under such conditions as describedabove, an objective substance is accumulated in the culture medium.

Production of an objective substance can be confirmed by known methodsused for detection or identification of compounds. Examples of suchmethods can include, for example, HPLC, UPLC, LC/MS, GC/MS, and NMR.These methods may be independently used, or may be used in anappropriate combination. These methods can also be used for determiningthe concentrations of various components present in the culture medium.

The produced objective substance can be appropriately collected. Thatis, the fermentation method may further comprise a step of collectingthe objective substance. This step can also be referred to as a“collection step”. The collection step may be a step of collecting theobjective substance from the culture broth, specifically from theculture medium. The objective substance can be collected by knownmethods used for separation and purification of compounds. Examples ofsuch methods can include, for example, ion-exchange resin method,membrane treatment, precipitation, extraction, distillation, andcrystallization. The objective substance can be collected specificallyby extraction with an organic solvent such as ethyl acetate or by steamdistillation. These methods may be independently used, or may be used inan appropriate combination.

Furthermore, when an objective substance precipitates in the culturemedium, it can be collected by, for example, centrifugation orfiltration. The objective substance precipitated in the culture mediumand the objective substance dissolved in the culture medium may beisolated together after the objective substance dissolved in the culturemedium is crystallized.

The collected objective substance may contain, for example, microbialcells, medium components, moisture, and by-product metabolites of themicroorganism, in addition to the objective substance. Purity of thecollected objective substance may be, for example, 30% (w/w) or higher,50% (w/w) or higher, 70% (w/w) or higher, 80% (w/w) or higher, 90% (w/w)or higher, or 95% (w/w) or higher.

<2-2> Bioconversion Method

An objective substance can also be produced by, for example,bioconversion using the microorganism as described herein. That is,another embodiment of the method as described herein may be a method forproducing an objective substance by bioconversion using themicroorganism. This embodiment can also be referred to as a“bioconversion method”. Also, the step of producing an objectivesubstance by bioconversion using the microorganism can also be referredto as a “bioconversion step”.

Specifically, in the bioconversion method, an objective substance can beproduced from a precursor of the objective substance. More specifically,in the bioconversion method, an objective substance can be produced byconverting a precursor of the objective substance into the objectivesubstance by using the microorganism. That is, the bioconversion stepmay be a step of converting a precursor of an objective substance intothe objective substance by using the microorganism.

A precursor of an objective substance can also be referred to simply asa “precursor”. Examples of the precursor can include substances of whichconversion into an object substance includes a step catalyzed byBacteroidetes OMT. Specific examples of the precursor can includeintermediates of the biosynthesis pathway of an object substance, suchas those recited in relation to the descriptions of the objectivesubstance biosynthesis enzymes, provided that conversion of theintermediates into the object substance includes a step catalyzed byBacteroidetes OMT. More specific examples of the precursor can include,for example, protocatechuic acid, protocatechualdehyde, L-phenylalanine,and L-tyrosine. Protocatechuic acid may be used as a precursor forproducing, for example, vanillin, vanillic acid, or guaiacol.Protocatechualdehyde may be used as a precursor for producing, forexample, vanillin. L-phenylalanine and L-tyrosine each may be used as aprecursor for producing, for example, ferulic acid, 4-vinylguaiacol, or4-ethylguaiacol. As the precursor, one kind of precursor may be used, ortwo or more kinds of precursors may be used in combination. In caseswhere the precursor is a compound that can form a salt, the precursormay be used as a free compound, a salt thereof, or a mixture thereof.That is, the term “precursor” can refer to a precursor in a free form, asalt thereof, or a mixture thereof, unless otherwise stated. Examples ofthe salt can include, for example, sulfate salt, hydrochloride salt,carbonate salt, ammonium salt, sodium salt, and potassium salt. As thesalt of the precursor, one kind of salt may be employed, or two or morekinds of salts may be employed in combination.

As the precursor, a commercial product may be used, or one appropriatelyprepared and obtained may be used. That is, the bioconversion method mayfurther include a step of producing a precursor. The method forproducing a precursor is not particularly limited, and for example,known methods can be used. A precursor can be produced by, for example,a chemical synthesis method, enzymatic method, bioconversion method,fermentation method, extraction method, or a combination of these. Thatis, for example, a precursor of an objective substance can be producedfrom a further precursor thereof using an enzyme that catalyzes theconversion of such a further precursor into the precursor of anobjective substance, which enzyme can also be referred to as a“precursor biosynthesis enzyme”. Furthermore, for example, a precursorof an objective substance can be produced from a carbon source or such afurther precursor by using a microorganism having a precursor-producingability. The phrase “microorganism having a precursor-producing ability”can refer to a microorganism that is able to generate a precursor of anobjective substance from a carbon source or a further precursor thereof.For example, examples of the method for producing protocatechuic acidaccording to an enzymatic method or bioconversion method can include themethod of converting para-cresol into protocatechuic acid usingPseudomonas putida KS-0180 (Japanese Patent Laid-open (Kokai) No.7-75589), the method of converting para-hydroxybenzoic acid intoprotocatechuic acid using an NADH-dependent para-hydroxybenzoic acidhydroxylase (Japanese Patent Laid-open (Kokai) No. 5-244941), the methodof producing protocatechuic acid by cultivating a transformant harboringa gene that is involved in the reaction of generating protocatechuicacid from terephthalic acid in a culture medium containing terephthalicacid (Japanese Patent Laid-open (Kokai) No. 2007-104942), and the methodof producing protocatechuic acid from a precursor thereof by using amicroorganism having protocatechuic acid-producing ability and having areduced activity of protocatechuic acid 5-oxidase or being deficient inthat activity (Japanese Patent Laid-open (Kokai) No. 2010-207094).Furthermore, examples of the method for producing protocatechuic acid byfermentation can include the method of producing protocatechuic acid byusing a bacterium of the genus Brevibacterium and acetic acid as acarbon source (Japanese Patent Laid-open (Kokai) No. 50-89592), themethod of producing protocatechuic acid by using a bacterium of thegenus Escherichia or Klebsiella into which a gene encoding3-dihydroshikimate dehydrogenase has been introduced, and glucose as acarbon source (U.S. Pat. No. 5,272,073). Furthermore,protocatechualdehyde can be produced by using protocatechuic acid as aprecursor according to an enzymatic method using ACAR or a bioconversionmethod using a microorganism having ACAR. The produced precursor can beused for the bioconversion method as it is, or after being subjected toan appropriate treatment such as concentration, dilution, drying,dissolution, fractionation, extraction, and purification, as required.That is, as the precursor, for example, a purified product purified to adesired extent may be used, or a material containing a precursor may beused. The material containing a precursor is not particularly limited solong as the microorganism can use the precursor. Specific examples ofthe material containing a precursor can include a culture broth obtainedby cultivating a microorganism having a precursor-producing ability, aculture supernatant separated from the culture broth, and processedproducts thereof such as concentrated products, such as concentratedliquid, thereof and dried products thereof.

In an embodiment, the bioconversion step can be performed by, forexample, cultivating the microorganism as described herein. Thisembodiment can also be referred to as a “first embodiment of thebioconversion method”. That is, the bioconversion step may be, forexample, a step of cultivating the microorganism in a culture mediumcontaining a precursor of an objective substance to convert theprecursor into the objective substance. The bioconversion step may be,specifically, a step of cultivating the microorganism in a culturemedium containing a precursor of an objective substance to produce andaccumulate the objective substance in the culture medium.

The culture medium to be used is not particularly limited, so long asthe culture medium contains a precursor of an objective substance, andthe microorganism can proliferate in it and produce the objectivesubstance. Culture conditions are not particularly limited, so long asthe microorganism can proliferate, and an objective substance isproduced. The descriptions concerning the culture mentioned for thefermentation method, such as those concerning the culture medium andculture conditions, can be applied mutatis mutandis to the culture inthe first embodiment of the bioconversion method, except that theculture medium contains the precursor in the first embodiment.

The precursor may be present in the culture medium over the whole periodof the culture, or may be present in the culture medium during only apartial period of the culture. That is, the phrase “cultivating amicroorganism in a culture medium containing a precursor” does notnecessarily mean that the precursor is present in the culture mediumover the whole period of the culture. For example, the precursor may beor may not be present in the culture medium from the start of theculture. When the precursor is not present in the culture medium at thetime of the start of the culture, the precursor is added to the culturemedium after the start of the culture. Timing of the addition can beappropriately determined according to various conditions such as thelength of the culture period. For example, after the microorganismsufficiently grows, the precursor may be added to the culture medium.Furthermore, in any case, the precursor may be added to the culturemedium as required. For example, the precursor may be added to theculture medium in proportion to decrease or depletion of the precursoraccompanying generation of an objective substance. Methods for addingthe precursor to the culture medium are not particularly limited. Forexample, the precursor can be added to the culture medium by feeding afeed medium containing the precursor to the culture medium. Furthermore,for example, the microorganism as described herein and a microorganismhaving a precursor-producing ability can be co-cultured to allow themicroorganism having a precursor-producing ability to produce theprecursor in the culture medium, and thereby add the precursor to theculture medium. These methods of addition may be independently used, ormay be used in an appropriate combination. The concentration of theprecursor in the culture medium is not particularly limited so long asthe microorganism can use the precursor as a raw material of anobjective substance. The concentration of the precursor in the culturemedium, for example, may be 0.1 g/L or higher, 1 g/L or higher, 2 g/L orhigher, 5 g/L or higher, 10 g/L or higher, or 15 g/L or higher, or maybe 200 g/L or lower, 100 g/L or lower, 50 g/L or lower, or 20 g/L orlower, or may be within a range defined with a combination thereof, interms of the weight of the free compound. The precursor may or may notbe present in the culture medium at a concentration within the rangeexemplified above over the whole period of the culture. For example, theprecursor may be present in the culture medium at a concentration withinthe range exemplified above at the time of the start of the culture, orit may be added to the culture medium so that a concentration within therange exemplified above is attained after the start of the culture. Incases where the culture is performed separately as seed culture and mainculture, it is sufficient that an objective substance is produced atleast during the main culture. Hence, it is sufficient that theprecursor is present in the culture medium at least during the mainculture, that is, over the whole period of the main culture or during apartial period of the main culture, and that is, the precursor may be ormay not be present in the culture medium during the seed culture. Insuch cases, terms regarding the culture, such as “culture period (periodof culture)” and “start of culture”, can be read as those regarding themain culture.

In another embodiment, the bioconversion step can also be performed by,for example, using cells of the microorganism as described herein. Thisembodiment can also be referred to as a “second embodiment of thebioconversion method”. That is, the bioconversion step may be, forexample, a step of converting a precursor of an objective substance in areaction mixture into the objective substance by using cells of themicroorganism. The bioconversion step may be, specifically, a step ofallowing cells of the microorganism to act on a precursor of anobjective substance in a reaction mixture to generate and accumulate theobjective substance in the reaction mixture. The bioconversion stepperformed by using such cells can also be referred to as a “conversionreaction”.

Cells of the microorganism can be obtained by cultivating themicroorganism. The culture method for obtaining the cells is notparticularly limited so long as the microorganism can proliferate. Atthe time of the culture for obtaining the cells, the precursor may ormay not be present in the culture medium. Also, at the time of theculture for obtaining the cells, an objective substance may or may notbe produced in the culture medium. The descriptions concerning theculture mentioned for the fermentation method, such as those concerningthe culture medium and culture conditions, can be applied mutatismutandis to the culture for obtaining the cells used for the secondembodiment of the bioconversion method.

The cells may be used for the conversion reaction while being present inthe culture broth (specifically, culture medium), or after beingcollected from the culture broth (specifically, culture medium). Thecells may also be used for the conversion reaction after being subjectedto a treatment as required. That is, examples of the cells can include aculture broth containing the cells, the cells collected from the culturebroth, and a processed product thereof. In other words, examples of thecells can include cells present in a culture broth of the microorganism,cells collected from the culture broth, or cells present in a processedproduct thereof. Examples of the processed product can include productsobtained by subjecting the cells to a treatment, specifically bysubjecting a culture broth containing the cells, or the cells collectedfrom the culture broth to a treatment. Cells in these forms may beindependently used, or may be used in an appropriate combination.

The method for collecting the cells from the culture medium is notparticularly limited, and for example, known methods can be used.Examples of such methods can include, for example, spontaneousprecipitation, centrifugation, and filtration. A flocculant may also beused. These methods may be independently used, or may be used in anappropriate combination. The collected cells can be washed as requiredby using an appropriate medium. The collected cells can be re-suspendedas required by using an appropriate medium. Examples of the mediumusable for washing or suspending the cells can include, for example,aqueous media (aqueous solvents) such as water and aqueous buffer.

Examples of the treatment of the cells can include, for example,dilution, condensation, immobilization on a carrier such as acrylamideand carrageenan, freezing and thawing treatment, and treatment forincreasing permeability of cell membranes. Permeability of cellmembranes can be increased by, for example, using a surfactant ororganic solvent. These treatments may be independently used, or may beused in an appropriate combination.

The cells used for the conversion reaction are not particularly limitedso long as the cells have the objective substance-producing ability. Itis preferred that the cells maintain their metabolic activities. Thephrase “the cells maintain their metabolic activities” may mean that thecells have an ability to utilize a carbon source to generate orregenerate a substance required for producing an objective substance.Examples of such a substance can include, for example, ATP, electrondonors such as NADH and NADPH, and methyl group donors such as SAM. Thecells may have or may not have proliferation ability.

The conversion reaction can be carried out in an appropriate reactionmixture. Specifically, the conversion reaction can be carried out byallowing the cells and the precursor to coexist in an appropriatereaction mixture. The conversion reaction may be carried out by thebatch method or may be carried out by the column method. In the case ofthe batch method, the conversion reaction can be carried out by, forexample, mixing the cells of the microorganism and the precursor in areaction mixture contained in a reaction vessel. The conversion reactionmay be carried out statically, or may be carried out with stirring orshaking the reaction mixture. In the case of the column method, theconversion reaction can be carried out by, for example, passing areaction mixture containing the precursor through a column filled withimmobilized cells. Examples of the reaction mixture can include thosebased on an aqueous medium (aqueous solvent) such as water and aqueousbuffer.

The reaction mixture may contain components other than the precursor asrequired, in addition to the precursor. Examples of the components otherthan the precursor can include ATP, electron donors such as NADH andNADPH, methyl group donors such as SAM, metal ions, buffering agents,surfactants, organic solvents, carbon sources, phosphate sources, andother various medium components. That is, for example, a culture mediumcontaining the precursor may also be used as a reaction mixture. Thatis, the descriptions concerning the culture medium mentioned for thefirst embodiment of the bioconversion method may also be applied mutatismutandis to the reaction mixture in the second embodiment of thebioconversion method. The types and concentrations of the componentspresent in the reaction mixture may be determined according to variousconditions such as the type of the precursor to be used and the form ofthe cells to be used.

Conditions of the conversion reaction, such as dissolved oxygenconcentration, pH of the reaction mixture, reaction temperature,reaction time, concentrations of various components, etc., are notparticularly limited so long as an objective substance is generated. Theconversion reaction can be performed with, for example, typicalconditions used for substance conversion using microbial cells such asresting cells. The conditions of the conversion reaction may bedetermined according to various conditions such as the type of chosenmicroorganism. The conversion reaction can be performed, for example,under an aerobic condition. The term “aerobic condition” can refer to acondition where the dissolved oxygen concentration in the reactionmixture is 0.33 ppm or higher, or 1.5 ppm or higher. The oxygenconcentration can be controlled to be, for example, 1 to 50%, or about5%, of the saturated oxygen concentration. The pH of the reactionmixture may be, for example, usually 6.0 to 10.0, or 6.5 to 9.0. Thereaction temperature may be, for example, 15 to 50° C., 15 to 45° C., or20 to 40° C. The reaction time may be, for example, 5 minutes to 200hours. In the case of the column method, the loading rate of thereaction mixture may be, for example, such a rate that the reaction timefalls within the range of the reaction time exemplified above.Furthermore, the conversion reaction can also be performed with, forexample, a culture condition, such as typical conditions used forculture of microorganisms such as bacteria and yeast. During theconversion reaction, the cells may or may not proliferate. That is, thedescriptions concerning the culture conditions for the first embodimentof the bioconversion method may also be applied mutatis mutandis to theconditions of the conversion reaction in the second embodiment of thebioconversion method, except that the cells may or may not proliferatein the second embodiment. In such a case, the culture conditions forobtaining the cells and the conditions of the conversion reaction may bethe same or different. The concentration of the precursor in thereaction mixture, for example, may be 0.1 g/L or higher, 1 g/L orhigher, 2 g/L or higher, 5 g/L or higher, 10 g/L or higher, or 15 g/L orhigher, or may be 200 g/L or lower, 100 g/L or lower, 50 g/L or lower,or 20 g/L or lower, or may be within a range defined with a combinationthereof, in terms of the weight of the free compound. The density of thecells in the reaction mixture, for example, may be 1 or higher, or maybe 300 or lower, or may be within a range defined with a combinationthereof, in terms of the optical density (OD) at 600 nm.

During the conversion reaction, the cells, the precursor, and the othercomponents may be added to the reaction mixture independently or in anyarbitrary combination thereof. For example, the precursor may be addedto the reaction mixture in proportion to decrease or depletion of theprecursor accompanying generation of an objective substance. Thesecomponents may be added once or a plurality of times, or may becontinuously added.

Methods for adding the various components such as the precursor to thereaction mixture are not particularly limited. These components each canbe added to the reaction mixture by, for example, directly adding themto the reaction mixture. Furthermore, for example, the microorganism asdescribed herein and a microorganism having a precursor-producingability can be co-cultured to allow the microorganism having aprecursor-producing ability to produce the precursor in the reactionmixture, and thereby supply the precursor to the reaction mixture.Furthermore, for example, components such as ATP, electron donors, andmethyl group donors each may be generated or regenerated in the reactionmixture, may be generated or regenerated in the cells of themicroorganism, or may be generated or regenerated by a coupling reactionbetween different cells. For example, when cells of the microorganismmaintain the metabolic activities thereof, they can generate orregenerate components such as ATP, electron donors, and methyl groupdonors within them by using a carbon source. For example, specifically,the microorganism may have an enhanced ability for generating orregenerating SAM, and the generated or regenerated SAM by it may be usedfor the conversion reaction. The generation or regeneration of SAM mayfurther be enhanced in combination with any other method for generatingor regenerating SAM. In addition, examples of the method for generatingor regenerating ATP can include, for example, the method of supplyingATP from a carbon source by using a Corynebacterium bacterium (Hori, H.et al., Appl. Microbiol. Biotechnol., 48(6):693-698 (1997)), the methodof regenerating ATP by using yeast cells and glucose (Yamamoto, S etal., Biosci. Biotechnol. Biochem., 69(4):784-789 (2005)), the method ofregenerating ATP using phosphoenolpyruvic acid and pyruvate kinase (C.Aug'e and Ch. Gautheron, Tetrahedron Lett., 29:789-790 (1988)), and themethod of regenerating ATP by using polyphosphoric acid andpolyphosphate kinase (Murata, K. et al., Agric. Biol. Chem.,52(6):1471-1477 (1988)).

Furthermore, the reaction conditions may be constant from the start tothe end of the conversion reaction, or they may vary during theconversion reaction. The expression “the reaction conditions vary duringthe conversion reaction” can include not only when the reactionconditions are temporally changed, but also includes when the reactionconditions are spatially changed. The expression “the reactionconditions are spatially changed” means that, for example, when theconversion reaction is performed by the column method, the reactionconditions such as reaction temperature and cell density differdepending on position in the flow.

A culture broth (specifically, culture medium) or reaction mixturecontaining an objective substance is obtained by carrying out thebioconversion step as described above. Confirmation of the production ofthe objective substance and collection of the objective substance can becarried out in the same manners as those for the fermentation methoddescribed above. That is, the bioconversion method may further comprisethe collection step, such as a step of collecting the objectivesubstance from the culture broth (specifically, culture medium) orreaction mixture. The collected objective substance may contain, forexample, microbial cells, medium components, reaction mixturecomponents, moisture, and by-product metabolites of the microorganism,in addition to the objective substance. Purity of the collectedobjective substance may be, for example, 30% (w/w) or higher, 50% (w/w)or higher, 70% (w/w) or higher, 80% (w/w) or higher, 90% (w/w) orhigher, or 95% (w/w) or higher.

<2-3> Method for Producing Vanillin and Other Objective Substances

When an objective substance is produced by using the microorganism asdescribed herein, that is, by the fermentation method or bioconversionmethod, the thus-produced objective substance can further be convertedto another objective substance. The present invention thus provides amethod for producing a second objective substance, that is objectivesubstance B, comprising steps of producing a first objective substance,that is objective substance A, by using the microorganism, that is, bythe fermentation method or bioconversion method, and converting thethus-produced first objective substance A to the second objectivesubstance B.

For example, when vanillic acid is produced by using the microorganismas described herein, that is, by the fermentation method orbioconversion method, the thus-produced vanillic acid can further beconverted to vanillin. The present invention thus provides a method forproducing vanillin comprising steps of producing vanillic acid by usingthe microorganism, that is, by the fermentation method or bioconversionmethod, and converting thus-produced vanillic acid into vanillin. Thismethod can also be referred to as a “vanillin production method”.

Vanillic acid produced by using the microorganism can be used for theconversion into vanillin as it is, or after being subjected to anappropriate treatment such as concentration, dilution, drying,dissolution, fractionation, extraction, and purification, as required.That is, as vanillic acid, for example, a purified product purified to adesired extent may be used, or a material containing vanillic acid maybe used. The material containing vanillic acid is not particularlylimited so long as a component that catalyzes the conversion, such as amicroorganism and an enzyme, can use vanillic acid. Specific examples ofthe material containing vanillic acid can include a culture broth orreaction mixture containing vanillic acid, a supernatant separated fromthe culture broth or reaction mixture, and processed products thereofsuch as concentrated products, such as concentrated liquid, thereof anddried products thereof.

The method for converting vanillic acid into vanillin is notparticularly limited.

Vanillic acid can be converted into vanillin by, for example, abioconversion method using a microorganism having ACAR. Themicroorganism having ACAR may be or may not be modified to have aBacteroidetes OMT gene. The descriptions concerning the microorganism asdescribed herein can be applied mutatis mutandis to the microorganismhaving ACAR, except that the microorganism having ACAR has ACAR and maybe or may not be modified to have a Bacteroidetes OMT gene. Themicroorganism having ACAR may be modified so that the activity oractivities of one or more of ACAR, PPT, and the vanillic acid uptakesystem is/are enhanced. In addition, the descriptions concerning thebioconversion method for producing an objective substance using themicroorganism can be applied mutatis mutandis to the bioconversionmethod for converting vanillic acid into vanillin using a microorganismhaving ACAR.

Vanillic acid can also be converted into vanillin by, for example, anenzymatic method using ACAR.

ACAR can be produced by allowing a host having an ACAR gene to expressthe ACAR gene. ACAR can also be produced with a cell-free proteinexpression system.

A host having an ACAR gene can also be referred to as a “host havingACAR”. The host having an ACAR gene may be a host inherently having theACAR gene or may be a host modified to have the ACAR gene. Examples ofthe host inherently having an ACAR gene can include organisms from whichACARs exemplified above are derived. Examples of the host modified tohave an ACAR gene can include hosts into which the ACAR gene has beenintroduced. Also, a host inherently having an ACAR gene may be modifiedso that the ACAR is increased. The host to be used for expression ofACAR is not particularly limited, so long as the host can express anACAR that can function. Examples of the host can include, for example,microorganisms such as bacteria and yeast (fungi), plant cells, insectcells, and animal cells.

An ACAR gene can be expressed by cultivating a host having the ACARgene. The culture method is not particularly limited so long as the hosthaving the ACAR gene can proliferate and express ACAR. The descriptionsconcerning the culture for the fermentation method can be appliedmutatis mutandis to the culture of the host having the ACAR gene. Asnecessarily, expression of the ACAR gene can be induced. As a result ofcultivation, a culture broth containing ACAR can be obtained. ACAR canbe accumulated in cells of the host and/or the culture medium.

ACAR contained in the cells of the host, the culture medium, or the likemay be used as they are for the enzymatic reaction, or ACAR purifiedtherefrom may be used for the enzymatic reaction. Purification can beperformed to a desired extent. That is, as ACAR, purified ACAR may beused, or a fraction containing ACAR may be used. Such a fraction is notparticularly limited, so long as ACAR contained therein can act tovanillic acid. Examples of such a fraction can include, a culture brothof a host having an ACAR gene, that is, a host having ACAR; cellscollected from the culture broth; processed products of the cells, suchas cell disruptant, cell lysate, cell extract, and immobilized cellssuch as those immobilized with acrylamide, carrageenan, or the like; aculture supernatant collected from the culture broth; partially purifiedproducts thereof, such as a crude product; and combinations thereof.These fractions may be used independently, or in combination withpurified ACAR.

The enzymatic reaction can be performed by allowing ACAR to act onvanillic acid. Conditions of the enzymatic reaction are not particularlylimited so long as vanillin is generated. The enzymatic reaction can beperformed with, for example, typical conditions used for substanceconversion using an enzyme or microbial cells such as resting cells. Forexample, the descriptions concerning the conversion reaction in in thesecond embodiment of the bioconversion method may also be appliedmutatis mutandis to the enzymatic reaction in the vanillin productionmethod.

A reaction mixture containing vanillin is obtained by carrying out theconversion as described above. Confirmation of the production ofvanillin and collection of vanillin can be carried out in the samemanners as those for the fermentation method described above. That is,the vanillin production method may further comprise a step of collectingvanillin from the reaction mixture. The collected vanillin may contain,for example, microbial cells, medium components, reaction mixturecomponents, ACAR, moisture, and by-product metabolites of themicroorganism, in addition to vanillin. Purity of the collected vanillinmay be, for example, 30% (w/w) or higher, 50% (w/w) or higher, 70% (w/w)or higher, 80% (w/w) or higher, 90% (w/w) or higher, or 95% (w/w) orhigher.

Vanillic acid can also be converted to guaiacol by, for example, abioconversion method using a microorganism having VDC or an enzymaticmethod using VDC. Ferulic acid can be converted to 4-vinylguaiacol by,for example, a bioconversion method using a microorganism having FDC oran enzymatic method using FDC. 4-vinylguaiacol can be converted to4-ethylguaiacol by, for example, a bioconversion method using amicroorganism having VPR or an enzymatic method using VPR. Ferulic acidcan also be converted to 4-ethylguaiacol by a combination of thesemethods. Specifically, ferulic acid can be converted to 4-ethylguaiacolby, for example, using FDC or a microorganism having FDC in combinationwith VPR or a microorganism having VPR simultaneously or sequentially,or using a microorganism having both FDC and VPR. The aforementioneddescriptions concerning the vanillin production method can be appliedmutatis mutandis to methods for producing other objective substances.

Examples

Hereafter, the present invention will be more specifically explainedwith reference to the following non-limiting examples.

In this example, strains harboring various OMT genes were constructedfrom the Corynebacterium glutamicum 2256 strain (ATCC 13869) as a parentstrain, and vanillic acid production was performed with the constructedstrains.

<1> Construction of Strain Deficient in Vanillate Demethylase Genes(FKS0165 Strain)

It has been reported that, in coryneform bacteria, vanillin ismetabolized in the order of vanillin→vanillic acid→protocatechuic acid,and utilized (Current Microbiology, 2005, Vol. 51, pp. 59-65). Theconversion reaction from vanillic acid to protocatechuic acid iscatalyzed by vanillate demethylase. The vanA gene and vanB gene encodethe subunit A and subunit B of vanillate demethylase, respectively. ThevanK gene encodes the vanillic acid uptake system, and constitutes thevanABK operon together with the vanAB genes (M. T. Chaudhry, et al.,Microbiology, 2007, 153:857-865). Therefore, a strain deficient inutilization ability of an objective substance such as vanillin andvanillic acid (FKS0165 strain) was first constructed from C. glutamicum2256 strain by deleting the vanABK operon. The procedure is shown below.

<1-1> Construction of Plasmid pBS4SΔvanABK56 for Deletion of vanABKGenes

PCR was performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 51 and 52as the primers to obtain a PCR product containing an N-terminus sidecoding region of the vanA gene. Separately, PCR was also performed byusing the genomic DNA of the C. glutamicum 2256 strain as the template,and the synthetic DNAs of SEQ ID NOS: 53 and 54 as the primers to obtaina PCR product containing a C-terminus side coding region of the vanKgene. The sequences of SEQ ID NOS: 52 and 53 are partially complementaryto each other. Then, the PCR product containing the N-terminus sidecoding region of the vanA gene and the PCR product containing theC-terminus side coding region of the vanK gene were mixed inapproximately equimolar amounts, and inserted into the pBS4S vector(WO2007/046389) treated with BamHI and PstI by using In Fusion HDCloning Kit (Clontech). With this DNA, competent cells of Escherichiacoli JM109 (Takara Bio) were transformed, and the cells were applied tothe LB medium containing 100 μM IPTG, 40 μg/mL of X-Gal, and 40 μg/mL ofkanamycin, and cultured overnight. Then, white colonies that appearedwere picked up, and separated into single colonies to obtaintransformants. Plasmids were extracted from the obtained transformants,and one into which the target PCR product was inserted was designated aspBS4SΔvanABK56.

<1-2> Construction of FKS0165 Strain

pBS4SΔvanABK56 obtained above does not contain the region enablingautonomous replication of the plasmid in cells of coryneform bacteria.Therefore, if coryneform bacteria are transformed with this plasmid, astrain in which this plasmid is incorporated into the genome byhomologous recombination appears as a transformant, although it occursat an extremely low frequency. Therefore, pBS4SΔvanABK56 was introducedinto the C. glutamicum 2256 strain by the electric pulse method. Thecells were applied to the CM-Dex agar medium (5 g/L of glucose, 10 g/Lof polypeptone, 10 g/L of yeast extract, 1 g/L of KH₂PO₄, 0.4 g/L ofMgSO₄-7H₂O, 0.01 g/L of FeSO₄-7H₂O, 0.01 g/L of MnSO₄-7H₂O, 3 g/L ofurea, 1.2 g/L of soybean hydrolysate, 10 μg/L of biotin, 15 g/L of agar,adjusted to pH 7.5 with NaOH) containing 25 μg/mL of kanamycin, andcultured at 31.5° C. It was confirmed by PCR that the grown strain was aonce-recombinant strain in which pBS4SΔvanABK56 was incorporated intothe genome by homologous recombination. This once-recombinant strain hadboth the wild-type vanABK genes, and the deficient-type vanABK genes.

The once-recombinant strain was cultured overnight in the CM-Dex liquidmedium (having the same composition as that of the CM-Dex agar mediumexcept that it does not contain agar), and the culture broth was appliedto the S10 agar medium (100 g/L of sucrose, 10 g/L of polypeptone, 10g/L of yeast extract, 1 g/L of KH₂PO₄, 0.4 g/L of MgSO₄-7H₂O, 0.01 g/Lof FeSO₄-7H₂O, 0.01 g/L of MnSO₄-4-5H₂O, 3 g/L of urea, 1.2 g/L ofsoybean protein hydrolysate solution, 10 μg/L of biotin, 20 g/L of agar,adjusted to pH 7.5 with NaOH, and autoclaved at 120° C. for 20 minutes),and cultured at 31.5° C. Among the colonies that appeared, a strain thatshowed kanamycin susceptibility was purified on the CM-Dex agar medium.By preparing genomic DNA from the purified strain, and using it toperform PCR with the synthetic DNAs of SEQ ID NOS: 55 and 56 as theprimers, deletion of the vanABK genes was confirmed, and the strain wasdesignated as FKS0165 strain.

<2> Construction of Strain Deficient in Alcohol Dehydrogenase HomologueGenes (FKFC14 Strain)

Subsequently, by using the Corynebacterium glutamicum FKS0165 strain asa parent strain, there was constructed a strain FKFC14, which isdeficient in alcohol dehydrogenase homologue genes, i.e. NCgl0324 gene(adhC), NCgl0313 gene (adhE), and NCgl2709 gene (adhA), via thefollowing procedure.

<2-1> Construction of FKFC5 Strain (FKS0165ΔNCgl0324 Strain)

<2-1-1> Construction of Plasmid pBS4SΔ2256adhC for Deletion of NCgl0324Gene

PCR was performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 57 and 58as the primers to obtain a PCR product containing an N-terminus sidecoding region of the NCgl0324 gene. Separately, PCR was performed byusing the genomic DNA of the C. glutamicum 2256 strain as the template,and the synthetic DNAs of SEQ ID NOS: 59 and 60 as the primers to obtaina PCR product containing a C-terminus side coding region of the NCgl0324gene. The sequences of SEQ ID NOS: 58 and 59 are partially complementaryto each other. Then, approximately equimolar amounts of the PCR productcontaining the N-terminus side coding region of the NCgl0324 gene andthe PCR product containing the C-terminus side coding region of theNCgl0324 gene were mixed, and inserted into the pBS4S vector(WO2007/046389) treated with BamHI and PstI by using In Fusion HDCloning Kit (Clontech). With this DNA, competent cells of Escherichiacoli JM109 (Takara Bio) were transformed, and the cells were applied tothe LB medium containing 100 μM IPTG, 40 μg/mL of X-Gal, and 40 μg/mL ofkanamycin, and cultured overnight. Then, white colonies that appearedwere picked up, and separated into single colonies to obtaintransformants. Plasmids were extracted from the obtained transformants,and one in which the target PCR product was inserted was designated aspBS4SΔ2256adhC.

<2-1-2> Construction of FKFC5 Strain (FKS0165ΔNCgl0324 Strain)

Since pBS4SΔ2256adhC obtained above does not contain the region enablingautonomous replication of the plasmid in cells of coryneform bacteria,if coryneform bacteria are transformed with this plasmid, a strain inwhich this plasmid is incorporated into the genome by homologousrecombination appears as a transformant, although it occurs at anextremely low frequency. Therefore, pBS4SΔ2256adhC was introduced intothe C. glutamicum FKS0165 strain by the electric pulse method. The cellswere applied to the CM-Dex agar medium containing 25 μg/mL of kanamycin,and cultured at 31.5° C. It was confirmed by PCR that the grown strainwas a once-recombinant strain in which pBS4SΔ2256adhC was incorporatedinto the genome by homologous recombination. This once-recombinantstrain had both the wild-type NCgl0324 gene, and the deficient-typeNCgl0324 gene.

The once-recombinant strain was cultured overnight in the CM-Dex liquidmedium, the culture broth was applied to the S10 agar medium, andculture was performed at 31.5° C. Among the colonies that appeared, astrain that showed kanamycin susceptibility was purified on the CM-Dexagar medium. Genomic DNA was prepared from the purified strain, and usedto perform PCR with the synthetic DNAs of SEQ ID NOS: 61 and 62 as theprimers to confirm deletion of the NCgl0324 gene, and the strain wasdesignated as FKFC5 strain.

<2-2> Construction of FKFC11 Strain (2256ΔvanABKΔNCgl0324ΔNCgl0313strain)

<2-2-1> Construction of Plasmid pBS4SΔ2256adhE for Deletion of NCgl0313Gene

PCR was performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 63 and 64as the primers to obtain a PCR product containing an N-terminus sidecoding region of the NCgl0313 gene. Separately, PCR was performed byusing the genomic DNA of the C. glutamicum 2256 strain as the template,and the synthetic DNAs of SEQ ID NOS: 65 and 66 as the primers to obtaina PCR product containing a C-terminus side coding region of the NCgl0313gene. The sequences of SEQ ID NOS: 64 and 65 are partially complementaryto each other. Then, approximately equimolar amounts of the PCR productcontaining the N-terminus side coding region of the NCgl0313 gene andthe PCR product containing the C-terminus side coding region of theNCgl0313 gene were mixed, and inserted into the pBS4S vector(WO2007/046389) treated with BamHI and PstI by using In Fusion HDCloning Kit (Clontech). With this DNA, competent cells of Escherichiacoli JM109 (Takara Bio) were transformed, and the cells were applied tothe LB medium containing 100 μM IPTG, 40 μg/mL of X-Gal, and 40 μg/mL ofkanamycin, and cultured overnight. Then, white colonies that appearedwere picked up, and separated into single colonies to obtaintransformants. Plasmids were extracted from the obtained transformants,and one in which the target PCR product was inserted was designated aspBS4SΔ2256adhE.

<2-2-2> Construction of FKFC11 Strain (2256ΔvanABKΔNCgl0324ΔNCgl0313Strain)

Since pBS4SΔ2256adhE obtained above does not contain the region enablingautonomous replication of the plasmid in cells of coryneform bacteria,if coryneform bacteria are transformed with this plasmid, a strain inwhich this plasmid is incorporated into the genome by homologousrecombination appears as a transformant, although it occurs at anextremely low frequency. Therefore, pBS4SΔ2256adhE was introduced intothe C. glutamicum FKFC5 strain by the electric pulse method. The cellswere applied to the CM-Dex agar medium containing 25 μg/mL of kanamycin,and cultured at 31.5° C. It was confirmed by PCR that the grown strainwas a once-recombinant strain in which pBS4SΔ2256adhE was incorporatedinto the genome by homologous recombination. This once-recombinantstrain had both the wild-type NCgl0313 gene, and the deficient-typeNCgl0313 gene.

The once-recombinant strain was cultured overnight in the CM-Dex liquidmedium, the culture broth was applied to the S10 agar medium, andculture was performed at 31.5° C. Among the colonies that appeared, astrain that showed kanamycin susceptibility was purified on the CM-Dexagar medium. Genomic DNA was prepared from the purified strain, and usedto perform PCR with the synthetic DNAs of SEQ ID NOS: 67 and 68 as theprimers to confirm deletion of the NCgl0313 gene, and the strain wasdesignated as FKFC11 strain.

<2-3> Construction of FKFC14 Strain(2256ΔvanABKΔNCgl0324ΔNCgl0313ΔNCgl2709 Strain)

<2-3-1> Construction of Plasmid pBS4SΔ2256adhA for Deletion of NCgl2709Gene

PCR was performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 69 and 70as the primers to obtain a PCR product containing an N-terminus sidecoding region of the NCgl2709 gene. Separately, PCR was performed byusing the genomic DNA of the C. glutamicum 2256 strain as the template,and the synthetic DNAs of SEQ ID NOS: 71 and 72 as the primers to obtaina PCR product containing a C-terminus side coding region of the NCgl2709gene. The sequences of SEQ ID NOS: 70 and 71 are partially complementaryto each other. Then, approximately equimolar amounts of the PCR productcontaining the N-terminus side coding region of the NCgl2709 gene andthe PCR product containing the C-terminus side coding region of theNCgl2709 gene were mixed, and inserted into the pBS4S vector treatedwith BamHI and PstI by using In Fusion HD Cloning Kit (Clontech). Withthis DNA, competent cells of Escherichia coli JM109 (Takara Bio) weretransformed, and the cells were applied to the LB medium containing 100μM IPTG, 40 μg/mL of X-Gal, and 40 μg/mL of kanamycin, and culturedovernight. Then, white colonies that appeared were picked up, andseparated into single colonies to obtain transformants. Plasmids wereextracted from the obtained transformants, and one in which the targetPCR product was inserted was designated as pBS4SΔ2256adhA.

<2-3-2> Construction of FKFC14 Strain(2256ΔvanABKΔNCgl0324ΔNCgl0313ΔNCgl2709 Strain)

Since pBS4SΔ2256adhA obtained above does not contain the region enablingautonomous replication of the plasmid in cells of coryneform bacteria,if coryneform bacteria are transformed with this plasmid, a strain inwhich this plasmid is incorporated into the genome by homologousrecombination appears as a transformant, although it occurs at anextremely low frequency. Therefore, pBS4SΔ2256adhA was introduced intothe C. glutamicum FKFC11 strain by the electric pulse method. The cellswere applied to the CM-Dex agar medium containing 25 μg/mL of kanamycin,and cultured at 31.5° C. It was confirmed by PCR that the grown strainwas a once-recombinant strain in which pBS4SΔ2256adhA was incorporatedinto the genome by homologous recombination. This once-recombinantstrain had both the wild-type NCgl2709 gene, and the deficient-typeNCgl2709 gene.

The once-recombinant strain was cultured overnight in the CM-Dex liquidmedium, the culture broth was applied to the S10 agar medium, andculture was performed at 31.5° C. Among the colonies that appeared, astrain that showed kanamycin susceptibility was purified on the CM-Dexagar medium. Genomic DNA was prepared from the purified strain, and usedto perform PCR with the synthetic DNAs of SEQ ID NOS: 73 and 74 as theprimers to confirm deletion of the NCgl2709 gene, and the strain wasdesignated as FKFC14 strain.

<3> Construction of Strain Deficient in Protocatechuic Acid DioxygenaseGenes (FKFC14ΔpcaGH Strain)

Subsequently, by using the Corynebacterium glutamicum FKFC14 strain as aparent strain, there was constructed a strain FKFC14ΔpcaGH, which isdeficient in NCgl2314 gene (pcaG) and NCgl2315 gene (pcaH) encoding thealpha subunit and beta subunit of protocatechuate 3,4-dioxygenase, byoutsourcing. The FKFC14ΔpcaGH strain can also be constructed via thefollowing procedure.

<3-1> Construction of Plasmid pBS4SΔ2256pcaGH for Deletion of NCgl2314and NCgl2315 Genes

NCgl2314 and NCgl2315 genes are adjacent to each other, and thereforethese genes can be deleted all together. PCR is performed by using thegenomic DNA of the C. glutamicum 2256 strain as the template, and thesynthetic DNAs of SEQ ID NOS: 75 and 76 as the primers to obtain a PCRproduct containing an upstream region of the NCgl2315 gene. Separately,PCR is performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 77 and 78as the primers to obtain a PCR product containing a downstream region ofthe NCgl2314 gene. The sequences of SEQ ID NOS: 76 and 77 are partiallycomplementary to each other. Then, approximately equimolar amounts ofthe PCR product containing the upstream region of the NCgl2315 gene andthe PCR product containing the downstream region of the NCgl2314 geneare mixed, and inserted into the pBS4S vector (WO2007/046389) treatedwith BamHI and PstI by using In Fusion HD Cloning Kit (Clontech). Withthis DNA, competent cells of Escherichia coli JM109 (Takara Bio) aretransformed, and the cells are applied to the LB medium containing 100μM IPTG, 40 μg/mL of X-Gal, and 40 μg/mL of kanamycin, and culturedovernight. Then, white colonies that appeared are picked up, andseparated into single colonies to obtain transformants. Plasmids areextracted from the obtained transformants, and one in which the targetPCR product is inserted is designated as pBS4SΔ2256pcaGH.

<3-2> Construction of FKFC14ΔpcaGH Strain

Since pBS4SΔ2256pcaGH obtained above does not contain the regionenabling autonomous replication of the plasmid in cells of coryneformbacteria, if coryneform bacteria are transformed with this plasmid, astrain in which this plasmid is incorporated into the genome byhomologous recombination appears as a transformant, although it occursat an extremely low frequency. Therefore, pBS4SΔ2256pcaGH is introducedinto the C. glutamicum FKFC14 strain by the electric pulse method. Thecells are applied to the CM-Dex agar medium containing 25 μg/mL ofkanamycin, and cultured at 31.5° C. It is confirmed by PCR that thegrown strain is a once-recombinant strain in which pBS4SΔ2256pcaGH isincorporated into the genome by homologous recombination. Thisonce-recombinant strain has both the wild-type NCgl2314 and NCgl2315genes, and the deficient-type NCgl2314 and NCgl2315 genes.

The once-recombinant strain is cultured overnight in the CM-Dex liquidmedium, the culture broth is applied to the S10 agar medium, and cultureis performed at 31.5° C. Among the colonies that appear, a strain thatshows kanamycin susceptibility is purified on the CM-Dex agar medium.Genomic DNA is prepared from the purified strain, and used to performPCR with the synthetic DNAs of SEQ ID NOS: 79 and 80 as the primers toconfirm deletion of the NCgl2314 and NCgl2315 genes, and the strain isdesignated as FKFC14ΔpcaGH strain.

<4> Construction of Dp2_0340 Strain (FKFC14ΔpcaGH P2::NCgl0120P8::NCgl2048 P4::NCgl0935 Strain)

<4-1> Construction of Ap1_0007 Strain (FKFC14ΔpcaGH P2::NCgl0120 Strain)

Subsequently, by using the Corynebacterium glutamicum FKFC14ApcaGHstrain as a parent strain, there was constructed a strain Ap1_0007, inwhich the promoter region of NCgl0120 gene (cysR) encoding a Crp familyexpression regulatory protein has been replaced with the P2 promoter toenhance the expression of this gene, by outsourcing. The nucleotidesequence of a genomic region containing the P2 promoter in this strainis shown as SEQ ID NO: 108, wherein position 942-1034 corresponds to theP2 promoter. The Ap1_0007 strain can also be constructed via thefollowing procedure.

<4-1-1> Construction of Plasmid pBS4SP2::NCgl0120 for Substitution ofNCgl0120 Gene Promoter

PCR is performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 81 and 82as the primers to obtain a PCR product containing an upstream region ofthe NCgl0120 gene. Separately, PCR is performed by using the genomic DNAof the C. glutamicum 2256 strain as the template, and the synthetic DNAsof SEQ ID NOS: 83 and 84 as the primers to obtain a PCR productcontaining an N-terminus side coding region of the NCgl0120 gene. Inaddition, a DNA fragment of SEQ ID NO: 85 containing P2 promoter regionis obtained by artificial gene synthesis. And then, PCR is performed byusing the DNA fragment of SEQ ID NO: 85 as the template, and thesynthetic DNAs of SEQ ID NOS: 86 and 87 as the primers to obtain a PCRproduct containing the P2 promoter. The sequences of SEQ ID NOS: 82 and86 are partially complementary to each other, and the sequences of SEQID NOS: 83 and 87 are partially complementary to each other. Then,approximately equimolar amounts of the PCR product containing theupstream region of the NCgl0120 gene, the PCR product containing theN-terminus side coding region of the NCgl0120 gene, and the PCR productcontaining the P2 promoter are mixed, and inserted into the pBS4S vector(WO2007/046389) treated with BamHI and PstI by using In Fusion HDCloning Kit (Clontech). With this DNA, competent cells of Escherichiacoli JM109 (Takara Bio) are transformed, and the cells are applied tothe LB medium containing 100 μM IPTG, 40 μg/mL of X-Gal, and 40 μg/mL ofkanamycin, and cultured overnight. Then, white colonies that appearedare picked up, and separated into single colonies to obtaintransformants. Plasmids are extracted from the obtained transformants,and one in which the target PCR product is inserted is designated aspBS4SP2::NCgl0120.

<4-1-2> Construction of Ap1_0007 Strain

Since pBS4SP2::NCgl0120 obtained above does not contain the regionenabling autonomous replication of the plasmid in cells of coryneformbacteria, if coryneform bacteria are transformed with this plasmid, astrain in which this plasmid is incorporated into the genome byhomologous recombination appears as a transformant, although it occursat an extremely low frequency. Therefore, pBS4SP2::NCgl0120 isintroduced into the C. glutamicum FKFC14ΔpcaGH strain by the electricpulse method. The cells are applied to the CM-Dex agar medium containing25 μg/mL of kanamycin, and cultured at 31.5° C. It is confirmed by PCRthat the grown strain is a once-recombinant strain in whichpBS4SP2::NCgl0120 is incorporated into the genome by homologousrecombination.

The once-recombinant strain is cultured overnight in the CM-Dex liquidmedium, the culture broth is applied to the S10 agar medium, and cultureis performed at 31.5° C. Among the colonies that appear, a strain thatshows kanamycin susceptibility is purified on the CM-Dex agar medium.Genomic DNA is prepared from the purified strain, and used to performnucleotide sequence analysis to confirm that P2 promoter is locatedupstream of the NCgl0120 gene, and the strain is designated as Ap1_0007strain.

<4-2> Construction of Bp1_0112 Strain (FKFC14ΔpcaGH P2::NCgl0120P8::NCgl2048 Strain)

Subsequently, by using the Corynebacterium glutamicum Ap1_0007 strain asa parent strain, there was constructed a strain Bp1_0112, in which thepromoter region of NCgl2048 gene has been replaced with the P8 promoterto attenuate the expression of this gene, by outsourcing. The nucleotidesequence of a genomic region containing the P8 promoter in this strainis shown as SEQ ID NO: 110, wherein position 901-1046 corresponds to theP8 promoter. The Bp1_0112 strain can also be constructed via thefollowing procedure.

<4-2-1> Construction of Plasmid pBS4SP8::NCgl2048 for Substitution ofNCgl2048 Gene Promoter

PCR is performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 112 and113 as the primers to obtain a PCR product containing an upstream regionof the NCgl2048 gene. Separately, PCR is performed by using the genomicDNA of the C. glutamicum 2256 strain as the template, and the syntheticDNAs of SEQ ID NOS: 114 and 115 as the primers to obtain a PCR productcontaining an N-terminus side coding region of the NCgl2048 gene. Inaddition, a DNA fragment of SEQ ID NO: 116 containing P8 promoter regionis obtained by artificial gene synthesis. And then, PCR is performed byusing the DNA fragment of SEQ ID NO: 116 as the template, and thesynthetic DNAs of SEQ ID NOS: 117 and 118 as the primers to obtain a PCRproduct containing the P8 promoter. The sequences of SEQ ID NOS: 113 and117 are partially complementary to each other, and the sequences of SEQID NOS: 114 and 118 are partially complementary to each other. Then,approximately equimolar amounts of the PCR product containing theupstream region of the NCgl2048 gene, the PCR product containing theN-terminus side coding region of the NCgl2048 gene, and the PCR productcontaining the P8 promoter are mixed, and inserted into the pBS4S vector(WO2007/046389) treated with BamHI and PstI by using In Fusion HDCloning Kit (Clontech). With this DNA, competent cells of Escherichiacoli JM109 (Takara Bio) are transformed, and the cells are applied tothe LB medium containing 100 μM IPTG, 40 μg/mL of X-Gal, and 40 μg/mL ofkanamycin, and cultured overnight. Then, white colonies that appearedare picked up, and separated into single colonies to obtaintransformants. Plasmids are extracted from the obtained transformants,and one in which the target PCR product is inserted is designated aspBS4SP8::NCgl2048.

<4-2-2> Construction of Bp1_0112 Strain

Since pBS4SP8::NCgl2048 obtained above does not contain the regionenabling autonomous replication of the plasmid in cells of coryneformbacteria, if coryneform bacteria are transformed with this plasmid, astrain in which this plasmid is incorporated into the genome byhomologous recombination appears as a transformant, although it occursat an extremely low frequency. Therefore, pBS4SP8::NCgl2048 isintroduced into the C. glutamicum Ap1_0007 strain by the electric pulsemethod. The cells are applied to the CM-Dex agar medium containing 25μg/mL of kanamycin, and cultured at 31.5° C. It is confirmed by PCR thatthe grown strain is a once-recombinant strain in which pBS4SP8::NCgl2048is incorporated into the genome by homologous recombination.

The once-recombinant strain is cultured overnight in the CM-Dex liquidmedium, the culture broth is applied to the S10 agar medium, and cultureis performed at 31.5° C. Among the colonies that appear, a strain thatshows kanamycin susceptibility is purified on the CM-Dex agar medium.Genomic DNA is prepared from the purified strain, and used to performnucleotide sequence analysis to confirm that P8 promoter is locatedupstream of the NCgl2048 gene, and the strain is designated as Bp1_0112strain.

<4-3> Construction of Dp2_0340 Strain (FKFC14ΔpcaGH P2::NCgl0120P8::NCgl2048 P4::NCgl0935 Strain)

Subsequently, by using the Corynebacterium glutamicum Bp1_0112 strain asa parent strain, there was constructed a strain Dp2_0340, in which thepromoter region of NCgl0935 gene (eno) encoding enolase has beenreplaced with the P4 promoter to attenuate the expression of this gene,by outsourcing. The nucleotide sequence of a genomic region containingthe P4 promoter in this strain is shown as SEQ ID NO: 109, whereinposition 872-969 corresponds to the P4 promoter. The Dp2_0340 strain canalso be constructed via the following procedure.

<4-3-1> Construction of Plasmid pBS4SP4::NCgl0935 for Substitution ofNCgl0935 Gene Promoter

PCR is performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 121 and122 as the primers to obtain a PCR product containing an upstream regionof the NCgl0935 gene. Separately, PCR is performed by using the genomicDNA of the C. glutamicum 2256 strain as the template, and the syntheticDNAs of SEQ ID NOS: 123 and 124 as the primers to obtain a PCR productcontaining an N-terminus side coding region of the NCgl0935 gene. Inaddition, a DNA fragment of SEQ ID NO: 125 containing P4 promoter regionis obtained by artificial gene synthesis. And then, PCR is performed byusing the DNA fragment of SEQ ID NO: 125 as the template, and thesynthetic DNAs of SEQ ID NOS: 126 and 127 as the primers to obtain a PCRproduct containing the P4 promoter. The sequences of SEQ ID NOS: 122 and126 are partially complementary to each other, and the sequences of SEQID NOS: 123 and 127 are partially complementary to each other. Then,approximately equimolar amounts of the PCR product containing theupstream region of the NCgl0935 gene, the PCR product containing theN-terminus side coding region of the NCgl0935 gene, and the PCR productcontaining the P4 promoter are mixed, and inserted into the pBS4S vector(WO2007/046389) treated with BamHI and PstI by using In Fusion HDCloning Kit (Clontech). With this DNA, competent cells of Escherichiacoli JM109 (Takara Bio) are transformed, and the cells are applied tothe LB medium containing 100 μM IPTG, 40 μg/mL of X-Gal, and 40 μg/mL ofkanamycin, and cultured overnight. Then, white colonies that appearedare picked up, and separated into single colonies to obtaintransformants. Plasmids are extracted from the obtained transformants,and one in which the target PCR product is inserted is designated aspBS4SP4::NCgl0935.

<4-3-2> Construction of Dp2_0340 Strain

Since pBS4SP4::NCgl0935 obtained above does not contain the regionenabling autonomous replication of the plasmid in cells of coryneformbacteria, if coryneform bacteria are transformed with this plasmid, astrain in which this plasmid is incorporated into the genome byhomologous recombination appears as a transformant, although it occursat an extremely low frequency. Therefore, pBS4SP4::NCgl0935 isintroduced into the C. glutamicum Bp1_0112 strain by the electric pulsemethod. The cells are applied to the CM-Dex agar medium containing 25μg/mL of kanamycin, and cultured at 31.5° C. It is confirmed by PCR thatthe grown strain is a once-recombinant strain in which pBS4SP4::NCgl0935is incorporated into the genome by homologous recombination.

The once-recombinant strain is cultured overnight in the CM-Dex liquidmedium, the culture broth is applied to the S10 agar medium, and cultureis performed at 31.5° C. Among the colonies that appear, a strain thatshows kanamycin susceptibility is purified on the CM-Dex agar medium.Genomic DNA is prepared from the purified strain, and used to performnucleotide sequence analysis to confirm that P4 promoter is locatedupstream of the NCgl0935 gene, and the strain is designated as Dp2_0340strain.

<5> Construction of Ep2_0055 Strain (FKFC14ΔpcaGH P2::NCgl0120P8::NCgl2048 P4::NCgl0935 P3::NCgl0719 Strain)

Subsequently, by using the Corynebacterium glutamicum Dp2_0340 strain asa parent strain, there was constructed a strain Ep2_0055, in which thepromoter region of NCgl0719 gene (sahH) encodingS-adenosyl-L-homocysteine hydrolase has been replaced with the P3promoter, by outsourcing. The nucleotide sequence the P3 promoter isshown as SEQ ID NO: 111. The Ep2_0055 strain can also be constructed viathe following procedure.

<5-1> Construction of Plasmid pBS4SP3::NCgl0719 for Substitution ofNCgl0719 Gene Promoter

PCR is performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 169 and170 as the primers to obtain a PCR product containing an upstream regionof the NCgl0719 gene. Separately, PCR is performed by using the genomicDNA of the C. glutamicum 2256 strain as the template, and the syntheticDNAs of SEQ ID NOS: 171 and 172 as the primers to obtain a PCR productcontaining an N-terminus side coding region of the NCgl0719 gene. Inaddition, a DNA fragment of SEQ ID NO: 111 containing P3 promoter regionis obtained by artificial gene synthesis. And then, PCR is performed byusing the DNA fragment of SEQ ID NO: 111 as the template, and thesynthetic DNAs of SEQ ID NOS: 173 and 174 as the primers to obtain a PCRproduct containing the P3 promoter. The sequences of SEQ ID NOS: 170 and173 are partially complementary to each other, and the sequences of SEQID NOS: 171 and 174 are partially complementary to each other. Then,approximately equimolar amounts of the PCR product containing theupstream region of the NCgl0719 gene, the PCR product containing theN-terminus side coding region of the NCgl0719 gene, and the PCR productcontaining the P3 promoter are mixed, and inserted into the pBS4S vector(WO2007/046389) treated with BamHI and PstI by using In Fusion HDCloning Kit (Clontech). With this DNA, competent cells of Escherichiacoli JM109 (Takara Bio) are transformed, and the cells are applied tothe LB medium containing 100 μM IPTG, 40 μg/mL of X-Gal, and 40 μg/mL ofkanamycin, and cultured overnight. Then, white colonies that appearedare picked up, and separated into single colonies to obtaintransformants. Plasmids are extracted from the obtained transformants,and one in which the target PCR product is inserted is designated aspBS4SP3::NCgl0719.

<5-2> Construction of Ep2_0055 Strain

Since pBS4SP3::NCgl0719 obtained above does not contain the regionenabling autonomous replication of the plasmid in cells of coryneformbacteria, if coryneform bacteria are transformed with this plasmid, astrain in which this plasmid is incorporated into the genome byhomologous recombination appears as a transformant, although it occursat an extremely low frequency. Therefore, pBS4SP3::NCgl0719 isintroduced into the C. glutamicum Dp2_0340 strain by the electric pulsemethod. The cells are applied to the CM-Dex agar medium containing 25μg/mL of kanamycin, and cultured at 31.5° C. It is confirmed by PCR thatthe grown strain is a once-recombinant strain in which pBS4SP3::NCgl0719is incorporated into the genome by homologous recombination.

The once-recombinant strain is cultured overnight in the CM-Dex liquidmedium, the culture broth is applied to the S10 agar medium, and cultureis performed at 31.5° C. Among the colonies that appear, a strain thatshows kanamycin susceptibility is purified on the CM-Dex agar medium.Genomic DNA is prepared from the purified strain, and used to performnucleotide sequence analysis to confirm that P3 promoter is locatedupstream of the NCgl0719 gene, and the strain is designated as Ep2_0055strain.

<6> Construction of C. glutamicum Ns1_0003 strain (FKFC14ΔpcaGHP2::NCgl0120 P8::NCgl2048 P4::NCgl0935 P3::NCgl0719 purH(S37F) Strain)

The Corynebacterium glutamicum Ns1_0003 strain, which corresponds to theC. glutamicum Ep2_0055 strain provided that the Ns1_0003 strain harborsthe purH(S37F) gene, which is a mutant purH gene, instead of thewild-type purH gene, was obtained by outsourcing. The purH(S37F) geneencodes PurH(S37F) protein, which has a mutation that the serine residueat position 37 is replaced with a phenylalanine residue. The nucleotidesequence of the corresponding wild-type purH gene is shown as SEQ ID NO:177, and the amino acid sequence of the corresponding wild-type purHprotein is shown as SEQ ID NO: 178. The nucleotide sequence of thepurH(S37F) gene is shown as SEQ ID NO: 179, and the amino acid sequenceof the purH(S37F) protein is shown as SEQ ID NO: 180. The Ns1_0003strain can also be constructed via the following procedure.

<6-1> Construction of Plasmid pBS4SΔ2256purH(S37F) for Introduction ofpurH(S37F) Mutation

PCR is performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 181 and182 as the primers to obtain a PCR product containing an N-terminus sidecoding region of the purH gene. Separately, PCR is performed by usingthe genomic DNA of the C. glutamicum 2256 strain as the template, andthe synthetic DNAs of SEQ ID NOS: 183 and 184 as the primers to obtain aPCR product containing a C-terminus side coding region of the purH gene.In addition, a DNA fragment of SEQ ID NO: 185 is obtained by artificialgene synthesis. The sequences of SEQ ID NOS: 182 and 185 are partiallycomplementary to each other, and the sequences of SEQ ID NOS: 183 and185 are partially complementary to each other. Then, approximatelyequimolar amounts of the PCR product containing the N-terminus sidecoding region of the purH gene, the DNA fragment of SEQ ID NO: 185, andthe PCR product containing the C-terminus side coding region of the purHgene are mixed, and inserted into the pBS4S vector treated with BamHIand PstI by using In Fusion HD Cloning Kit (Clontech). With this DNA,competent cells of Escherichia coli JM109 (Takara Bio) are transformed,and the cells are applied to the LB medium containing 100 μM IPTG, 40μg/mL of X-Gal, and 40 μg/mL of kanamycin, and cultured overnight. Then,white colonies that appeared are picked up, and separated into singlecolonies to obtain transformants. Plasmids are extracted from theobtained transformants, and one in which the target PCR product isinserted is designated as pBS4SΔ2256purH(S37F).

<6-2> Construction of Ns1_0003 Strain

Since pBS4SΔ2256purH(S37F) obtained above does not contain the regionenabling autonomous replication of the plasmid in cells of coryneformbacteria, if coryneform bacteria are transformed with this plasmid, astrain in which this plasmid is incorporated into the genome byhomologous recombination appears as a transformant, although it occursat an extremely low frequency. Therefore, pBS4SΔ2256purH(S37F) isintroduced into the C. glutamicum Ep2_0055 strain by the electric pulsemethod. The cells are applied to the CM-Dex agar medium containing 25μg/mL of kanamycin, and cultured at 31.5° C. It is confirmed by PCR thatthe grown strain is a once-recombinant strain in whichpBS4SΔ2256purH(S37F) is incorporated into the genome by homologousrecombination. The once-recombinant strain has both the wild-type purHgene, and the S37F type purH gene.

The once-recombinant strain is cultured overnight in the CM-Dex liquidmedium, the culture broth is applied to the S10 agar medium, and cultureis performed at 31.5° C. Among the colonies that appeared, a strain thatshowed kanamycin susceptibility is purified on the CM-Dex agar medium.Genomic DNA is prepared from the purified strains, and used to performPCR with the synthetic DNAs of SEQ ID NOS: 186 and 187 as the primers toconfirm introduction of the purH(S37F) gene, and the strain isdesignated as Ns1_0003 strain.

<7> Construction of Plasmids for Expression of OMT Genes

<7-1> Construction of Plasmid pVK9::PcspB-hsomt for Expression of OMTGene of Homo sapiens

<7-1-1> Construction of Plasmid pEPlac-COMT2

Four kinds of transcript variants and two kinds of OMT isoforms areknown for the OMT gene of Homo sapiens. The nucleotide sequences ofthese four transcript variants (transcript variant 1-4, GenBankAccession No. NM_000754.3, NM_001135161.1, NM_001135162.1, andNM_007310.2) are shown as SEQ ID NOS: 11 to 14, the amino acid sequenceof the longer OMT isoform (MB-COMT, GenBank Accession No. NP_000745.1)is shown as SEQ ID NO: 15, and the amino acid sequence of the shorterOMT isoform (S-COMT, GenBank Accession No. NP_009294.1) is shown as SEQID NO: 16. The nucleotide sequence of wild-type cDNA encoding S-COMT isshown as SEQ ID NO: 130. The wild-type cDNA of S-COMT wascodon-optimized for the expression in Escherichia coli (E. coli) andchemically synthesized using the service provided by ATG Service Gen(Russian Federation, Saint-Petersburg). To facilitate further cloning,the DNA fragment of gene was synthesized with sites for the restrictionenzymes NdeI and SacI at 3′ and 5′ ends respectively. Thecodon-optimized S-COMT cDNA can also be referred to as COMT2 gene. Thenucleotide sequence of the synthesized DNA fragment containing the COMT2gene is shown as SEQ ID NO: 131. The synthesized DNA fragment containingthe COMT2 gene was obtained in pUC57 vector (GenScript).

The expression of the COMT2 gene was confirmed in the T7 system. TheCOMT2 gene inserted in pUC57 vector was re-cloned into NdeI and SacIrestriction sites of pET22(+) vector (Novagen). The obtained plasmid wasintroduced into E. coli BL21(DE3) cells (Novagen). Cells containing theplasmid were grown in LB medium (Tryptone, 10 g/l; yeast extract, 5 g/l;NaCl, 10 g/l) containing ampicillin, 200 mg/l, and induced by IPTG, 1 mMwithin 2 h in the exponential phase of growth. Cells were disrupted bysonication. The crude protein extracts were analyzed usingelectrophoresis in 12% SDS-PAGE. The bands corresponding to S-OMT (about24 kDa) was identified and cut out from the gel. The objective proteinwas isolated from gel and treated with trypsin. The obtained tryptichydrolysates were analyzed using mass-spectroscopy to confirm theexpression of the COMT2 gene.

The COMT2 gene inserted in pUC57 vector was re-cloned into the NdeI andSacI restriction sites of the pELAC vector (SEQ ID NO: 132, Smirnov S.V. et al., Appl. Microbiol. Biotechnol. 2010, 88(3):719-726). The pELACvector was constructed by replacing BglII-XbaI-fragment of pET22b(+)(Novagen) with synthetic BglII-XbaI-fragment containing P_(lacUV5)promoter. To insert the COMT2 gene into the pELAC vector, ligationreaction using T4 DNA ligase (Fermentas, Lithuania) was performed asrecommended by the supplier. The ligation mixture was treated withethanol, and the obtained precipitate was dissolved in water andintroduced into E. coli TG1 cells using electroporation (Micro Pulser,BioRad) under the conditions recommended by the supplier. The cells wereapplied onto LA plates supplemented with ampicillin (200 mg/L) (SambrookJ. and Russell D. W., Molecular Cloning: A Laboratory Manual (3^(rd)ed.), Cold Spring Harbor Laboratory Press, 2001) and cultured overnightat 37° C. The obtained colonies were tested using PCR analysis to selectthe required clones. Primers P1 and P2 (SEQ ID NOS: 133 and 134) wereused to select colonies containing the COMT2 gene. A DNA-fragment (713bp) was obtained when vector-specific primer P1 and the reverse primerP2 for the ending of the COMT2 gene were used. Thus, the vectorpEPlac-COMT2 was constructed. The sequence of the cloned COMT2 gene wasdetermined using primers P1 and P3 (SEQ ID NOS: 133 and 135).

<7-1-2> Construction of Plasmid pVK9::PcspB-hsomt

PCR was performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 136 and137 as the primers to obtain a PCR product containing a PCR productcontaining a promoter region and SD sequence of cspB gene. Separately,PCR was also performed by using the plasmid pEPlac-COMT2 as thetemplate, and the synthetic DNAs of SEQ ID NOS: 138 and 139 as theprimers to obtain a PCR product containing the COMT2 gene. Then, thesePCR products were inserted into the pVK9 vector (WO2007/046389) treatedwith BamHI and PstI by using In Fusion HD Cloning Kit (Clontech). ThepVK9 vector is a shuttle-vector for coryneform bacteria and Escherichiacoli. With this DNA, competent cells of Escherichia coli JM109 (TakaraBio) were transformed, and the cells were applied to the LB mediumcontaining 100 μM IPTG, 40 μg/mL of X-Gal, and 25 μg/mL of kanamycin,and cultured overnight. Then, white colonies that appeared were pickedup, and separated into single colonies to obtain transformants. Plasmidswere extracted from the obtained transformants, and one into which thetarget PCR product was inserted was designated as pVK9::PcspB-hsomt.

<7-2> Construction of Plasmid pVK9::PcspB-omt35 for Expression of OMTGene of Niastella koreensis

The plasmid pVK9::PcspB-omt35 was obtained by outsourcing. The plasmidpVK9::PcspB-omt35 harbors OMT gene of Niastella koreensiscodon-optimized for the codon usage of C. glutamicum. This gene can alsobe referred to as “omt35 gene”, and OMT encoded by this gene can also bereferred to as “OMT35”. The nucleotide sequence of omt35 gene is shownas SEQ ID NO: 145, and the amino acid sequence of OMT35 is shown as SEQID NO: 141. The plasmid pVK9::PcspB-omt35 can also be constructed viathe following procedure.

PCR is performed by using the genomic DNA of the C. glutamicum 2256strain as the template, and the synthetic DNAs of SEQ ID NOS: 142 and143 as the primers to obtain a PCR product containing a PCR productcontaining a promoter region and SD sequence of cspB gene. Separately, aDNA fragment of SEQ ID NO: 144 containing an ORF of omt35 gene isobtained by artificial gene synthesis. Then, the PCR product and the DNAfragment are inserted into the pVK9 vector (WO2007/046389) treated withBamHI and PstI by using In Fusion HD Cloning Kit (Clontech). With thisDNA, competent cells of Escherichia coli JM109 (Takara Bio) aretransformed, and the cells are applied to the LB medium containing 100μM IPTG, 40 μg/mL of X-Gal, and 25 μg/mL of kanamycin, and culturedovernight. Then, white colonies that appeared are picked up, andseparated into single colonies to obtain transformants. Plasmids areextracted from the obtained transformants, and one into which the targetstructure is inserted is designated as pVK9::PcspB-omt35.

<7-3> Construction of Plasmids for Expression of Mutant OMT Genes ofNiastella koreensis

The plasmids pVK9::PcspB-omt202, pVK9::PcspB-omt301, pVK9::PcspB-omt302,pVK9::PcspB-omt304, pVK9::PcspB-omt305, pVK9::PcspB-omt306,pVK9::PcspB-omt307, pVK9::PcspB-omt308, pVK9::PcspB-omt309,pVK9::PcspB-omt311, pVK9::PcspB-omt312, pZK1::PcspB-omt312,pZK1::PcspB-omt401, pZK1::PcspB-omt402, pZK1::PcspB-omt403,pZK1::PcspB-omt404, pZK1::PcspB-omt406, pZK1::PcspB-omt407, andpZK1::PcspB-omt408 were obtained by outsourcing. These plasmids eachharbor a mutant OMT gene encoding a mutant OMT that corresponds to OMT35into which the mutation shown in Table 1 has been introduced due tocodon change shown in Table 2. The mutant OMT genes harbored by theseplasmids are also referred to as “omt202 gene”, “omt301 gene”, “omt302gene”, “omt304 gene”, “omt305 gene”, “omt306 gene”, “omt307 gene”,“omt308 gene”, “omt309 gene”, “omt311 gene”, “omt312 gene” (for bothpVK9::PcspB-omt312 and pZK1::PcspB-omt312), “omt401 gene”, “omt402gene”, “omt403 gene”, “omt404 gene”, “omt406 gene”, “omt407 gene”, and“omt408 gene”, respectively. The mutant OMTs encoded by these mutant OMTgenes are also referred to as “OMT202”, “OMT301”, “OMT302”, “OMT304”,“OMT305”, “OMT306”, “OMT307”, “OMT308”, “OMT309”, “OMT311”, “OMT312”,“OMT401”, “OMT402”, “OMT403”, “OMT404”, “OMT406”, “OMT407”, and“OMT408”, respectively. These plasmids can also be constructed via thefollowing procedure.

TABLE 1 Mutation introduced Mutant Parent into Parent OMT OMT MutationOMT 1^(st) 2^(nd) 202 M36K 35 M36K — 401 M36K/L67F/Y90C 312 Y90C — 402M36K/L67F/Y90G 312 Y90G — 403 M36K/L67F/P144Y 312 P144Y — 404M36V/L67F/P144S 312 M36V P144S(1) 406 M36K/L67F/Y90S/P144G 312 Y90SP144G 407 M36K/L67F/Y90C/P144V 401 P144V — 408 M36K/L67F/P144S 312P144S(2) — 301 M36K/P144E 302 D21Y/M36K/L67F/Y90A 304 M36K/L67F/Y90A 305L31H/M36K/L67F/P144V 306 M36K/Y90A/P144V 307 L31H/L67F/Y90A 308M36K/L67F/Y90A/P144E 309 M36K/S42C/L67F 311 D21Y/M36K/L67F 312 M36K/L67F

TABLE 2 Codon Primer F Primer R Mutation Codon change position SEQ ID NOSEQ ID NO D21Y GAT → TAT 61-63 — — L31H CTG → CAT 91-93 — — M36K ATG →AAG 106-108 146 147 M36V ATG → GTT 106-108 148 149 S42C TCC → TGT124-126 — — L67F TTG → TTT 199-203 — — Y90A TAC → GCG 268-270 — — Y90CTAC → TGT 268-270 150 151 Y90G TAC → GGG 268-270 152 153 Y90S TAC → AGT268-270 154 155 P144E CCA → GAG 430-432 — — P144G CCA → GGT 430-432 156157 P144S(1) CCA → TCT 430-432 158 159 P144S(2) CCA → AGT 430-432 160161 P144V CCA → GTG 430-432 162 163 P144Y CCA → TAT 430-432 164 165

Introduction of mutation for constructing pVK9::PcspB-omt202 isperformed by using QuikChange Site-Directed Mutagenesis Kit (AgilentTechnologies). That is, PCR is performed with Pfu Ultra DNA Polymeraseby using the plasmid pVK9::PcspB-omt35 as the template, and thesynthetic DNAs of SEQ ID NOS: 146 and 147 as the primers. Then, the PCRproduct is treated with DpnI to digest the template. With this DNA,XL1-Blue super competent cells are transformed, and the cells areapplied to the LB medium containing 25 μg/mL of kanamycin, and culturedovernight. Then, colonies that appeared are picked up, and separatedinto single colonies to obtain transformants. Plasmids are extractedfrom the obtained transformants, the nucleotide sequences thereof areconfirmed, and one into which the objective mutation is inserted isdesignated as pVK9::PcspB-omt202.

All the other pVK9-based plasmids for expression of mutant OMT genes areconstructed by artificial gene synthesis. These pVK9-based plasmids eachconsist of the nucleotide sequence shown in SEQ ID NO: 166 and thecorresponding mutant OMT gene, wherein the mutant OMT gene is insertedbetween position 4879 and position 4880 of SEQ ID NO: 166. Thenucleotide sequence of each mutant OMT gene is identical to that ofomt35 gene (SEQ ID NO: 145) except for codon change(s) for thecorresponding mutation(s).

pZK1::PcspB-OMT312 was constructed from pVK9::PcspB-omt312 in order tointroduce the tcg0610 terminator sequence from Corynebacteriumglutamicum ATCC 13032 and remove a known tn10 transposon targeting site.PCR was performed using synthetic DNAs of SEQ ID NOS: 167 and 168 asprimers and pVK9::PcspB-omt312 as the template. This PCR product wasthen phosphorylated using T4 polynucleotide kinase (New England Biolabs)and the resulting phosphorylated blunt ends were self-ligated using aQuick Ligation Kit (New England Biolabs). The resulting ligation mix wastransformed into Escherichia coli 10-beta competent cells (New EnglandBiolabs) and transformed cell mix applied to LB medium containing 25μg/mL of kanamycin, and cultured overnight. Single colonies were pickedinto liquid LB medium containing kanamycin and grown overnight, andplasmids were extracted. Sanger sequencing was performed to confirm thesequence of the resulting plasmids was as expected, and a plasmid withthe correct sequence was designated pZK1::PcspB-OMT312.

All the other pZK1-based plasmids for expression of mutant OMT genes areconstructed with the same procedure as that used for constructingpVK9::PcspB-omt202, except that PCR is performed using the pZK1-basedplasmids encoding the respective parent OMTs indicated in Table 1 as thetemplates and using the primer sets indicated in Table 2. Forconstructing pZK1::PcspB-omt404 and pZK1::PcspB-omt406, two mutationsare successively introduced into the respective parent OMTs in the orderindicated in Table 1. That is, for example, pZK1::PcspB-omt404 isconstructed as follows: the M36V mutation is introduced usingpZK1::PcspB-omt312 as the template to construct an intermediate plasmid;then, the P144S(1) mutation is introduced using the intermediate plasmidas the template to construct pZK1::PcspB-omt404.

<8> Construction of Vanillic Acid-Producing Strains

The C. glutamicum FKFC14ΔpcaGH/pVK9::PcspB-hsomt,Dp2_0340/pVK9::PcspB-omt35, Dp2_0340/pVK9::PcspB-omt202,Dp2_0340/pVK9::PcspB-omt301, Dp2_0340/pVK9::PcspB-omt302,Dp2_0340/pVK9::PcspB-omt304, Dp2_0340/pVK9::PcspB-omt305,Dp2_0340/pVK9::PcspB-omt306, Dp2_0340/pVK9::PcspB-omt307,Dp2_0340/pVK9::PcspB-omt308, Dp2_0340/pVK9::PcspB-omt309,Dp2_0340/pVK9::PcspB-omt311, Dp2_0340/pVK9::PcspB-omt312,Ep2_0055/pZK1::PcspB-omt312, Ns1_0003/pZK1::PcspB-omt401,Ns1_0003/pZK1::PcspB-omt402, Ns1_0003/pZK1::PcspB-omt403,Ns1_0003/pZK1::PcspB-omt404, Ns1_0003/pZK1::PcspB-omt406,Ns1_0003/pZK1::PcspB-omt407, and Ns1_0003/pZK1::PcspB-omt408 strains,which harbor the respective plasmids for expression of OMT genes, wereconstructed by outsourcing. These strains can also be constructed viathe following procedure.

The plasmids pVK9::PcspB-hsomt, pVK9::PcspB-omt35, pVK9::PcspB-omt202,pVK9::PcspB-omt301, pVK9::PcspB-omt302, pVK9::PcspB-omt304,pVK9::PcspB-omt305, pVK9::PcspB-omt306, pVK9::PcspB-omt307,pVK9::PcspB-omt308, pVK9::PcspB-omt309, pVK9::PcspB-omt311,pVK9::PcspB-omt312, pZK1::PcspB-omt312, pZK1::PcspB-omt401,pZK1::PcspB-omt402, pZK1::PcspB-omt403, pZK1::PcspB-omt404,pZK1::PcspB-omt406, pZK1::PcspB-omt407, and pZK1::PcspB-omt408 are eachintroduced into the C. glutamicum FKFC14ΔpcaGH strain (forpVK9::PcspB-hsomt), the C. glutamicum Dp2_0340 strain (for the otherpVK9-based plasmids), the C. glutamicum Ep2_0055 strain (forpZK1::PcspB-omt312), or the C. glutamicum Ns1_0003 strain (for the otherpZK1-based plasmids) by the electric pulse method. The cells are appliedto the CM-Dex agar medium containing 25 μg/mL of kanamycin, and culturedat 31.5° C. The grown strains are purified on the same agar medium, anddesignated as FKFC14ΔpcaGH/pVK9::PcspB-hsomt,Dp2_0340/pVK9::PcspB-omt35, Dp2_0340/pVK9::PcspB-omt202,Dp2_0340/pVK9::PcspB-omt301, Dp2_0340/pVK9::PcspB-omt302,Dp2_0340/pVK9::PcspB-omt304, Dp2_0340/pVK9::PcspB-omt305,Dp2_0340/pVK9::PcspB-omt306, Dp2_0340/pVK9::PcspB-omt307,Dp2_0340/pVK9::PcspB-omt308, Dp2_0340/pVK9::PcspB-omt309,Dp2_0340/pVK9::PcspB-omt311, Dp2_0340/pVK9::PcspB-omt312,Ep2_0055/pZK1::PcspB-omt312, Ns1_0003/pZK1::PcspB-omt401,Ns1_0003/pZK1::PcspB-omt402, Ns1_0003/pZK1::PcspB-omt403,Ns1_0003/pZK1::PcspB-omt404, Ns1_0003/pZK1::PcspB-omt406,Ns1_0003/pZK1::PcspB-omt407, and Ns1_0003/pZK1::PcspB-omt408,respectively.

These strains were each inoculated into 4 mL of the CM-Dex w/o mamenomedium (5 g/L of glucose, 10 g/L of Polypeptone, 10 g/L of YeastExtract, 1 g/L of KH₂PO₄, 0.4 g/L of MgSO₄-7H₂O, 0.01 g/L of FeSO₄-7H₂O,0.01 g/L of MnSO₄-7H₂O, 3 g/L of urea, 10 μg/L of biotin, adjusted to pH7.5 with KOH) containing 25 μg/mL of kanamycin present in a test tube,and cultured at 31.5° C. with shaking for about 16 hr. A 0.9 mL aliquotof the obtained culture broth was mixed with 0.6 mL of 50% glycerolaqueous solution to obtain a glycerol stock, and stored at −80° C.

<9> Vanillic Acid Production by C. glutamicum Vanillic Acid-ProducingStrains

A 5 μL aliquot of each of the glycerol stocks of the constructedvanillic acid-producing strains was inoculated into 4 mL of the CM-Dexw/o mameno medium containing 25 μg/mL of kanamycin present in a testtube, and cultured at 31.5° C. with shaking for 20 hr as preculture. A0.5 mL aliquot of the obtained preculture broth was inoculated into 50mL of the CM-Dex w/o mameno medium containing 25 μg/mL of kanamycinpresent in a conical flask with baffles, and cultured at 31.5° C. withshaking for 20 hr. The obtained culture broth was centrifuged at 8000rpm for 5 minutes, the supernatant was removed, and the cells weresuspended in sterilized physiological saline. The optical density (OD)of the cell suspension was measured, and the cell suspension was dilutedwith physiological saline to obtain an OD at 600 nm of 50. A 5 mLaliquot of the diluted cell suspension was inoculated into 20 mL of avanillic acid production medium (75 g/L of glucose, 0.6 g/L ofMgSO₄-7H₂O, 6.3 g/L of (NH₄)₂SO₄, 2.5 g/L of KH₂PO₄, 12.5 mg/L ofFeSO₄-7H₂O, 12.5 mg/L of MnSO₄-4-5H₂O, 2.5 g/L of Yeast Extract, 150μg/L of Vitamin B1, 150 μg/L of Biotin, 6.9 g/L of Protocatechuic acid,adjusted to pH 7 with KOH, and then mixed with 37.5 g/L of CaCO₃(sterilized with hot air at 180° C. for 3 hours)) containing 25 μg/mL ofkanamycin present in a conical flask with baffles, and cultured at 31.5°C. with shaking for 24 hr.

At the start and completion of the culture, the concentrations ofsubstances in the medium were analyzed by outsourcing. Theconcentrations of substances can also be analyzed via the followingprocedure.

The concentration of glucose in the medium is analyzed with BiotechAnalyzer AS-310 (Sakura SI). The concentrations of protocatechuic acid,vanillic acid, and isovanillic acid in the medium are analyzed by usingUltra Performance Liquid Chromatography NEXERA X2 System (SHIMADZU) withthe following conditions.

Conditions of UPLC analysis:

Column: KINETEX 2.6 μm XB-C18, 150×30 mm (Phenomenex)

Oven temperature: 40° C.

Mobile phase (A): 0.1% Trifluoroacetic acid

Mobile phase (B): 0.1% Trifluoroacetic acid/80% acetonitrile

Gradient program (time, A (%), B (%)): (0, 90, 10)→(3, 80, 20)

Flow rate: 1.5 ml/min

The results are shown in Tables 3 and 4. In the Tables, “VA/(VA+iVA)”can refer to the ratio of the production amount of vanillic acid withrespect to the total production amount of vanillic acid and isovanillicacid. The VA/(VA+iVA) ratio observed for the strains introduced with theomt35 gene was higher than that observed for the strain introduced withthe COMT2 (hsomt) gene. Therefore, it was revealed that OMT35 waseffective for reducing the by-production of isovanillic acid. Inaddition, the VA/(VA+iVA) ratio observed for the strains introduced withthe mutant OMT genes was higher than that observed for the strainsintroduced with the COMT2 (hsomt) gene or the omt35 gene. Therefore, itwas also revealed that these mutations were effective for reducing theby-production of isovanillic acid.

TABLE 3 Vanillic acid production by C. glutamicum vanillicacid-producing strains Plasmid VA/(VA + iVA) pVK9::PcspB-hsomt 0.57pVK9::PcspB-omt35 0.68 pVK9::PcspB-omt202 0.80 pVK9::PcspB-omt301 0.85pVK9::PcspB-omt302 0.86 pVK9::PcspB-omt304 0.89 pVK9::PcspB-omt305 0.90pVK9::PcspB-omt306 0.86 pVK9::PcspB-omt307 0.81 pVK9::PcspB-omt308 0.89pVK9::PcspB-omt309 0.88 pVK9::PcspB-omt311 0.87 pVK9::PcspB-omt312 0.88Abbreviations: VA, vanillic acid; iVA, isovanillic acid.

TABLE 4 Vanillic acid production by C. glutamicum vanillicacid-producing strains Plasmid VA/(VA + iVA) pVK9::PcspB-hsomt 0.59pZK1::PcspB-omt312 0.89 pZK1::PcspB-omt401 0.88 pZK1::PcspB-omt402 0.89pZK1::PcspB-omt403 0.89 pZK1::PcspB-omt404 0.90 pZK1::PcspB-omt406 0.91pZK1::PcspB-omt407 0.91 pZK1::PcspB-omt408 0.91 Abbreviations: VA,vanillic acid; iVA, isovanillic acid.

INDUSTRIAL APPLICABILITY

According to the present invention, an ability of a microorganism forproducing an objective substance such as vanillin and vanillic acid canbe improved, and the objective substance can be efficiently produced.

<Explanation of Sequence Listing>

SEQ ID NOS:

1: Nucleotide sequence of aroG gene of Escherichia coli MG1655

2: Amino acid sequence of AroG protein of Escherichia coli MG1655

3: Nucleotide sequence of aroB gene of Escherichia coli MG1655

4: Amino acid sequence of AroB protein of Escherichia coli MG1655

5: Nucleotide sequence of aroD gene of Escherichia coli MG1655

6: Amino acid sequence of AroD protein of Escherichia coli MG1655

7: Nucleotide sequence of asbF gene of Bacillus thuringiensis BMB171

8: Amino acid sequence of AsbF protein of Bacillus thuringiensis BMB171

9: Nucleotide sequence of tyrR gene of Escherichia coli MG1655

10: Amino acid sequence of TyrR protein of Escherichia coli MG1655

11-14: Nucleotide sequences of transcript variants 1 to 4 of OMT gene ofHomo sapiens

15: Amino acid sequence of OMT isoform (MB-COMT) of Homo sapiens

16: Amino acid sequence of OMT isoform (S-COMT) of Homo sapiens

17: Nucleotide sequence of ACAR gene of Nocardia brasiliensis

18: Amino acid sequence of ACAR protein of Nocardia brasiliensis

19: Nucleotide sequence of ACAR gene of Nocardia brasiliensis

20: Amino acid sequence of ACAR protein of Nocardia brasiliensis

21: Nucleotide sequence of entD gene of Escherichia coli MG1655

22: Amino acid sequence of EntD protein of Escherichia coli MG1655

23: Nucleotide sequence of PPT gene of Corynebacterium glutamicum ATCC13032

24: Amino acid sequence of PPT protein of Corynebacterium glutamicumATCC 13032

25: Nucleotide sequence of vanK gene of Corynebacterium glutamicum 2256(ATCC 13869)

26: Amino acid sequence of VanK protein of Corynebacterium glutamicum2256 (ATCC 13869)

27: Nucleotide sequence of pcaK gene of Corynebacterium glutamicum 2256(ATCC 13869)

28: Amino acid sequence of PcaK protein of Corynebacterium glutamicum2256 (ATCC 13869)

29: Nucleotide sequence of vanA gene of Corynebacterium glutamicum 2256(ATCC 13869)

30: Amino acid sequence of VanA protein of Corynebacterium glutamicum2256 (ATCC 13869)

31: Nucleotide sequence of vanB gene of Corynebacterium glutamicum 2256(ATCC 13869)

32: Amino acid sequence of VanB protein of Corynebacterium glutamicum2256 (ATCC 13869)

33: Nucleotide sequence of pcaG gene of Corynebacterium glutamicum ATCC13032

34: Amino acid sequence of PcaG protein of Corynebacterium glutamicumATCC 13032

35: Nucleotide sequence of pcaH gene of Corynebacterium glutamicum ATCC13032

36: Amino acid sequence of PcaH protein of Corynebacterium glutamicumATCC 13032

37: Nucleotide sequence of yqhD gene of Escherichia coli MG1655

38: Amino acid sequence of YqhD protein of Escherichia coli MG1655

39: Nucleotide sequence of NCgl0324 gene of Corynebacterium glutamicum2256 (ATCC 13869)

40: Amino acid sequence of NCgl0324 protein of Corynebacteriumglutamicum 2256 (ATCC 13869)

41: Nucleotide sequence of NCgl0313 gene of Corynebacterium glutamicum2256 (ATCC 13869)

42: Amino acid sequence of NCgl0313 protein of Corynebacteriumglutamicum 2256 (ATCC 13869)

43: Nucleotide sequence of NCgl2709 gene of Corynebacterium glutamicum2256 (ATCC 13869)

44: Amino acid sequence of NCgl2709 protein of Corynebacteriumglutamicum 2256 (ATCC 13869)

45: Nucleotide sequence of NCgl0219 gene of Corynebacterium glutamicumATCC 13032

46: Amino acid sequence of NCgl0219 protein of Corynebacteriumglutamicum ATCC 13032

47: Nucleotide sequence of NCgl2382 gene of Corynebacterium glutamicumATCC 13032

48: Amino acid sequence of NCgl2382 protein of Corynebacteriumglutamicum ATCC 13032

49: Nucleotide sequence of aroE gene of Escherichia coli MG1655

50: Amino acid sequence of AroE protein of Escherichia coli MG1655

51-84: Primers

85: Nucleotide sequence of DNA fragment containing P2 promoter region

86 and 87: Primers

88: Nucleotide sequence of cysI gene of Corynebacterium glutamicum 2256(ATCC 13869)

89: Amino acid sequence of CysI protein of Corynebacterium glutamicum2256 (ATCC 13869)

90: Nucleotide sequence of cysX gene of Corynebacterium glutamicum 2256(ATCC 13869)

91: Amino acid sequence of CysX protein of Corynebacterium glutamicum2256 (ATCC 13869)

92: Nucleotide sequence of cysH gene of Corynebacterium glutamicum 2256(ATCC 13869)

93: Amino acid sequence of CysH protein of Corynebacterium glutamicum2256 (ATCC 13869)

94: Nucleotide sequence of cysD gene of Corynebacterium glutamicum 2256(ATCC 13869)

95: Amino acid sequence of CysD protein of Corynebacterium glutamicum2256 (ATCC 13869)

96: Nucleotide sequence of cysN gene of Corynebacterium glutamicum 2256(ATCC 13869)

97: Amino acid sequence of CysN protein of Corynebacterium glutamicum2256 (ATCC 13869)

98: Nucleotide sequence of cysY gene of Corynebacterium glutamicum 2256(ATCC 13869)

99: Amino acid sequence of CysY protein of Corynebacterium glutamicum2256 (ATCC 13869)

100: Nucleotide sequence of cysZ gene of Corynebacterium glutamicum 2256(ATCC 13869)

101: Amino acid sequence of CysZ protein of Corynebacterium glutamicum2256 (ATCC 13869)

102: Nucleotide sequence of fpr2 gene of Corynebacterium glutamicum 2256(ATCC 13869)

103: Amino acid sequence of Fpr2 protein of Corynebacterium glutamicum2256 (ATCC 13869)

104: Nucleotide sequence of cysR gene of Corynebacterium glutamicum 2256(ATCC 13869)

105: Amino acid sequence of CysR protein of Corynebacterium glutamicum2256 (ATCC 13869)

106: Nucleotide sequence of ssuR gene of Corynebacterium glutamicum 2256(ATCC 13869)

107: Amino acid sequence of SsuR protein of Corynebacterium glutamicum2256 (ATCC 13869)

108: Nucleotide sequence containing P2 promoter

109: Nucleotide sequence containing P4 promoter

110: Nucleotide sequence containing P8 promoter

111: Nucleotide sequence containing P3 promoter

112-115: Primers

116: Nucleotide sequence of DNA fragment containing P8 promoter region

117 and 118: Primers

119: Nucleotide sequence of NCgl2048 gene of Corynebacterium glutamicum2256 (ATCC 13869)

120: Amino acid sequence of NCgl2048 protein of Corynebacteriumglutamicum 2256 (ATCC 13869)

121-124: Primers

125: Nucleotide sequence of DNA fragment containing P4 promoter region

126 and 127: Primers

128: Nucleotide sequence of eno gene of Corynebacterium glutamicum 2256(ATCC 13869)

129: Amino acid sequence of Eno protein of Corynebacterium glutamicum2256 (ATCC 13869)

130: Nucleotide sequence of cDNA encoding S-COMT of Homo sapiens

131: Nucleotide sequence of synthesized DNA fragment containing COMT2gene

132: pELAC vector

133-139: Primers

140: Nucleotide sequence of OMT gene of Niastella koreensis

141: Amino acid sequence of OMT of Niastella koreensis

142 and 143: Primers

144: Nucleotide sequence of DNA fragment containing omt35 gene

145: Nucleotide sequence of omt35 gene (codon-optimized OMT gene ofNiastella koreensis)

146-165: Primers

166: Nucleotide sequence of common part of some pVK9-based plasmids forexpression of mutant OMT genes

167-174: Primers

175: Nucleotide sequence of sahH gene of Corynebacterium glutamicum 2256(ATCC 13869)

176: Amino acid sequence of SahH protein of Corynebacterium glutamicum2256 (ATCC 13869)

177: Nucleotide sequence of purH gene of Corynebacterium glutamicum 2256(ATCC 13869)

178: Amino acid sequence of PurH protein of Corynebacterium glutamicum2256 (ATCC 13869)

179: Nucleotide sequence of purH(S37F) gene (mutant purH gene)

180: Amino acid sequence of purH(S37F) protein (mutant purH protein)

181-184: Primers

185: Nucleotide sequence of DNA fragment

186 and 187: Primers

The invention claimed is:
 1. A method for producing an objectivesubstance, the method comprising the following step: producing theobjective substance by using a microorganism that has been modified tohave an ability to produce the objective substance, wherein amodification of the microorganism is to have an O-methyltransferase genederived from a bacterium belonging to the phylum Bacteroidetes, andwherein the objective substance is selected from the group consisting ofvanillin, vanillic acid, ferulic acid, guaiacol, 4-vinylguaiacol,4-ethylguaiacol, and combinations thereof.
 2. The method according toclaim 1, wherein said producing comprises: cultivating the microorganismin a culture medium containing a carbon source to produce and accumulatethe objective substance in the culture medium.
 3. The method accordingto claim 1, wherein said producing comprises: converting a precursor ofthe objective substance into the objective substance by using themicroorganism.
 4. The method according to claim 3, wherein saidconverting comprises: cultivating the microorganism in a culture mediumcontaining the precursor to produce and accumulate the objectivesubstance in the culture medium.
 5. The method according to claim 3,wherein said converting comprises: allowing cells of the microorganismto act on the precursor in a reaction mixture to produce and accumulatethe objective substance in the reaction mixture.
 6. The method accordingto claim 5, wherein the cells are cells present in a culture broth ofthe microorganism, cells collected from the culture broth, cells presentin a processed product of the culture broth, cells present in aprocessed product of the collected cells, or a combination of these. 7.The method according to claim 3, wherein the precursor is selected fromthe group consisting of protocatechuic acid, protocatechualdehyde,L-phenylalanine, L-tyrosine, and combinations thereof.
 8. The methodaccording to claim 1, the method further comprising collecting theobjective substance.
 9. The method according to claim 1, wherein thebacterium belonging to the phylum Bacteroidetes is a bacterium belongingto the genus Niastella, Terrimonas, or Chitinophaga.
 10. The methodaccording to claim 1, wherein the O-methyltransferase gene is a geneencoding a protein is selected from a group consisting of: (a) a proteincomprising the amino acid sequence of SEQ ID NO: 141, (b) a proteincomprising the amino acid sequence of SEQ ID NO: 141 but that includessubstitution, deletion, insertion, and/or addition of 1 to 10 amino acidresidues, and wherein said protein has O-methyltransferase activity, (c)a protein comprising an amino acid sequence having an identity of 90% orhigher to the amino acid sequence of SEQ ID NO: 141, and wherein saidprotein has O-methyltransferase activity, and (d) a protein comprisingthe amino acid sequence of the protein defined in (a), (b), or (c) buthaving a specific mutation, wherein the specific mutation is a mutationat an amino acid residue selected from the group consisting of D21, L31,M36, S42, L67, Y90, P144, and combinations thereof.
 11. The methodaccording to claim 10, wherein the specific mutation is selected fromthe group consisting of D21Y, L31H, M36(K, V), S42C, L67F, Y90(A, C, G,S), P144(E, G, S, V, Y), and combinations thereof.
 12. The methodaccording to claim 10, wherein the specific mutation is selected fromthe group consisting of D21Y/M36K/L67F, D21Y/M36K/L67F/Y90A,L31H/M36K/L67F/P144V, L31H/L67F/Y90A, M36K/S42C/L67F, M36K/L67F,M36K/L67F/Y90A, M36K/L67F/Y90A/P144E, M36K/L67F/Y90C,M36K/L67F/Y90C/P144V, M36K/L67F/Y90G, M36K/L67F/Y90S/P144G,M36K/L67F/P144S, M36K/L67F/P144Y, M36K/Y90A/P144V, M36K/P144E, andM36V/L67F/P144S.
 13. The method according to claim 1, wherein themicroorganism is a bacterium belonging to the family Enterobacteriaceae,a coryneform bacterium, or yeast.
 14. The method according to claim 13,wherein the microorganism is a bacterium belonging to the genusCorynebacterium.
 15. The method according to claim 14, wherein themicroorganism is Corynebacterium glutamicum.
 16. The method according toclaim 13, wherein the microorganism is a bacterium belonging to thegenus Escherichia.
 17. The method according to claim 16, wherein themicroorganism is Escherichia coli.
 18. The method according to claim 1,wherein the microorganism has been further modified so that the activityof an enzyme that is involved in the biosynthesis of the objectivesubstance is increased as compared with a non-modified microorganism byincreasing the expression of a gene encoding the enzyme.
 19. The methodaccording to claim 18, wherein the enzyme that is involved in thebiosynthesis of the objective substance is selected from the groupconsisting of 3-deoxy-D-arabino-heptulosonic acid 7-phosphate synthase,3-dehydroquinate synthase, 3-dehydroquinate dehydratase,3-dehydroshikimate dehydratase, aromatic aldehyde oxidoreductase, andcombinations thereof.
 20. The method according to claim 1, wherein themicroorganism has been further modified so that the activity ofphosphopantetheinyl transferase is increased as compared with anon-modified microorganism by increasing the expression of a geneencoding the enzyme.
 21. The method according to claim 1, wherein themicroorganism has been further modified so that the activity of anenzyme that is involved in the by-production of a substance other thanthe objective substance is reduced as compared with a non-modifiedmicroorganism by attenuating the expression of a gene encoding theenzyme or disrupting a gene encoding the enzyme.
 22. The methodaccording to claim 21, wherein the enzyme that is involved in theby-production of a substance other than the objective substance isselected from the group consisting of vanillate demethylase,protocatechuate 3,4-dioxygenase, shikimate dehydrogenase, andcombinations thereof.
 23. The method according to claim 1, wherein themicroorganism has been further modified so that the activity of anL-cysteine biosynthesis enzyme is increased as compared with anon-modified microorganism by increasing the expression of a geneencoding the enzyme.
 24. The method according to claim 23, wherein theL-cysteine biosynthesis enzyme is a protein encoded by a gene selectedfrom the group consisting of cysI gene, cysX gene, cysH gene, cysD gene,cysN gene, cysY gene, cysZ gene, fpr2 gene, and combinations thereof.25. The method according to claim 23, wherein the activity of theL-cysteine biosynthesis enzyme is increased by increasing the activityof a protein encoded by cysR gene.
 26. The method according to claim 1,wherein the microorganism has been further modified so that the activityof a protein encoded by NCgl2048 gene is reduced as compared with anon-modified microorganism by attenuating the expression of a geneencoding the protein or disrupting a gene encoding the protein.
 27. Themethod according to claim 1, wherein the microorganism has been furthermodified so that the activity of enolase is reduced as compared with anon-modified microorganism by attenuating the expression of a geneencoding enolase or disrupting a gene encoding enolase.
 28. The methodaccording to claim 1, wherein the microorganism has been furthermodified so that the activity of S-adenosyl-L-homocysteine hydrolase isincreased as compared with a non-modified microorganism by increasingthe expression of a gene encoding S-adenosyl-L-homocysteine hydrolase.29. The method according to claim 1, wherein the microorganism has beenfurther modified to have a result selected from the group consisting of:(i) the activity of AICAR formyltransferase/IMP cyclohydrolase isreduced as compared with a non-modified microorganism by attenuating theexpression of a gene encoding AICAR formyltransferase/IMP cyclohydrolaseor disrupting a gene encoding AICAR formyltransferase/IMPcyclohydrolase, (ii) a gene encoding AICAR formyltransferase/IMPcyclohydrolase has a mutation that improves the ability of themicroorganism to produce the objective substance, and (iii) combinationsthereof.
 30. The method according to claim 1, wherein the objectivesubstance is selected from the group consisting of vanillin, vanillicacid, and combinations thereof.
 31. The method according to claim 1wherein the objective substance is vanillic acid, the method furthercomprising: converting said vanillic acid to vanillin.
 32. The methodaccording to claim 31, wherein the microorganism is a bacteriumbelonging to the genus Corynebacterium.
 33. The method according toclaim 31, wherein the microorganism is Corynebacterium glutamicum.